Clinical Development  
Secukinumab (AIN457) 
Clinical Trial 
Protocol for Study CAIN457A2302E1 / [STUDY_ID_REMOVED]
A multicenter, d ouble -blind, randomized withdrawal 
extensi on study of subcutaneous s ecukinumab in prefilled 
syringes to demonstrate l ong-term efficacy, safety and 
tolerability up to 4 years in subject s with moderate to 
severe chron ic plaque-typ e psoriasis completing preceding 
psoriasis phase III stud ies with secu kinumab 
Authors:   
 
Document type:  Amended Protocol Version  
EUDRACT number:  2012 -000533 -39 
Version number:  v03 Clean  
Development phase:  III 
Release date:  29-Apr-2015
Property of Novartis  
Confidential  
May not be used, divulged, published, or otherwise disclosed 
without the consent of Novartis  

Novartis  Confidential  Page 2 
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
Table of contents 
Table of contents ................................................................................................................. 2 
List of tables  ........................................................................................................................ 5 
List of figures  ...................................................................................................................... 5 
List of abbreviations ............................................................................................................ 6 
Glossary of terms  ................................................................................................................. 8 
Amendment 3 ............................................................................................................................. 9 
Amendment 2, 09- Sep-2014 ..................................................................................................... 10 
Amendment 1, 08- April -2014 .................................................................................................. 11 
Protocol synopsis ............................................................................................................... 13 
1 Introduction ....................................................................................................................... 21 
1.1 Background ............................................................................................................ 21 
1.2 Purpose .................................................................................................................. 21 
2 Study objectives ................................................................................................................. 22 
2.1 Primary objective  ................................................................................................... 22 
2.2 Secondary objectives ............................................................................................. 22 
2.3 Exploratory objectives ........................................................................................... 24 
3 Investigational plan  ........................................................................................................... 25 
3.1 Study design........................................................................................................... 25 
3.2 Rationale of study design  ....................................................................................... 31 
3.3 Rationale of dose/regimen, duration of treatment ................................................. 33 
3.4 Rationale for choice of comparator ....................................................................... 35 
3.5 Purpose and timing of interim analyses/design adaptations .................................. 35 
3.6 Risks and benefits .................................................................................................. 35 
4 Population .......................................................................................................................... 36 
4.1 Inclusion criteria  .................................................................................................... 36 
4.2 Exclusion criteria  ................................................................................................... 36 
5 Treatment  ........................................................................................................................... 38 
5.1 Protocol requested treatment  ................................................................................. 38 
5.1.1  Investigational treatment  ....................................................................... 38 
5.1.2  Additional study treatment .................................................................... 38 
5.2 Treatment groups  ................................................................................................... 38 
5.3 Treatment assignment, randomization  ................................................................... 39 
5.4 Treatment blinding  ................................................................................................. 41 
5.5 Treating the subject  ................................................................................................ 41 
5.5.1  Subject numbering ................................................................................ 41 
Novartis  Confidential  Page 3 
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
5.5.2  Dispensing the investigational treatment  .............................................. 42 
5.5.3  Storage of investigational treatment ...................................................... 42 
5.5.4  Instructions for prescribing and taking study treatment ........................ 43 
5.5.5  Permitted dose adjustments and interruptions of study treatment ........ 44 
5.5.6  Rescue medication  ................................................................................ 45 
5.5.7  Concomitant treatment .......................................................................... 45 
5.5.8  Prohibited Treatment ............................................................................. 45 
5.5.9  Discontinuation of study treatment and premature subject 
withdrawal  ............................................................................................. 46 
5.5.10  Emergency unblinding of treatment assignment ................................... 48 
5.5.11  Study completion and post- study treatment .......................................... 48 
5.5.12  Early study termination  ......................................................................... 49 
6 Visit schedule and assessments  ......................................................................................... 49 
6.1 Information to be collected on screening failures .................................................. 58 
6.2 Subject demographics/other baseline characteristics  ............................................. 58 
6.2.1  Subject demographics ........................................................................... 58 
6.2.2  Other baseline characteristics  ................................................................ 58 
6.3 Treatment exposure and compliance  ..................................................................... 58 
6.4 Efficacy  .................................................................................................................. 59 
6.4.1  Investigator’s global assessment (IGA mod 2011) ............................... 59 
6.4.2  Assessment of psoriasis area and severity index (PASI)  ...................... 59 
6.4.3  Assessment of rebound ......................................................................... 61 
6.4.4  Appropriateness of efficacy assessments  .............................................. 62 
6.5 Safety  ..................................................................................................................... 62 
6.5.1  Physical examination  ............................................................................ 62 
6.5.2  Vital signs .............................................................................................. 63 
6.5.3  Height and weight ................................................................................. 63 
6.5.4  Laboratory evaluations  .......................................................................... 63 
6.5.5  Electrocardiogram (ECG)  ..................................................................... 65 
6.5.6  Pregnancy and assessments of fertility  ................................................. 65 
6.5.7  Appropriateness of safety measurements  .............................................. 65 
6.6 Other assessments  .................................................................................................. 65 
6.6.1  Waist circumference and hip circumferen ce ......................................... 66 
6.6.2  Fasting laboratory evaluations .............................................................. 66 
6.6.3  Resource utilization  ............................................................................... 67 
6.6.4  Health -related Quality of Life (HRQoL)  .............................................. 67 
Novartis  Confidential  Page 4 
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
6.6.5  Pharmacokinetics  .................................................................................. 69 
  70 
6.6.7  Other biomarkers ................................................................................... 70 
6.6.8  Prospective suicidality assessment  ........................................................ 70 
7 Safety monitoring  .............................................................................................................. 70 
7.1 Adverse events  ....................................................................................................... 70 
7.2 Serious adverse events  ........................................................................................... 72 
7.3 Pregnancy reporting  ............................................................................................... 73 
7.4 Data Monitoring Committee  .................................................................................. 74 
8 Data review and database management  ............................................................................. 74 
8.1 Site monitoring  ...................................................................................................... 74 
8.2 Data collection  ....................................................................................................... 74 
8.3 Database management and quality control  ............................................................ 74 
9 Data analysis  ...................................................................................................................... 75 
9.1 Analysis sets  .......................................................................................................... 76 
9.2 Subject demographics and other baseline characteristics  ...................................... 76 
9.3 Treatments  ............................................................................................................. 77 
9.4 Analysis of the primary variable  ............................................................................ 77 
9.4.1  Variable  ................................................................................................. 77 
9.4.2  Statistical model, hypothesis, and method of analysis .......................... 78 
9.4.3  Handling of missing values/censoring/discontinuations ....................... 79 
9.4.4  Supportive analys es ............................................................................... 80 
9.5 Analysis of secondary variables ............................................................................ 80 
9.5.1  Efficacy variables  .................................................................................. 80 
9.5.2  Safety variables  ..................................................................................... 83 
9.5.3  Health -related Quality of Life (HRQoL)  .............................................. 85 
9.5.4  Pharmacokinetics  .................................................................................. 86 
  86 
9.5.6  Biomarkers  ............................................................................................ 86 
 . 86 
9.6 Interim analyses  ..................................................................................................... 86 
9.7 Sample size calculation  .......................................................................................... 87 
10 Ethical considerations ........................................................................................................ 87 
10.1  Regulatory and ethical compliance ........................................................................ 87 
10.2  Informed consent procedures ................................................................................. 87 
10.3  Responsibilities of the investigator and IRB/IEC  .................................................. 88 

Novartis  Confidential  Page 5 
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
10.4  Publication of study protocol and results............................................................... 88 
11 Protocol adherence  ............................................................................................................ 88 
11.1  Protocol Amendments ........................................................................................... 89 
12 References  ......................................................................................................................... 89 
13 Appendices ........................................................................................................................ 91 
13.1  Appendix 1: Clinically notable laboratory values and vital signs ......................... 91 
13.2  Appendix 2: Blood collection log for pharmacokinetics (PK) and 
immunogenicity (IG)  ............................................................................................. 92 
13.3  Appendix 3: Pharmacokinetics (PK) and immunogenicity (IG) sample labeling information  ............................................................................................... 94
 
13.3.1  PK sample handling .............................................................................. 94 
13.3.2  IG sample handling ............................................................................... 94 
 
List of tables 
Table 3 -1 Loading dose regimen at time of first full relapse* and treatment thereafter (treatment period) between Week 52 and Week 156 ............ 29
 
Table 5 -1 Prohibited treatment .............................................................................. 45 
Table 6 -1 Assessment schedule  ............................................................................. 51 
Table 6 -2 The IGA mod 2011 rating scale ............................................................ 59 
Table 6 -3 The PASI scor ing system ...................................................................... 60 
Table 13 -1 Blood collection log for PK .................................................................. 92 
Table 13 -2 Blood collection log for IG ................................................................... 93 
 
List of figures 
Figure 3 -1 Study design .......................................................................................... 25 
Figure 3 -2 Model-based prediction of % PASI  75 responders and % of 
subjects relapsing during a period of 6 months after either continuous treatment or of withdrawal (based on responders at Week 52) ............................................................................................... 34
 
Figure 3 -3 Observed loss of PASI 75 response during “fixed interval” maintenance treatment of study CAIN457A2211 ................................. 34
 
Figure 9 -1 Testing strategy  ..................................................................................... 79 
 
Novartis  Confidential  Page 6 
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
List of abbreviations 
AE adverse event  
ALT  alanine aminotransferase/glutamic pyruvic transaminase/GPT  
ANCOVA  analysis of covariance  
AST  aspartate aminotransferase/glutamic oxaloacetic transaminase/GOT  
ATC  anatomical therapeutic classification  
CHMP  the European Union Committee for Medicinal Products for Human Use  
CPO  country pharma organization 
CRF  case report/record form (paper or electronic [e])  
CRO  contract research organization  
CS corticosteroid (s) 
CSR  clinical study report  
DS&E  Drug Safety & Epidemiology  
DLQI  Dermatology Life Quality Index© 
DMC  data monitoring committee  
ECG  electrocardiogram  
EDC  electronic data capturing  
EQ-5D EuroQOL 5- Dimension© Health Questionnaire 
FAS full analysis set  
FDA  United States Food and Drug Administration 
HAQ  Health Assessment Questionnaire© 
HAQ- DI Health Assessment Ques tionnaire© – Disability Index  
HDL  high density lipoprotein 
HRQoL  health -related quality of life 
IA&R  Integrated Analytics & Reporting 
ICH International Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use  
IEC Independent Ethics Committee 
ICF informed consent form 
IGA investigator’s global assessment 
IGA mod 2011 Novartis investigator’s global assessment modified 2011 
IIS Integrated Information Sciences 
Novartis  Confidential  Page 7 
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
IG immunogenicity  
IL interleukin  
IRB institutional re view board 
IRT interactive response technology 
IVRS  interactive voice response system  
MedDRA  Medical Dictionary for Regulatory Activities  
OC/RDC  oracle clinical/remote data capturing  
PASI  Psoriasis Area and Severity Index  
PD  pharmacodynamic(s)  
PFS prefilled syringe  
PK pharmacokinetic (s)  
PMDA Pharmaceutical and Medical Devices Agency (Japan)  
PsA psoriatic arthritis  
PUVA psoralen + UVA treatment  
REB  research ethics board  
s.c. subcutaneous 
SAE  serious adverse event  
VAS  visual analog scale  
Novartis  Confidential  Page 8 
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
Glossary of terms 
 
Term  Definition  
Assessment  A procedure used to generate data required by the study  
Control treatment  Drugs(s) used as a comparator to reduce assessment bias, preserve 
blinding of investigational drug, assess internal study validity, and/or 
evaluate comparative effects of the investigational drug.  
Core studies  Refers to the secukinumab phase III studies (e.g., CAIN457A2302 or CAIN457A2303 and other secukinumab phase III studies) from which subjects meeting the inclusion/exclusion criteria will potentially enter the 
extension study CAIN457A2302E1  
Enrollment  Point/time of subject entry into the study; the point at which informed consent must be obtained (i.e. prior to starting any of the procedures 
described in the protocol).  
Epoch  The plann ed stage of the subjects’ participation in the study. Each epoch 
serves a purpose in the study as a whole. Typical epochs are: 
determination of subject eligibility, wash-out of previous treatments, 
exposure of subject to treatment or to follow -up on subjec ts after 
treatment has ended.  
Investigational treatment  The drug whose properties are being tested in the study; this definition is consistent with US CFR 21 Section 312.3 and is synonymous with 
“investigational new drug” or “investigational medicinal pro duct.”  
Medication number  A unique identifier on the label of each investigational/study drug 
package in studies that dispense medication using an IRT system  
Period A minor subdivision of the study timeline; divides phases into smaller 
functional segments  such as screening, baseline, titration, washout, etc.  
Premature subject withdrawal  Point/time when the subject exits from the study prior to the planned 
completion of all study treatment administration and assessments; at 
this time all study treatment ad ministration is discontinued and no further 
assessments are planned  
Randomization number  A unique identifier assigned to each randomized subject, corresponding  
to a specific treatment arm assignment  
Stop study participation  Point/time at which the subject came in for a final evaluation visit or 
when study treatment was discontinued whichever is later  
Study treatment  Any treatment administered to the subject as part of the required study procedures; includes investigational treatment and any control 
treatments  
Study treatment discontinuation Point/time when subject permanently stops taking study treatment for any reason; may or may not also be the point/time of premature subject 
withdrawal  
Subject Number  A number assigned to each subject who enrolls in the study. When 
combined with the site number, a unique identifier is created for each 
subject in the study.  
Variable Information used in the data analysis; derived directly or indirectly from 
data collected using specified assessments at speci fied time points  
 
Novartis  Confidential  Page 9 
Amendment Protocol v03 Clean  Protocol No. CAIN457A2302E1  
Amendment 3  
Amendment rationale 
 
       
 
Subjects who complete treatment period and follow -up period are  evaluated for 4 years 
regarding respective adverse events.  However, patient who prematurely discontinue treatment are evaluated for less than 4 years.  
Therefor e, this amendment extends the evaluation of subjects who prematurely discontinue 
treatment regarding respective adverse events and concomitant medications  in order to achieve 
a 4 year evaluation period. Evaluation of subjects should continue when achievabl e even if 
treatment is not continued for the duration. All subjects who prematurely discontinue treatment should complete all assessment of Week 260 (end of treatment visit) and of the follow -up period 
visits (Weeks 264 and 268). Subsequently, adverse events and use of concomitant medication will be evaluated by the investigator through telephone calls every 3 months for a duration of 4 years from the time when subject has been enrolled into CAIN457A2302E1 study. If deemed necessary by the investigator unpl anned assessments at site might be scheduled during this time. 
In addition, the study will NOT be terminated in selected countries where the drug is 
commercially available. 
Changes to the protocol  
The protocol introduces a follow -up 2 period to assess adverse events and concomitant 
mediations through telephone calls for all subjects who have prematurely discontinued 
treatment.  
Protocol Synopsis , Section 3.1, Figure 3 -1, Section 6  and Table 6 -1 were updated to introduce 
follow-up 2 period 
Section 3.5 was updated to specify the impact of follow-up 2 period on final database lock. Section 5.5.9 was updated to specify that subjects who prematurely discontinue treatment 
should enter follow-up 2 period  after completion of follow-up period assessments  
Section 5.5.10 was updated to reflect that subjects who are prematurely unblinded and 
discontinued from treatment should also enter follow-up 2 period Section 5.5.12 was updated to reflect that the study will NOT be terminated in selected countries 
where the drug is commercially available.  

Novartis  Confidential  Page 10  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
Section 7.1 was updated to reflect that AE evaluation is done at each telephone call during 
follow-up 2 period as well. 
Section 7.2 was updated to reflect t hat SAE reporting is extended for subjects who enter follow -
up 2 period Section 6.5.4 and Table 6 -1 were updated to add Amylase and Lipase to the Chemistry analysis 
panel to collect additional safety information  
Section 9.2 was updated to reflect that the test of baseline balance is not considered as 
appropriate use of significance test and may cause misinterpretation of the data . 
Section 9.5.2 was updated to specify data collection within the follow -up 2 period. Other minor 
corrections, clarifications, and editing changes of the protocol text were made in various 
sections  
 
All changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions. 
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
The changes described in this amended protocol require IRB/IEC approval prior to implementation.  The changes herein affect  the Informed Consent, and sites are required to 
update and submit for approval a revised Informed Consent that takes into account the changes described in this amended protocol. 
Amendment 2, 09 -Sep-2014  
Amendment rationale  
The purpose of this amendment is to clarify the wording for countries not selected for early trial termination when the drug is commercially available, this study will continue up to the end of additional 104 weeks of treatment. It also clarifies a discrepancy in the Assessment Schedule  
that PK samples at Week 140 are collected for all subjects and at Week 144 in case of relapse. This is consistent with Appendix 2. 
Changes to the protocol  
These changes were made to the protocol:  
• Secti on 5.5.12 was updated to reflect the clarification to early study termination.  
• Table 6 -1 included a correction that PK samples are collected for all subjects at Week 
140 and at Week 144 in case of relapse.   
At the time of this amendment, recruitment is complete with 1146 patients randomized into the 
trial. It is not expected that this amendment will influence the study population or have a significant impact on the primary objective of the trial 

Novartis  Confidential  Page 11  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
Amendme nt 1, 08- April-2014  
Amendment rationale  
The purpose of this amendment is to provide continued treatment for patients in the trial for an 
additional 104 weeks (or overall up to four years) or until the drug is commercially available in the market in the country of participation, whichever occurs first. This extension of treatment 
will allow for safety, tolerability, and efficacy data to be collected from the participating patients for a longer time period.  
All subjects will be unblinded and start open label at week 156.  Subjects on secukinumab 150 
mg may continue on 150 mg every 4 weeks or switch to 300 mg at Week 156 or any other regular site visit if the investigator feels the subject would benefit from the higher dose. Patients on 300 mg will continue on 300 mg. Patients who were on placebo during the randomized withdrawal period will start secukinumab 150 mg or 300 mg if the investigator decides the subject would benefit from the higher dose.   
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions. The 
changes described in this amended protocol require IRB/IEC approval prior to implementation. In addition, if the changes herein affect the Informed Consent, sites are required to update and submit for approval a revised Informed Consent that takes into account the changes described in this amended protocol. 
Changes to the protocol included: 
• Synopsis was updated to reflect the changes in the main protocol text. 
• Added one study figure to describe the updated study design ( Fig 3 -1). 
• Section 1.1 was updated to reflect the purpose of extending the study for additional 2 
years to obtain safety data.  
• Study design ( Section 3.1) was updated to include the open label period of the study and  
to allow the subj ects to self -inject at home.  It will also allow the subjects receiving 150mg 
secukinumab to switch to a higher 300 mg dose of secukinumab during this period of the study.  
• Rationale of the study design ( Section 3.2) was updated to clarify that the added open 
label period is primarily designed to collect additional safety data.  
• Section 3.5 was updated to allow possible Interim Analysis in the future if needed  
• Section 3.6 refers to Investigator Brochure for the most updated Risk/Benefit profile 
• Inclusion criteria ( Section 4.1) were updated to specify the eligibility for the subjects to 
enter the extension maintenance period.  
• Treatment groups ( Section 5.2) were updated to include the extension maintenance period. 
• Treatment blinding ( Section 5.4) was updated to include the open label period, which is an 
unblinded study period.  
• Dispensing the investigational treatment ( Section 5.5.2) describes that investigator will 
dispense via IRT, treatment packages for self- injection at home.  
• Section 5.5.4 was updated with the Home Administration instructions 
Novartis  Confidential  Page 12  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
• Prohibited treatment ( Section 5.5.8) was updated to further clarify the use of prohibited 
concomitant medications to allow the use of antihistamines and topical corticosteroids 
• Section Discontinuation from  treatment period ( Section 5.5.9) clarifies the procedures for 
patient who discontinue during the withdraw treatment /treatment period vs. the open label 
period 
• Section 5.5.12 clarifies  that the study treatment might be discontinued  in those countries  when  the study drug becomes commercially available  
• Visit schedule ( Section 6 ) was updated with assessments for the extension  maintenance 
period 
• PK sample stability  was clarified in Section 6.6.5  
• Section 9.6 clarifies  that additional interim analyses may be conducted  at various time points for publications or health authority request 
Novartis  Confidential  Page 13  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
Protocol synopsis  
Title of study : A multicenter, double- blind, randomized withdrawal extension study of subcutaneous 
secukinumab in prefilled syringes to demonstrate long- term efficacy, safety, and tolerability up to 4 years 
in subjects with moderate to severe chronic plaque- type psoriasis completing preceding psoriasis phase 
III studies with secukinumab.  
Purpose and rationale : This extension study (CAIN457A2302E1) is planned to collect an additional  
four years of long- term efficacy, safety, and tolerability data of secukinumab in either continuous or 
interrupted therapy (randomized withdrawal period) in subjects completing either one of the two phase 
III studies CAIN457A2302 or CAIN457A2303 (and potentially other secukinumab phase III studies) and showing at least partial response to secukinumab at Week 52 of the core study  . 
An interim analysis on safety data only at time of submission and a primary endpoint analysis (PEA) up to Week 68 will be conducted. The data collected in this study up to the time of the interim analysis may 
be part of the submission package. The data collected beyond the time of the interim analysis will deliver 
important long- term information on the effect of long- term treatment of chronic plaque- type psoriasis 
with secukinumab. Additional interim analyses may be conducted  at various time points for publications or health authority requests.  
The double- blind randomized withdrawal period will allow assessing whether continuation of treatment 
with secukinumab is of benefit to subjects after having been treated with secukinumab for up to 52 weeks 
in the preceding phase III studies, compared to stopping treatment with secukinumab. In addition, this 
treatment period will deliver important information on the effect of stopping treatment with secukinumab, including time to relapse (i.e., loss of ≥50% of previous gain in PASI reduction) and frequency of rebounds, and therefore addresses the needs brought forward by Health Authorities.  
Objectives:  
Primary objective  
To demonstrate the efficacy of secukinumab 150 mg or 300 mg in subjects with moderate to severe chronic plaque- type psoriasis, who were PASI 75 responders at Week 52 of the core study, with respect 
to loss of PASI 75  up to Week 68, compared to placebo.  
Secondary objectives  
• To assess the efficacy of secukinumab 150 mg or 300 mg with respect to PASI 50/75/90/100 response and IGA 0 or 1 response, compared to placebo over time in subjects who were PASI 75 responders at Week 52, over time for subjects who were re- treated after relapse with 
secukinumab 150 mg or 300 mg, and over time in subjects who were partial responders at Week 52.  
• To assess the efficacy of secukinumab 150 mg or 300 mg with respect to PASI score and IGA mod 2011 score, compared to placebo over time in subjects who were PASI 75 
responders at Week 52, over time for subjects who were re- treated after relapse with 
secukinumab 150 mg or 300 mg, and over time in subjects who were partial responders at Week 52.  
• To assess time to PASI 75 response for subjects who were re -treated after relapse with 
secukinumab 150 mg or 300 mg . 
• To assess the efficacy of secukinumab 150 mg or 300 mg in subjects with moderate to severe chronic plaque- type psoriasis with respect to loss of IGA 0 or 1 response, compared to 
placebo in subjects who were PASI 75 responders and IGA 0 or 1 responders at Week 
52. 
• To assess time to IGA 0 or 1 response for subjects who were IGA 0 or 1 responders at re-randomization, and who lost IGA 0 or 1 response during randomized withdrawal, and who 
were re -treated after relapse with secukinumab 150 mg or 300 mg.  
• To assess the clinical safety of secukinumab 150 mg or 300 mg as assessed by vital signs, clinical laboratory values, electrocardiograms (ECGs), and adverse events (AEs) monitoring, 
Novartis  Confidential  Page 14  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
compared to placebo in subjects who were PASI 75 responders at Week 52, in subjects who 
were re- treated after relapse with secukinumab 150 mg or 300 mg, and in subjects who were 
partial responders at Week 52.  
• To assess the efficacy of secukinumab 150 mg or 300 mg in subjects with moderate to severe chronic plaque- type psoriasis with respect to changes in Dermatology Life Quality 
Index
© (DLQI©), compared to placebo over time in subjects who were PASI 75 responders at 
Week 52 , over time for subjects who were re- treated after relapse with secukinumab 150 mg 
or 300 mg, and over time in subjects who were partial responders at Week 52.  
• To assess the efficacy of secukinumab 150 mg or 300 mg in subjects with moderate to severe chronic plaque- type psoriasis with respect to DLQI 0 or 1 achievement, compared to 
placebo over time in subjects who were PASI 75 responders at Week 52, over time for 
subjects who were re- treated after relapse with secukinumab 150 mg or 300 mg, and over 
time in subjects who were partial responders at Week 52.  
• To assess the efficacy of secukinumab 150 mg or 300 mg in subjects with moderate to 
severe chronic plaque- type psoriasis with respect to EuroQOL 5- Dimension
© Health 
Questionnaire (EQ -5D©) score, compared to placebo over time in subjects who were PASI 75 
responders at Week 52, over time for subjects who were re- treated after relapse with 
secukinumab 150 mg or 300 mg, and over time in subjects who were partial responders at Week 52.  
• To investigate the effects of treatment with secukinumab 150 mg or 300 mg on the 
occurrence of rebound following cessation of therapy, in subjects who were PASI 75 
responders at Week 52, for subjects who were re- treated after relapse with secukinumab 150 
mg or 300 mg, and in subjects who were partial responders at Week 52.  
• To assess the efficacy of secukinumab 150 mg or 300 mg in subjects with moderate to severe chronic plaque- type psoriasis with respect to relapse, compared to placebo in 
subjects who were PASI 75 responders at Week 52.  
• To investigate the development of immunogenicity (IG) against secukinumab over time.  
Exploratory objectives  
•  
  
•  
 
  
• To explore the effects of treatment with secukinumab with respect to the Health Assessment Questionnaire
©– Disability Index (HAQ©-DI) in subjects with psoriatic arthritis (PsA) at 
baseline of core study over time.  
Study design: 
CAIN457A2302E1 is a four year multicenter, double- blind, randomized withdrawal extension study of 
two ongoing phase III studies CAIN457A2302 and CAIN457A2303 and will potentially include subjects 
rolling over from other secukinumab phase III studies (preceding studies collectively referred as core 
studies). About 1,220 subjects from approximately 300 sites in studies CAIN457A2302 and CAIN457A2303 are rolling over to this extension study.  
In this extension study, the prefilled syringe (PFS) liquid formulation of secukinumab will be used. In order to maintain double- blind in this study, matching placebo is used.  
This 4 year extension study will include a 2- year double blind period (between Week 52 and Week 156), 
during whic h randomized withdrawal analysis will be performed, followed by an additional 2- year open 
label period (between Week 156 to Week 260). The subjects will receive the last blinded treatment at Week 152.  At Week 156, after performing the scheduled study assessments, the site will contact IRT 

Novartis  Confidential  Page 15  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
to unblind the study treatment. Therefore Week 156 is the end of blinded withdrawal treatment/treatment 
period (EoT) and the beginning of the open label period. Week 156 will be the first open label treatment. 
Subject wil l receive the last dose of the study drug at Week 256. Week 260 will be the end of open label 
treatment period (OL- EoT). Subjects completing the maintenance period (52 weeks) in the core studies 
(e.g., CAIN457A2302 and CAIN457A2303) will be classified based on Week 52 PASI response as PASI 
75 responders  (achieving at least PASI 75) or partial responders  (achieving at least PASI 50, but not 
PASI 75) or non-responders (not achieving at least a PASI 50 response). This Week 52 visit in the 
core studies is the randomization visit for CAIN457A2302E1 (extension study).  
For the subjects classified as PASI 75 responders at Week 52 the study consists of 5 or 6 
periods  
(i) screening period: is the duration between signing the informed consent form (ICF) and randomization 
registered with Interactive Response Technology (IRT).  
(ii) randomized withdrawal period: the duration of randomized withdrawal period for each subject is different i.e., starting from Week 52 until the subject experiences the relapse or up t o Week 156.  
(iii) treatment period: A placebo subject experiencing a relapse during the withdrawal period will receive four doses of secukinumab s.c. at weekly intervals followed by secukinumab s.c. every four weeks. Subjects on secukinumab in the randomized withdrawal period who have a relapse, will be given four weekly doses of placebo s.c. Following the loading doses, subjects will continue on secukinumab treatment at 4 week intervals. Any subject, whether randomized to placebo or active treatment, will  only 
be treated once with the weekly loading dose regimen. For subsequent relapses, patients will continue on secukinumab at 4 week intervals. Week 152 will be the last dose of the blinded treatment period. At Week 156 subjects will enter the open label period. The site must call IRT in order to unblind the subject to enter the open label period prior to performing the dosing.  
(iv) open label period: The treatment will be unblinded at Week 156 and the subjects will enter the open 
label period. During this  period, the subjects will be given pre- filled syringes and instructed to perform 
self-injection at home every 4 weeks and return to the site every 12 or 16 weeks (please see Table 6-1  
Assessment schedule).  The first open label dose will be given at the site at Week 156.  Subjects previously randomized to receive 150 mg secukinumab may continue with 150 mg secukinumab open label or may switch to 300 mg s.c. at the discretion of the investigator. Subjects previously randomized to 300 mg secukinumab will continue with 300 mg secukinumab open label. Subjects receiving placebo during randomized withdrawal period will start secukinumab 150 mg or 300 mg at the discretion of the 
investigator. Any subject on 150  mg s.c. may be switched to 300 mg s.c. at the discretion of the 
investigator at a regularly scheduled visit. Note: the Week 244 visit will be the last scheduled visit at 
which the subjects will be allowed to switch to 300 mg dose. Decreasing the dose from  300 mg to 150 
mg is not allowed.  
Placebo patients who enter the open label period will be given once weekly s.c. injections of secukinumab for 4 consecutive weeks and then s.c. injections every 4 weeks. Patients who choose not 
to switch from placebo to secukinumab will be allowed to exit the study. For subjects, who will not enter 
the open label period, Week 156 will be the EoT visit at which no treatment will be administered. After completing the Week 156 EoT visit, these subjects will enter the follow up period. For all the subjects 
who enter the open label period, the last dose of the study medication will be administered at Week 256. Week 260 is the end of the open label treatment period (OL- EoT).  
(v) follow -up period (for all subjects): treatment free period (Week 264 to Week 268).  
(vi) follow -up 2 period: treatment free period only for patients who prematurely discontinued treatment  
All subjects who prematurely discontinue treatment should complete all assessment of Week 260 (end of treatment visit) and of the follow -up period visits (Weeks 264 and 268). Subsequently, adverse events 
and use of concomitant medication will be evaluated by the investigator through telephone calls every 3 months for a duration of 4 years from the time when subject has been enrolled into CAIN457A2302E1 
study  
Novartis  Confidential  Page 16  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
For the subjects classified as partial responders at Week 52 the study consists of 4 or 5 
periods  
(i) screening period: is the duration between signing the informed consent form (ICF) and randomization  
registered wi th IRT.  
(ii) treatment period: starting from the randomization visit at Week 52 continuing through Week 156. The patients will receive secukinumab s.c. every 4 weeks at the dose which they were originally assigned in the core study. At Week 156 they will enter the open label period. For subjects who don’t enter the open label period, Week 156 visit is the EoT.  
 (iii) open label period: At Week 156, the subjects will be given pre- filled syringes and starting Week 160 
the subjects will be asked to perform sel f-injection at home every 4 weeks and return to the site every 
12 or 16 weeks (please see Table 6-1  Assessment schedule). Also, at Week 156 subjects receiving 150 
s.c. may be switched to 300 mg s.c. if the subject and the PI agree that the subject would benefit from the higher dosage at a regularly scheduled visit. The subjects will receive the last dose of the study medication at Week 256.  
(iv) follow -up period (for all subjects): treatment free period (Week 264 to Week  268).  
(v) follow -up 2 period: treatment free period only for patients who prematurely discontinued treatment  
All subjects who prematurely discontinue treatment should complete all assessment of Week 260 (end of treatment visit) and of t he follow -up period visits (Weeks 264 and 268). Subsequently, adverse events 
and use of concomitant medication will be evaluated by the investigator through telephone calls every 3 
months for a duration of 4 years from the time when subject has been enrolled into CAIN457A2302E1 
study .  
 
 NOTE: Partial responders DO NOT  participate in the randomized withdrawal and DO NOT  receive any 
loading dose even if they experience a full relapse (a loss of >50% of the maximum PASI gain compared 
to baseline of the core study).  
Subjects classified as  partial responders  at Week 52 of the core studies will continue the same 
treatment dose in PFS (secukinumab s.c. 150 mg or 300 mg) that they were receiving at the time of 
completing the maintenance period (Week 52) in the core study.  
In the follow -up period  (Week 26 4 to Week 268)  all subjects will visit the study site for safety and 
effica cy assessments while being off -treatment.  
In the follow -up 2 period  safety will be evaluated by the investigator through telephone calls every 3 
months for a duration of 4 years from the time when subject has been enrolled into CAIN457A2302E1 study  for pa tients who have prematurely discontinued treatment  only.  
Population: All subjects from study CAIN457A2302 or CAIN457A2303 (and potentially rolling over from other secukinumab phase III studies) who were randomized to and have been receiving secukinumab treatment during the maintenance period of the core studies (e.g., CAIN457A2302 or CAIN457A2303), 
and who completed the full study treatment period (52 weeks) in the core studies, and who have at least a partial response at Week 52 of the core studies, and who comply with the inclusion and exclusion criteria of this study, are eligible to enter into this extension study.  
Inclusion/Exclusion criteria:  
Inclusion criteria  
Subjects eligible for inclusion in this study have to fulfill all of the following criteri a: 
1. Subjects who completed the full study treatment period (52 weeks) in the core studies (e.g., 
CAIN457A2302 or CAIN457A2303), and after randomization have been receiving 
Novartis  Confidential  Page 17  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
secukinumab treatment during the maintenance phase of the core studies, and show at least 
a partial response (PASI 50 or better)  at Week 52 of the core studies.  
2. Written informed consent must be obtained before any assessment is performed.  
3. For inclusion in the open label period, written informed consent for protocol amendment 1 
must be obtained.  
4. For inclusion in the open label period, the subject must be deemed to benefit from the study 
drug based on the investigator's clinical judgment.  
Exclusion criteria  
Subjects fulfilling any of the following criteria are NOT  eligible for inclusion in this study:  
1. A protocol deviation in the core studies which according to the investigator will prevent the meaningful analysis of the extension study for the individual subject  
2. Ongoing use of prohibited psoriasis or non- psoriasis treatments. Time period to use of 
prohibited treatments in the core study detailed in the Table below have to be adhered.  
 
Prohibited treatments
†,‡  Time period before randomization visit at 
Week 52  
Alefacept, briakinumab, efalizumab, ustekinumab  6 months  
Biological immunomodulating agents other than 
above (e.g., adalimumab, etanercept, infliximab)  12 weeks  
Other systemic immunomodulating treatments§ (e.g., 
MTX, cyclosporine A, corticosteroids§, 
cyclophosphamide)  4 weeks  
Other systemic psoriasis treatments* (e.g., retinoids, 
fumarates)  4 weeks  
Photochemotherapy (e.g., PUVA)  4 weeks  
Phototherapy (e.g., UVA, UVB)  2 weeks  
Use of topical treatment ** that is likely to impact signs 
and symptoms of  psoriasis for >14 days* (e.g., corticosteroids [CS], vitamin D analogues,  
pimecrolimus, retinoids, salicylvaseline, salicylic acid, 
lactic acid,  tacrolimus, tar, urea, α -hydroxy or fruit 
acids)  2 weeks  
Live virus vaccinations during extension study  6 weeks  
Any investigational treatment or participation in any 
interventio nal clinical trial during extension trial  4 weeks or 5 half -lives (whichever Is longer)  
†If a subject inadvertently used the prohibited treatment in core study (e.g., CAIN457A2302 or 
CAIN457A2303) without undue safety risk till completion of Week 52, he/she must have completed the 
time period as defined in the table above. Subjects who have not completed an adequate time period (table above) will not be eligible for the current extension study.  
‡In case of undue safety risk for the subject, the subject should discontinue study treatment at the 
discretion of the investigator. If the subject received a live virus vaccination during the study, the subject must discontinue study treatment.
 
§Inhalative CS with only a topical effect (e.g., to treat asthma) are not considered “ systemic 
immunomodulating treatments” and are therefore acceptable as co- treatment.  
*There is no restriction on the use of anti -histamines or the use of corticosteroids in the eye or ear   
**Topical corticosteroid (CS) treatment, or use of  other topical treatment that is likely to impact signs 
and symptoms of psoriasis, is not allowed for treatment of psoriasis, except when applied to the face, scalp, and/or genitoanal area for ≤14 consecutive days. Topical corticosteroid use for indications other than psoriasis not on an area affected with psoriasis is allowed for ≤14 consecutive days  
Novartis  Confidential  Page 18  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
 
3. Subjects not expected to benefit from participation in the extension study, as assessed by the 
subject and investigator  
4. Subjects expected to be exposed to an undue safety risk if participating in the study  
5. Current severe progressive or uncontrolled disease which in the judgment of the investigator renders the subject unsuitable for the study 
6. Plans for administration of live vaccines during the study period  
7. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (>10 mIU/mL)  
8. Women of child- bearing potential, defined as all women physiologically capable of becoming 
pregnant, unwilling to use effective contraception during the study and for 16 weeks after stopping treatment. Effective contraception is defined as either:  
• Barrier method: Condom or occlusive cap (diaphragm or cervical/vault caps) with spermicide (where available). Spermicides alone are not a barrier method of contraception and should not be used alone  
The following methods are considered more effective than the barrier method and are also acceptable:  
• Total abstinence: When this is in line with the preferred and usual lifestyle of the subject (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post -ovulation methods] and 
withdrawal are not acceptable methods of contraception)  
• Female sterilization: have had a surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow -up hormone lev el assessment  
• Male partner sterilization (at least 6 months prior to screening). For female subjects on the study, the vasectomized male partner should be the sole partner for that subject  
• Use of established oral, injected or implanted hormonal methods of contraception, intrauterine device (IUD) or intrauterine system (IUS)  
NOTE: Women are considered post -menopausal and not of child bearing potential if they have had:  
• 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. , age 
appropriate, history of vasomotor symptoms) or  
• six months of spontaneous amenorrhea with serum FSH levels >40 mIU/mL [for US only: and estradiol <20 pg/mL] or  
• surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six 
weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow -up hormone level 
assessment is she considered not of child bearing potential.  
No additional exclusion criteria may be applied by the investigator, in order to ensure that the study population will be representative of all eligible subjects.  
Investigational and reference therapy :  
Novartis will provide the following study treatments  
1. Investigational treatment: Secukinumab 150 mg/1 mL solution for injection is provided in PFS 
for s.c. administration. The 150 mg/1 mL solution in PFS is used for both s.c.150 mg dose (1 
syringe) and s.c. 300 mg dose (2 syringes). For blinding purpose the subject in 150 mg 
treatment group will also receive one syringe of placebo secukinumab 150 mg.  
2. Reference therapy: Placebo secukinumab 150 mg/1 mL solution for injection is provided in 
PFS for s.c. administration. It contains a mixture of inactive excipients, matching the 
composition of secukinumab 150 mg.  
Novartis  Confidential  Page 19  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
Secukinumab 150 mg/1 mL and placebo secukinumab 150 mg/1 mL is labeled as AIN457 150 mg/1 mL/ 
Placebo.  
Efficacy assessments : All efficacy assessments should be performed prior to administration of study 
treatment. The following order should be applied when performing the efficacy assessments during study visits:  
• Investigator’s Global Assessment (IGA mod 2011; scale from 0 – 4) 
• Psoriasis Area and Severity Index (PASI; score from 0 – 72) 
• Rebound assessment  
Other assessments:  
• Safety asses sments:  
• Evaluation of all AEs and SAEs including injection site reactions, physical examination; vital signs; weight and height, laboratory assessments including hematology, clinical chemistry, local urinalysis, immunogenicity (IG) (assessment of anti -secu kinumab 
antibody development), ECG ,pregnancy and assessments of fertility  
•  
• Fasting laboratory evaluations; plasma glucose, lipid panel  
• PK 
• Health- related Quality of life (HRQoL): The impact of psoriasis on various aspects of subject’s 
health- related quality of life will be assessed by the following validated instruments:  
• Dermatology Life Quality Index (DLQI
©) 
• EuroQOL 5- Dimension© Health Status Questionnaire (EQ -5D©) 
• Health Assessment Questionnaire- Disability Index (HAQ©-DI) (subjects with psoriatic 
arthritis [PsA] at baseline of the core study)  
Data analysis:  
Treatment groups for analysis will include:  
• Subjects who were PASI 75 responders at Week 52 
• Secukinumab 150 mg 
• Secukinumab 300 mg 
• Placebo (secukinumab 150 mg in core studies)  
• Placebo (secukinumab 300 mg in core studies)  
• Subjects who were re- treated after relapse with secukinumab 150 mg or 300 mg  
• Secukinumab 150 mg 
• Secukinumab 300 mg 
• Subjects who were partial responders at Week 52 
• Secukinumab 150 mg 
• Secukinumab 300 mg 
The following hypotheses will be tested for 52 weeks≤ t ≤68 weeks 
• H1: Secukinumab 150 mg is not different from placebo with respect to the cumulative rate for subjects who lost PASI 75 response up to Week 68 
• H2: Secukinumab 300 mg is not different from placebo with respect to the cumulative rate for subjects who lost PASI 75 response up to Week 68 
The familywise error will be set to α=2.5% (one- sided). The two hypotheses H1 (referring to 150 mg) 
and H2 (referring to 300 mg) will be tested at α/2=1.25% one-s ided. In case, a null hypothesis has been 

Novartis  Confidential  Page 20  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
rejected for one dose, but not for the other dose, the alpha can be shifted to the other dose and the null 
hypotheses can be retested at level α=2.5% (one- sided).  
For loss of PASI 75 response, between- treatment differences will be evaluated using a log- rank test, 
stratified by geographical region and body weight stratum, to compare the survival functions between secukinumab treatment groups versus placebo. The hazard ratios for these comparisons for loss of PASI 75 response and their corresponding 95% confidence intervals will be computed using a stratified 
Cox proportional hazards regression model with treatment group, core study and baseline PASI of core study and baseline (at Week 52) PASI of extension study as explanatory variable and stratified by 
geographical region and body weight stratum. The primary analysis will be the log- rank test. Subjects 
who have not lost PASI 75 response up to Week 68 will be considered as censored observations.  
Separate analyses will be performed for comparison of 150 mg secukinumab with placebo and 300 mg 
secukinumab with placebo. The two placebo groups will not be pooled for this analysis.  
Novartis  Confidential  Page 21  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
1 Introduction  
1.1 Background 
CAIN457A2302E1 is an extension study to two ongoing phase III studies CAIN457A2302 and 
CAIN457A2303, and will potentially include subjects from other secukinumab phase III studies (preceding studies collectively referred as core studies). Study CAIN457A2302 and study CAIN457A2303, each, is multicenter, randomized, controlled trial to investigate the efficacy 
of secukinumab after twelve weeks of treatment, and safety, tolerability and long -term efficacy 
up to one year in subjects with moderate to severe chronic plaque -type psoriasis. Both the 
studies are planned to demonstrate superiority of secukinumab compared with placebo. In addition, the study CAIN457A2303 aims also to show the non- inferiority versus etanercept. 
Please refer to the protocols of the respective studies for full details.  
At the end -of-phase- II meetings with se veral Health Authorities (FDA, EMA, and PMDA) in 
the first quarter of 2011, it was agreed to submit data from core studies along with interim data from at least one extension study to show long -term efficacy, safety, and tolerability of 
secukinumab in subjects with psoriasis. This study will also provide information from a randomized withdrawal period for subjects who have shown a PASI  75 response to 
secukinumab at Week 52 of the core studies (e.g., CAIN457A2302 or CAIN457A2303) for 2 years until Week 156. The long- term efficacy, safety, and tolerability data (open label) will be 
collected for an additional 2 years. The overall treatment period (core study [52 weeks] plus extension [268 weeks]) is 320 weeks. 
Subjects (PASI 75 responders and partial responders) randomized to and completing Week 52 
of the core studies (e.g., CAIN457A2302 or CAIN457A2303) on secukinumab treatment will be eligible to join this extension study, which is planned to collect up to- four  years of long -
term efficacy, safety, and toler ability data of secukinumab in either continuous or interrupted 
therapy (randomized withdrawal period). Subjects on placebo treatment or etanercept in the maintenance phase of the core studies, as well as subjects on secukinumab, but not showing at least a partial response, will not be eligible to enter this extension study.  
The study design, objectives, and other procedures of this extension study are applicable to 
other secukinumab phase III studies from which subjects meeting the inclusion/exclusion criteria will potentially enter the extension study CAIN457A2302E1.  
In this extension study, the prefilled syringe (PFS) liquid formulation of secukinumab will be used. 
1.2 Purpose  
This extension study (CAIN457A2302E1) is planned to collect an additional four years of long-term efficacy, safety, and tolerability data of secukinumab in either continuous or interrupted therapy (randomized withdrawal period) in subjects completing either one of the two phase III studies CAIN457A2302 or CAIN457A2303 (and potentially  other secukinumab phase III 
studies) and showing at least partial response to secukinumab at Week 52 of the core study. An interim analysis on safety data only and a primary endpoint analysis (PEA) up to Week 68 will be conducted.  
Novartis  Confidential  Page 22  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
The data collected in t his study up to the time of the interim analysis will be part of the 
submission package. The data collected beyond the time of the Week 68 interim analysis will 
deliver important  information on the effect of long -term treatment of chronic plaque -type 
psoriasis with secukinumab. Additional interim analyses may be conducted at various time 
points for publications or health authority requests. 
The two year double -blind randomized withdrawal period will allow assessing whether 
continuation of treatment with secukinumab is of benefit to subjects after having been treated 
with secukinumab for up to 52 weeks in the preceding phase III studies, compared to stopping treatment with secukinumab. In addition, this treatment period will deliver important information on the effect of stopping treatment with secukinumab, including time to relapse (i.e., loss of ≥50% of previous gain in PASI reduction) and frequency of rebounds, and therefore addresses needs brought forward by Health Authorities. The two year double –blind period of 
the study will be followed by a two year open label period. D uring the open label treatment 
period, subjects initially on the lower dose (150 mg) will be offered to switch to the higher dose 
(300 mg), at the discretion of the investigator. This allows all subjects in the study to receive 
the most efficacious dose of secukinumab.  
2 Study objectives  
For study treatments and description of treatment subgroups refer Section 3.1. 
2.1 Primary objective  
To demonstrate the efficacy of secukinumab 150 mg or 300 mg in subjects with moderate to 
severe chronic plaque- type psoriasis, who were PASI 75 responders at Week 52 of the core 
study, with respect to loss of PASI 75 up to Week 68, compared to placebo.  
2.2 Se condary objectives  
• To assess the efficacy of secukinumab 150 mg or 300 mg with respect to PASI 
50/75/90/100 response and IGA 0 or 1 response, compared to placebo over time in 
subjects who were PASI 75 responders at Week 52, over time for subjects who were re -
treated after relapse with secukinumab 150 mg or 300 mg, and over time in subjects who were partial responders at Week 52   
• To assess the efficacy of secukinumab 150 mg or 300 mg with respect to PASI score and IGA mod 2011 score, compared to placebo over time in subjects who were PASI 75 responders at Week 52, over time for subjects who were re- treated after relapse with 
secukinumab 150 mg or 300 mg, and over time in subjects who were partial responders at Week 52   
• To assess time to PASI 75 response for subjects who were re- treated after relapse with 
secukinumab 150 mg or 300 mg. 
• To assess the efficacy of secukinumab 150 mg or 300 mg in subjects with moderate to severe chronic plaque-type psoriasis with respect to loss of IGA 0 or 1 response, compared 
Novartis  Confidential  Page 23  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
to placebo in subjects who were PASI 75 responders and IGA 0 or 1 responders at 
Week 52.   
• To assess time to IGA 0 or 1 response for subjects who were IGA 0 or 1 responders at re-
randomization, and who lost IGA 0 or 1 response during randomized withdrawal, and who 
were re-treated after relapse with secukinumab 150 mg or 300 mg.  
• To assess the clinical safety of secukinumab 150 mg or 300 mg as assessed by vital signs, clinical laboratory values, electrocardiograms (ECGs), and adverse events (AEs) monitoring, compared to placebo in subjects who were PASI 75 responders at Week 52, in subjects who were re -treated after relapse with secukinumab 150 mg or 300 mg, and in 
subjects who were partial responders at Week 52.   
• To assess the efficacy of secukinumab 150 mg or 300 mg in subjects with moderate to severe chronic plaque- type psoriasis with respect to changes in Dermatology Life Quality 
Index
© (DLQI©), compared to placebo over time in subjects who were PASI 75 
responders at Week 52, over time for subjects who were re-treated after relapse with 
secukinumab 150 mg or 300 mg, and over time in subjects who were partial responders at Week 52. 
• To assess the efficacy of secukinumab 150 mg or 300 mg in subjects with moderate to 
severe chronic plaque-type psoriasis with respect to DLQI 0 or 1 achievement, compared to placebo over time in subjects who were PASI 75 responders at Week 52, over time for 
subjects who were re -treated after relapse with secukinumab 150 mg or 300 mg, and over 
time in subjects who were partial responders at Week 52.  
• To assess the efficacy of secukinumab 150 mg or 300 mg in subjects with moderate to 
severe chronic plaque-type psoriasis with respect to EuroQOL 5- Dimension
© Health 
Questionnaire (EQ-5D©) score, compared to placebo over time in subjects who were PASI 
75 responders at Week 52, over time for subjects who were re- treated after relapse with 
secukinumab 150 mg or 300 mg, and over time in subjects who were partial responders at 
Week 52. 
• To investigate the effects of treatment with secukinumab 150 mg or 300 mg on the 
occurrence of rebound following cessation of therapy, in subjects who were PASI 75 responders at Week 52, for subjects who were re- treated after relapse with secukinumab 
150 mg or 300 mg, and in subjects who were partial responders at W eek 52.  
• To assess the efficacy of secukinumab 150 mg or 300 mg in subjects with moderate to severe chronic plaque- type psoriasis with respect to relapse, compared to placebo in 
subjects who were PASI 75 responders at Week 52 . 
• To investigate the development  of immunogenicity (IG) against secukinumab over time. 
Novartis  Confidential  Page 24  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
2.3 Exploratory objectives  
•  
  
•  
 
 
• To explore the effects of treatment with secukinumab w ith respect to the Health 
Assessment Questionnaire© – Disability Index (HAQ©-DI) in subjects with psoriatic 
arthritis (PsA) at baseline of core study over time.  

Novartis  Confidential  Page 25  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
3 Investigational plan 
3.1 Study design 
Figure 3-1 Study design 
 
 
 
PFS: prefilled syringe;  Week 52 – end of maintenance period in core studies (e.g., CAIN457A2302 or 
CAIN457A2303) which is randomization (Rand*) visit for CAIN457A2302E1 (extension study); The 
screening period will be the duration between signing the informed consent form and randomization 
registered with Interactive Response Technology (IRT); s.c.: subcutaneous; Week 156 end of 
treatment period (EoT); Week 260 – open label end of treatment (O L-EoT) period; q4wk – every four 
weeks; end of follow up (EOF)  
Primary endpoint analysis (PEA) at Week 68;  PASI 75 Responders: subjects with PASI 75 at 
Week 52 of core study;   Partial responders: subjects with PASI 50, but not PASI 75 response at 
Week  52 of core study; first full relapse – a loss of > 50% of the maximum PASI gain compared to the 
baseline of core study  
(A) PASI 75 Responders entering randomized withdrawal period  
Subjects who were PASI 75 responders  at Week 52 visit of the core studies (e.g.,CAIN457A2302 or 
CAIN457A2303) and have been on secukinumab s.c. 150 mg or 300 mg in the core studies will be randomized to continue same s.c. doses of secukinumab in PFS or receive placebo every 4 weeks up to Week 152. Randomization in each group will be 2:1 (refer protocol text for details)  
R
PR
Novartis  Confidential  Page 26  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
a. Secukinumab 150 mg PFS group: One s.c. injection of secukinumab 150 mg in PFS plus s.c. 
injection of placebo secukinumab 150 mg in PFS at randomization (Week 52) and thereafter every 4 
weeks up to Week 152 (or until first relapse). Subjects with first full relapse will be treated with two 
s.c. injections of placebo secukinumab 150 mg in PFS once weekly for three weeks (1 week, 2 weeks 
and 3 weeks later). After 4 weeks following relapse the routine dosing with secukinumab 150 mg regimen every 4 weeks dosing is continued thereafter. Subjects who enter the open label period to continue beyond Week 152 will receive one injection of 150 s.c. every 4 weeks. Starting Week 156, subjects on 150 mg s.c. will have the option to switch to 300 mg s.c.at regularly scheduled visits.  
b. Placebo secukinumab 150 mg PFS: Two s.c. injections of placebo secukinumab 150 mg in PFS at randomization (Week 52) and thereafter every 4 weeks up to Week 152 (or until first relapse). Subjects with first full relapse will be treated with one s.c. injection of secukinumab 150 mg in PFS plus one 
s.c. injection of placebo secukinumab 150 mg in PFS once weekly for four weeks (at the visit where the relapse was diagnosed, 1 week, 2 weeks and 3 weeks later). After 4 weeks following relapse the routine dosing with secukinumab 150 mg regimen every 4 weeks dosing is continued thereafter. 
Subjects on placebo who enter the open label period to continue beyond Week 152 will be treated with 
one  injection of secukinumab 150 mg s.c. in PFS once weekly for four weeks and then one injection  s.c. every 4 weeks. Starting Week 156, subjects on 150 mg s.c. will have the option to switch to 300mg s.c.( two injections of 150 s.c.) at regularly scheduled visits.  
c. Sec ukinumab 300 mg PFS group: Two s.c. injections of secukinumab 150 mg in PFS at 
randomization (Week 52) and thereafter every 4 weeks up to Week 152 (or until first relapse). Subjects with first full relapse will be treated with two s.c. injections of placebo secukinumab 150 mg in PFS 
once weekly for three weeks (1 week, 2 weeks and 3 weeks later). After 4 weeks following relapse the routine dosing with secukinumab 300 mg regimen every 4 weeks dosing is continued thereafter. Subjects who enter the open label period to continue beyond Week 152 will receive two injections of 150 s.c. every 4 weeks.  
d. Placebo secukinumab 300 mg PFS : Two s.c. injections of placebo secukinumab 150 mg in PFS at randomization (Week 52) and thereafter every 4 weeks up to Week152 (or  until first relapse). Subjects 
with first full relapse will be treated with two s.c. injection of secukinumab 150 mg in PFS plus once 
weekly for four weeks (at the visit where the relapse was diagnosed, 1 week, 2 weeks and 3 weeks later). After 4 weeks following relapse the routine dosing with secukinumab 300 mg regimen every 4 weeks dosing is continued thereafter. Subjects on placebo who enter the open label period to continue 
beyond Week 152  will be treated with two s.c. injections of secukinumab 150 mg in PFS once weekly 
for four weeks and then two s.c. injections of secukinumab 150 mg s.c. every 4 weeks.  
● Refer protocol text for details and for treatment at relapse.  
(B) Partial responders  not entering the randomized withdrawal period  
● Subjects who were partial responders  at Week 52 visit in core studies (e.g., CAIN457A2302 or 
CAIN457A2303) and have been on secukinumab s.c. 150 mg or 300 mg in core studies do not 
participate in the randomized withdrawal. These subjects will continue same treatment s.c. dose in 
PFS (secukinumab s.c. 150 mg or 300 mg) as they were receiving at the time of completing the maintenance period (Week 52) in the core studies. Subjects continuing beyond week 152 will be given open label secukinumab.  Starting Week 156, subjects on 150 mg s.c. will have the option to switch to 300 mg s.c.at regularly scheduled visits.  
● NOTE: Subjects who are non-responders  at Week 52 of the core studies (e.g., CAIN457A2302 or 
CAIN457A2303) are not eligible to enter this extension study, and will  complete follow -up visits in the 
core studies.  
Follow -up 2 period: treatment free period only for patients who prematurely discontinued treatment  
 
An outline of the study design is presented in Figure 3-1, while a detailed visit and assessment 
schedule can be found in Table 6 -1. The study design is applicable to other secukinumab phase 
III studies from which subjects meeting the inclusion/exclusion criteria will potentially enter 
the extension study CAIN457A2302E1. 
Novartis  Confidential  Page 27  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
This 4 year extension study will include a 2 -year double blind period (between Week 52 and 
Week 156) during which randomized withdrawal analysis will be performed, followed by an 
additional 2- year open label period (between Week 156 to Week 260). The subjects will receive 
the last blinded treatment at Week 152. At Week 156, after performing the scheduled study assessments and  prior to receiving the first unblinded dose of the study drug, the  site will be 
asked to contact IRT to unblind the study treatment.  For subjects who will continue into the open label period, Week 156 will be the beginning of the open label period. The subjects who will not continue into the open label period Week 156 will be the end of blinded withdrawal treatment/treatment period (EoT) at which no study drug will be administered. During the open label period, subjects will receive the last dose of the study drug at Week 256. Week 260 will be the end of open label treat ment period (OL- EoT).  
Subjects completing the maintenance period (52 weeks) in the core studies (e.g., CAIN457A2302 or CAIN457A2303) will be classified based on Week 52 PASI response as “PASI 75 responders” or “partial responders” or “non- responders”. This Week 52 visit in the 
core studies is the randomization visit for CAIN457A2302E1 (extension study).  
• PASI 75 Responders :  subjects with a PASI 75 response (subjects achieving ≥ 75% 
improvement [reduction] in PASI score compared to baseline of the core study) at Week 52 of core study 
• Partial responders : subjects with a PASI 50 response (subjects achieving ≥ 50% 
improvement [reduction] in PASI score compared to baseline of the core study, but not PASI 75 response) at Week 52 of core study  
• Non-responders : not achieving at least a PASI 50 response at Week 52 of core study  
For the subjects classified as PASI 75 responders at Week 52 the study consists of 5 or 6 periods  
At Week 52 of the core studies subjects enrolling in the extension trial will go through a 
screening period, a randomized withdrawal period, a treatment period, a two year secukinumab open label period and a follow up period. 
(i) screening period: is the duration between signing the informed consent form (ICF) and 
randomization registered with interactive response technology (IRT). 
(ii) randomized withdrawal period (double blind): Subjects will be randomized to either 
secukinumab or placebo. The subjects will continue on either secukinumab or placebo until there is a relapse or up to Week 156.  I f there is a relapse the patient will enter the treatment 
period.  
 In randomized withdrawal period (between Week 52 and Week 156), subjects in the group of 
PASI 75  responders  who have been receiving secukinumab s.c. 150 mg dose during the 
maintenance peri od of core studies will be randomized 2:1 to continue  same s.c. doses of 
secukinumab in PFS from the core studies or receive s.c. placebo secukinumab in PFS. Similarly, those subjects who were receiving secukinumab s.c. 300 mg dose during the maintenance p eriod of core studies will be randomized 2:1 to continue  same s.c. doses of 
secukinumab in PFS from the core studies or receive s.c. placebo secukinumab in PFS. Randomization will be stratified by geographical region and by body weight (< 90 kg or ≥90 kg) collected at Week 52. In order to maintain double -blind in this study, matching placebo is 
Novartis  Confidential  Page 28  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
used. Therefore subjects classified as PASI 75 responders and entering the randomized 
withdrawal period will be randomized (as explained above) at Week 52 in either of four treatment groups ( Figure 3 -1). Subjects who were on s.c. secukinumab 150 mg in the core study 
will be randomized to (a) or (b) treatments and subjects who were on s.c. secukinumab 300 mg in the co re study will be randomized to (c) or (d) treatments, as explained below:  
a. Secukinumab 150 mg PFS group: One s.c. injection of secukinumab 150 mg in PFS plus 
s.c. injection of placebo secukinumab 150 mg in PFS at randomization (Week 52) and thereafter every  4 weeks up to Week 152 (or until first full relapse). 
b. Placebo secukinumab 150 mg PFS: Two s.c. injections of placebo secukinumab 150 mg in 
PFS at randomization (Week 52) and thereafter every 4 weeks up to Week 152 (or until first full relapse).  
c. Secukinumab 300 mg PFS group: Two s.c. injections of secukinumab 150 mg in PFS at 
randomization (Week 52) and thereafter every 4 weeks up to Week 152 (or until first full relapse).  
d. Placebo secukinumab 300 mg PFS: Two s.c. injections of placebo secukinumab 150 mg in 
PFS at randomization (Week 52) and thereafter every 4 weeks up to Week 152 (or until first full relapse).  
Subjects in the randomized withdrawal period experiencing a first full relapse  (a loss of >50% 
of the maximum PASI gain compared to baselin e of the core study) at any scheduled visit after 
Week 52 during the randomized withdrawal period, will enter the treatment period . The dose 
regimen in treatment period ( loading dose and treatment thereafter ) is described in Table 3 -
1. 
Novartis  Confidential  Page 29  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
Table 3-1 Loading dose regimen at time of first full relapse* and treatment 
thereafter (treatment period) between Week 52 and Week 156  
Grou ps at time of randomization 
(Week 52)  Treatment period  
Loading dose regimen at time of first full relapse* 
and treatment thereafter  
Secukinumab 150 mg PFS  Two s.c. injections of placebo secukinumab 150 mg in 
PFS once weekly for three weeks (1 week, 2 weeks and 
3 weeks later). After 4 weeks following relapse the 
routine dosing with secukinumab 150 mg regimen every 
4 weeks dosing is continued thereafter.  
Placebo secukinumab 150 mg PFS  One s.c. injection of secukinumab 150 mg in PFS plus one s.c. injection of placebo secukinumab 150 mg in PFS once weekly for four weeks (at the visit where the relapse was diagnosed, 1 week, 2 weeks and 3 weeks later). After 4 weeks following relapse the routine dosing with secukinumab 150 mg regimen every 4 weeks dosing is continued thereafter.  
Secukinumab 300 mg PFS  Two s.c. injections of placebo secukinumab 150 mg in PFS once weekly for three weeks (1 week, 2 weeks and 3 weeks later). After 4 weeks following relapse the routine dosing with secukinumab 300 mg regimen every 4 weeks dosing is continued thereafter.  
Placebo secukinumab 300 mg PFS  Two s.c. injection of secukinumab 150 mg in PFS plus 
once weekly for four weeks (at the visit where the relapse 
was diagnosed, 1 week, 2 weeks and 3 weeks later). 
After 4 weeks following relapse the routine dosing with 
secukinumab 300 mg regimen every 4 weeks dosing is continued thereafter.  
*first full relapse: (a loss of >50% of the maximum PASI gain compared to baseline of the core study)  
Those subjects experiencing a second relapse will NOT  receive any loading dose regimen, 
regardless of the group they are randomized at Week 52 of the core studies. However, they 
will continue secukinumab s.c. 150 mg (one s.c. injection of secukinumab 150 mg in PFS with matching placebo ) or 300 mg (two s.c. injections of secukinumab 150 mg) dose given 
every four weeks through Week 152 and at Week 156 they will enter the open label period.  
Subjects who do not experience first full relapse will continue the treatment to which they were randomized at Week 52 through Week 152 at Week 156 they will enter the open label period.  
(iii) treatment period (double blind):  A placebo subject experiencing a relapse during the 
withdrawal period will receive four doses of secukinumab s.c. at weekly intervals followed by secukinumab s.c. every four weeks.  Subjects on secukinumab in the randomized withdrawal period who have a relapse, will be given four weekly doses of placebo s.c.  Following the loading doses subjects will continue on secukinumab treatm ent at 4 week intervals. Any subject, 
whether randomized to placebo or active treatment, will only be treated once with the weekly loading dose regimen. For subsequent relapses patients will continue on secukinumab at 4 week intervals. At Week 152 subjects  will receive the last treatment of the blinded treatment period. 
Week 156 will be the end of the treatment period (EoT). 
Novartis  Confidential  Page 30  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
(iv)  open label period:  The treatment will be unblinded at Week 156 and the subjects will  enter 
the open label period. During this period, the subjects will be given pre -filled syringes and 
instructed to perform self-injection at home every 4 weeks and return to the site every 12 or 16 weeks (see Table 6 -1 Assessment schedule). The  first open label dose will be given at the site 
at Week 156. Subjects on 150mg s.c may continue on 150mg s.c. and subjects on 300 mg s.c. will continue on 300 mg s.c secukinumab. Subjects who were on placebo during the randomized withdrawal period will start on secukinumab 150 mg s.c. or 300 mg s.c. if the investigator decides the subject would benefit from the higher dose. Placebo subjects who enter the open label period will be given once weekly s.c. injections of secukinumab for 4 consecutive weeks and then s.c. injections every 4 weeks. Any subject starting on secukinumab 150 mg may 
continue on 150 mg every 4 weeks or switch to 300 mg at Week 156 or any other regular site visit if the investigator decides the subject would benefit from the higher dose. Note: the Week 
244 visit will be the last scheduled visit at which the subjects will be allowed to switch to 300mg dose. Decreasing the dose from 300 mg to 150 mg is not allowed. For all subjects, who will not enter the open label period, Week 156 will be the EoT visit at which no treatment will be 
administered. After completing the Week 156 EoT visit, these subjects will enter the follow up period. For all subjects who enter the open label period, the last dose of the study medication will be given at Week  256. Week 260 is the end open label treatment period
. 
(v) follow-up period (for all subjects) : treatment free period (Week 26 4 to Week 268). 
(vi) follow -up 2 period: treatment free period for patients who prematurely discontinued 
treatment . All subjects w ho prematurely discontinue treatment should complete all assessment 
of Week 260 (end of treatment visit) and of the follow -up period visits (Weeks 264 and 268). 
Subsequently, adverse events and use of concomitant medication will be evaluated by the investi gator through telephone calls every 3 months for a duration of 4 years from the time 
when subject has been enrolled into CAIN457A2302E1 study  
 
For the subjects classified as partial responders at Week 52 the study consists 
of 4 or 5 periods  
(i) screening period: is the duration between signing the informed consent form (ICF) and 
randomization registered with IRT.  
(ii) treatment period (double blind): starting from the randomization visit at Week 52 continuing 
through Week 156 ,   subjects in the group of partial responders  who have been receiving s.c. 
secukinumab150 mg or 300 mg dose during the maintenance period of core studies will continue the same treatment dose in PFS (secukinumab s.c. 150 mg or 300 mg) that they were receiving at the time of completin g the maintenance period (Week 52) in the core study ( Figure 
3-1), i.e., a subject continuing secukinumab s.c. 150 mg will use one s.c. injection of secukinumab 150 mg in PFS plus s.c. injection of placebo secukinumab 150 mg in PFS at randomization (Week 52) and thereafter every 4 weeks until Week 152; and a subject continuing secukinumab s.c. 300 mg will use two s.c. injections of secukinumab 150 mg in PFS at randomization (Week 52) and thereafter every 4 weeks until Week 152. At Week 152 subjects will receive the last treatment of the blinded treatment period. Week 156 will be the end of the treatment period (EoT). 
Novartis  Confidential  Page 31  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
(iii) open label period: The first open label dose will be given at the site at Week 156. At Week 
156, the subjects will be given pre -filled syringes and starting Week 160, the subjects will be 
asked to perform self -injection at home every 4 weeks and return to the site every 12 or 16 
weeks (see Table 6 -1 Assessment schedule). Also, at regularly scheduled visits at the site, the 
subject receiving 150 mg s.c. may be switched to 300 mg s.c. if the subject and the PI agree that 
there would be a benefit from a higher dosage. The last visit a t which the subjects may be 
switched to the higher dosage is Week 244. For all subjects, who will not enter the open label period, Week 156 will be the EoT visit at which no treatment will be administered. After completing the Week 156 EoT visit, these subjects will enter the treatment- free follow up 
period. For all subjects who enter the open label period, the last dose of the study medication will be given at Week 256. Week 260 is the end open label treatment period
.  
(iv) follow -up period: treatment free period (Week 264 to Week 268). 
(v) follow -up 2 period: treatment free period for patients who prematurely discontinued 
treatment  
NOTE:  Partial responders DO NOT  participate in the randomized withdrawal and DO NOT  
receive any loading dose even if they experience a full relapse (a loss of >50% of the maximum PASI gain compared to baseline of the core study) 
Subjects on placebo treatment or etanercept in the maintenance phase of the core studies will 
not be eligible to enter this extension study, and will com plete follow -up visits in the core 
studies. 
Follow -up period (Week 26 4 to Week 268)  
The treatment -free follow -up period (no study treatment administered during follow -up period) 
includes visits at Week 264 (Follow-up visit F4, which is 4 w eeks after the Eo T/OL -EoT visit, 
and 8 weeks after last study treatment administration) and Week 268 (follow -up visit F8 [or 
End of follow -up {EOF}]), which is 8 weeks after the EoT/OL -EoT visit, and 12 weeks after 
the last study treatment administration.  
Follow -up 2 period  
Subjects who have prematurely discontinued treatment prior to the  end of treatment phase 
(Week 260), and completed the subsequent follow -up period visits (Weeks 264 and 268) should 
enter the treatment free follow -up 2 period. Follow -up 2 period cons ists of telephone calls every 
3 months and unplanned assessments e.g. physical examinations, vital signs and laboratory 
assessments at the site if investigator considers this necessary. The end of Follow -up 2 period 
(EOF2) for an individual subject will be  after 4 years from the time when subject has been 
enrolled into the CAIN457A2302E1 study ( Figure 3 -1).  
 
3.2 Rationale of study design 
The first two years (104 weeks), of this multicenter, double -blind, randomized withdrawal 
extension study is set up to collect the long -term efficacy, safety and tolerability of secukinumab 
Novartis  Confidential  Page 32  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
in either continuous or interrupted therapy (randomized withdrawal/treatment period). The 
second two years of the study is open label and primarily designed to collect additional safety 
data.  
Since interruptions of treatment for various reasons are common in chronic diseases such as psoriasis, the first two years of this extension study will investigate the effect of treatment interrupti on as well as re- treatment following treatment interruption in a “randomized 
withdrawal” design.  
In addition, the “randomized withdrawal” period will allow assessing whether continuation of treatment with secukinumab is of benefit to subjects after having been treated with secukinumab 
for up to 52 weeks, compared to stopping treatment with secukinumab. 
The concept of “randomized withdrawal” is in line with recommendations from the EMA as 
outlined in the guidelines for the development of drugs to treat psori asis 
(CHMP/EWP/2454/02), and with feedback received at the end -of-phase- II meetings with the 
FDA, the EMA, and the PMDA. 
Because a relapse can only reasonably be assessed if a subject has a response to start with, only 
subjects that have a PASI 75 at Week 52 of one of the core studies will be re -randomized into 
the randomized withdrawal period of this extension study. The “randomized withdrawal” period does not have a defined end. Instead, retreatment 
(including loa ding dose) will be initiated for each subject individually if at any scheduled visit 
a relapse is experienced. This is considered appropriate, since a subject not suffering from a relapse is not considered in need of active treatment at that time, and hence should not be exposed to treatment until the worsening of the disease (relapse). After two years any subjects on placebo in the randomized withdrawal arm will either be discontinued or started on secukinumab.  
Partial responders (i.e., subjects having a PASI  50 response, but not a PASI  75 response) are 
also allowed to enter the extension study; they will continue the treatment they received during 
the maintenance of the core study. This is based on the rationale that a subject could have been a responder during most of the core study, but suffered from a minor loss of response at Week 
52 (e.g., because of seasonal variation), and could still be regarded to benefit from continuous treatment with secukinumab. In addition, even for a subject responding to secukinumab only with a partial response, continuous treatment with secukinumab might still be the best available treatment option for this subject (e.g., due to intolerance or non- availability of other options). 
Therefore, at Week 52 of the core study, investigator and subject will perform an assessment of whether the subject is expected to benefit from inclusion in the extension study; if that assessment is positive, the subject is eligible to enter the extension study.  
In the last two years of the study during the open label period subjects on 150 mg s.c. will be allowed to switch to 300 mg s.c. at the discretion of the investigator. The switch will be allowed starting Week 156 and only during the scheduled visit. Once subjects switch into the higher dose, they will not be allowed to switch back to the lower dose. Also, subjects initially randomized to 300 mg s.c. will not be allowed to switch to 150 mg sc at any time during the study. Non-responders to secukinumab (i.e., subjects not having at least a PASI 50 response) at 
Novartis  Confidential  Page 33  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
Week  52 of the core studies are not eligible to enter the extension study, since they do not show 
a meaningful response to the active treatment.  
Subjects on placebo in the core studies until Week 52 are not eligible to enter the extension 
study because they have shown that their disease status is not in need of active treatment. Hence, 
there is no benefit expected for these subjects from entering the extension study. 
Subjects on etanercept in the core study (CAIN457A2303) until Week 52 are not  eligible to 
enter the extension study because the extension study has no objective that would justify 
comparison of secukinumab against an active comparator; instead, the main focus of the study objectives is to compare different secukinumab regimens agai nst each other. Since etanercept 
is an approved treatment in the countries where the study CAIN457A2303 is performed in, subjects can receive etanercept by prescription.  
3.3 Rationale of dose/regimen, duration of treatment 
The doses and regimens selected for secukinumab are projected to deliver high efficacy while at the same time ensuring subject safety. The proposal to continue treatment with s.c. doses of 150 mg and 300 mg administered every four weeks, as well as the additional treatment duration of 208 weeks (leading to an overall treatment period [core plus extension] of 260 weeks) is based on the need for efficacy and safety information during chronic treatment in subjects suffering from chronic plaque- type psoriasis.  
The rationale of the dose/regimen for  re-treatment after full relapse is supported by model- based 
considerations. These model -based predictions are subject to caveats and assumptions, but 
appear to provide plausible guidance. The predictions are considered as extrapolations, as they are made for regimens, time points, subject subsets and withdrawal/re -treatment patterns for 
which limited or no data is available, as they have not (or not in exactly this way) been studied so far (which is the nature of the current status of development of secukinumab in psoriasis). 
The inclusion of a randomized withdrawal treatment period will allow assessing time to relapse 
and frequency of rebound after cessation of treatment, compared to continuous treatment. This is in line with guidelines for the development  of drugs to treat psoriasis (CHMP/EWP/2454/02).  
The switch from the lyophilisate to the more convenient prefilled syringe is supported by the results of clinical study CAIN457A2106, which has shown that the exposure profiles of both formulations are virtually identical. This will also remove the need to have unblinded pharmacists involved in the study; these were necessary in the core studies to ensure the double -
blind. 
Model-based predictions in Figure 3 -2 suggest: 
• Subjects lose PASI  75 response after withdrawal at an approximate rate of 10% per month 
(see Figure 3 -2 left).  
Novartis  Confidential  Page 34  
Amendment Protocol v03 Clean  Protocol No. CAIN457A2302E1  
•Substantially less subjects show a full relapse, the predictions reaching 10% after four
months (see Figure 3 -2 right).
Figure 3-2 Model -based prediction of %  PASI  75 responders and % of subjects 
relapsing during a period of 6 months after either continuous 
treatment or of withdrawal (based on responders at Week 52)  
Model base exploration with high and unquantifiable uncertainty, thus no intervals are provided  
The use of loss of PASI 75 as primary objective is supported by results from study 
CAIN457A2211 wherein a loss of PASI 75 was observed during treatment -free maintenance 
periods in an increasing number of subjects over time (see Figure 3 -3).  
Figure 3-3 Observed loss of PASI 75 response during “fixed interval” 
maintenance treatment of study CAIN457 A2211 
AIN457: Secukinumab 
AIN457 150 mg  
 AIN457 150 mg  
Novartis  Confidential  Page 35  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
During each 4- week interval, an additional approximately 10% of subjects lost PASI 75 
response; twelve weeks after last administration of secukinumab, 33.3% of the subjects had lost 
PASI 75 response. While data from Week 16 is not available from that study, since subjects were retreated after 12 weeks, it can reasonably be expected that around 40% of subjects will have lost PASI 75 response 16 weeks after last administration of secukinumab. This pe rcentage 
is large enough to allow for a meaningful comparison as outlined in the primary endpoint of extension study CAIN457A2302E1. 
It is understood that the trough level of secukinumab after 12 weeks of treatment in study 
CAIN457A2211 might be somewhat different than at Week 52 of studies CAIN457A2302 and CAIN457A2303, but this is expected to have no major impact on the time to loss of PASI 75. 
3.4 Rationale for choice of comparator 
Use of placebo (i.e. withdrawal of active therapy) in a randomized withdrawal  study design 
until retreatment is necessary (in the case of psoriasis a “relapse”, i.e., loss of >50% of the previous gain in PASI reduction) is in accordance with Health Authority Guidelines on Choice of Control Group in Clinical Trials (e.g., CPMP/ICH/364/96 2001). This is also be supported 
by the fact that all subjects will have the opportunity to receive active treatment after experiencing a relapse. All patients in the last two years of the trial will be on active treatment.  
 
3.5 Purpose and timing of interim analyses/design adaptations 
A PEA will be conducted when all subjects have completed Week 68 of treatment. Data from this PEA will be provided for the Day 120 update during the process of market authorization. Of note, the study procedures will not be modified as a result of this PEA. 
Additional interim analyses may be conducted at various time points for publications or health 
authority requests. The study procedures will not be modified as a result of these i nterim 
analyses.  
When  each subject of the study  has either completed treatment period and follow -up period or  
discontinued treatment and completed follow -up and follow -up 2 periods (last telephone 
contact)  or withdrawn from study the final database lock occurs .  
3.6 Risks and benefits 
Non-clinical studies have not shown any impediment to using secukinumab either intravenously 
(i.v.) or s.c. in man. Study CAIN457A2302E1 will use secukinumab drug substance solution in PFS; this formulation has already been used  in a biocomparability study, CAIN457A2106, and 
has shown almost identical properties compared to the lyophilisate. 
Secukinumab is expected to show good to excellent efficacy in the treatment of psoriasis, as 
outlined in Section 1.1. 
At the time of Amendment 1, over 6200 subjects with a variety of autoimmune diseases have 
received secukinumab. Details of the risk and benefits are outlined in the current version of the Investigator Brochure. 
Novartis  Confidential  Page 36  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
 
The risk to subjects in this trial will be minimized by compliance with the inclusion/exclusion 
criteria, proper study design and close clinical monitoring. In the extension study CAIN457A2302E1, all subjects will receive active treatment, either from 
the start of the study, or a fter they have experienced a relapse. To ensure a double- blind design, 
some subjects will receive  placebo up to 156 weeks or until the first relapse, according to the group to which they were randomized. 
All quality, non -clinical pharmacology and toxicolo gy data, as well as the available clinical  
efficacy and safety data, are considered sufficient to expect a positive benefit / risk ratio for the 
treatment of psoriasis with secukinumab, and therefore to initiate extension study CAIN457A2302E1. 
4 Population 
All subjects from study CAIN457A2302 and CAIN457A2303 (and potentially rolling over from other secukinumab phase III studies) who were randomized to and have been receiving secukinumab treatment during the maintenance period of the core studies (e.g., CAIN 457A2302 
or CAIN457A2303), and who completed the full study treatment period (52 weeks) in core studies and who have at least a partial response at Week 52 of the core studies, and who comply with the inclusion and exclusion criteria of this study, are eli gible to enter into this extension 
study.  
Assuming drop-outs rates of 5% for secukinumab and 15% for placebo in the induction phases of the core studies, 15% drop- out rate in the maintenance phases of the core studies, and a PASI 
50 response rate of about 95%, it is aimed that a total of about 1,220 subjects will be eligible to 
enter this extension study across approximately 300 sites worldwide.  
4.1 Inclusion criteria 
Subjects eligible for inclusion in this study have to fulfill all of the following criteria:  
1. Subjects who completed the full study treatment period (52 weeks) in the core studies (e.g., CAIN457A2302 or CAIN457A2303), and after randomization have been receiving secukinumab treatment during the maintenance phase of the core studies, and show at least a partial response (PASI 50 or better) at Week 52 of the core studies. 
2. Written informed consent must be obtained before any assessment is performed. 
3. For inclusion in the open label period, written informed consent for protocol amendment1 must be obtained.  
4. For inclusion in the open label period, the subject must be deemed to benefit from the study drug based on the investigator's clinical judgment.  
4.2 Exclusion criteria 
Subjects fulfilling any of the following criteria are NOT  eligible for inclusion in this  study:  
1. A protocol deviation in the core studies which according to the investigator will prevent the meaningful analysis of the extension study for the individual subject 
Novartis  Confidential  Page 37  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
2. Ongoing use of prohibited psoriasis or non-psoriasis treatments. Time period to use of 
prohibited treatments in the core study detailed in the protocol have to be adhered to Table 5-1. 
3. Subjects not expected to benefit from participation in the extension study, as assessed by the subject and investigator 
4. Subjects expected to be exposed to an undue safety risk if participating in the study 
5. Current severe progressive or uncontrolled disease which in the judgment of the investigator renders the subject unsuitable for the study 
6. Plans f or administration of live vaccines during the study period 
7. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (>10 mIU/mL)  
8. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unwilling to use effective contraception during the study and for 16 weeks after stopping treatment. Effective contraception is defined as either: 
• Barrier method: Condom or occlusive cap (diaphragm or cervical/vault caps) with 
spermicide (where available). Spermicides alone are not a barrier method of contraception and should not be used alone  
The following methods are considered more effective than the barrier method and are also 
acceptable:  
• Total abstinence: When this is in line with the preferred and usual lifestyle of the subject (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception) 
• Female sterilization: have had a surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment  
• Male partner sterilization (at least 6 months prior to screening). For female subjects on the study, the vasectomized male partner should be the sole partner for that subject  
• Use of  established oral, injected or implanted hormonal methods of contraception, 
intrauterine device (IUD) or intrauterine system (IUS)  
NOTE: Women are considered post -menopausal and not of child bearing potential if they have 
had: 
• 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms) or  
• six months of spontaneous amenorrhea with serum FSH levels >40 mIU/mL [for US only: and estradiol <20 pg/mL] or 
• surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment is she considered not of child bearing potential. 
Novartis  Confidential  Page 38  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
No additional exclusion criteria may be applied by the investigator, in order to ensure that the 
study population will be representative of all eligible subjects.  
5 Treatment  
5.1 Protocol requested treatment  
5.1.1  Investigational treatment  
Novartis will provide the following study treatments  
1. Investigational treatment: Secukinumab 150 mg/1 mL solution for injection is provided in PFS for s.c. administration. The 150 mg/1 mL solution in PFS is used for both s.c.150 mg dose (1 syringe) and s.c. 300 mg dose (2 syringes). For blinding purpose the subject in 150 mg treatment group will also receive one syringe of placebo 150 mg during the blinded period of the study 
2. Reference therapy: Placebo secukinumab 150 mg/1 mL solution for injection is provided in PFS for s.c. administration. It contains a mixture of inactive excipients, matching the composition of secukinumab 150 mg. 
Secukinumab 150 mg/1 
mL and placebo secukinumab 150 mg/1 mL is labeled as AIN457 150 
mg/1 mL/Placebo.  
5.1.2  Additional study treatme nt 
No additional treatment beyond investigational treatment is requested for this study.  
5.2 Treatment groups 
The study treatment will be provided in individual boxes that contain secukinumab or placebo PFS sealed in a plastic wrapper. Each study treatment box  consists of actual PFS and a safety 
device type X100L . The safety syringe is aided with a needle guard 
system that will aid protection from accidental needle sticks.  
For the subjects classified as PASI 75 responders at Week 52 the study consists of 5 or 6 periods  
(i) screening period: is the duration between signing the informed consent form (ICF) and randomization registered with IRT.  
(ii) randomized withdrawal period: the duration of randomized withdrawal period for each subject i s different i.e., starting from Week 52 until the subject experiences the relapse or up to 
Week 156 (see Section 3.1 on Study Design  for additional details) 
(iii) treatment period: starting from the visit in randomized withdrawal period at which a subject experiences relapse and continuing through Week 156. During the Week 152 visit subject will 
receive the last blinded dose of the study treatment. At Week 156 the subjects will enter the 
open label period. For subject who will not move to the open label period, the Week 156 visit is the EoT. For subjects who will move to the open label period, the Week 156 visit will be the first open label treatment.  

Novartis  Confidential  Page 39  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
(iv) open label period: starting from Week 156 to Week 260 all subjects will be on open label 
secukinumab. The subjects will receive the last dose of the study medication at Week 256.  The Week 260 visit is the OL –EoT.  
(v) follow -up period (for all subjec ts): treatment free period (Week 264 to Week 268) 
(vi) follow -up 2 period: treatment free period only for patients who prematurely discontinued 
treatment . All subjects who prematurely discontinue treatment should complete all assessment 
of Week 260 (end of  treatment visit) and of the follow -up period visits (Weeks 264 and 268). 
Subsequently, adverse events and use of concomitant medication will be evaluated by the investigator through telephone calls every 3 months for a duration of 4 years from the time when subject has been enrolled into CAIN457A2302E1 study. 
  
For the subjects classified as partial responders at Week 52 the study consists 
of 4 or 5 periods  
(i) screening period: is the duration between signing the informed consent form (ICF) and 
randomizat ion registered with IRT.  
(ii) treatment period: starting from the randomization visit at Week 52 continuing through Week 
156 the subjects will receive secukinumab s.c. every 4 weeks  at the dose which they were originally assigned  in the core study.  During the Week 152 visit subject will receive the 
last blinded dose of the study treatment. At Week 156 the subjects will enter the open label period. For subject who will not move to the open label period, the Week 156 visit is the EoT. For subjects who will  move to the open label period, the Week 156 visit will be the 
first open label treatment.  
(iii) open label period:  starting from Week 156 to Week 260 all subjects will be on open label 
secukinumab. The subjects will receive the last dose of the study med ication at Week 256.  
The Week 260 visit is the OL –EoT.  
(iv) follow -up period (for all subjects) : treatment free period (Week 26 4 to Week 268). 
(v) follow -up 2 period: treatment free period only for patients who prematurely discontinued 
treatment . All sub jects who prematurely discontinue treatment should complete all 
assessment of Week 260 (end of treatment visit) and of the follow -up period visits (Weeks 
264 and 268). Subsequently, adverse events and use of concomitant medication will be evaluated by the investigator through telephone calls every 3 months for a duration of 4 
years from the time when subject has been enrolled into CAIN457A2302E1 study. 
 NOTE: Partial responders DO NOT  participate in the randomized withdrawal and DO NOT  
receive any loading dose even if they experience a full relapse (a loss  of >50% of the maximum 
PASI gain compared to baseline of the core study)  
5.3 Treatment assignment, randomization 
At the end of Week 52 visit in the core study (e.g., Visit 21 of study CAIN457A2302 or CAIN457A2303) the investigator will complete Week 52 assessments, enter the PASI response into the eCRF and register the completion of Week 52 visit in the IRT.  
Novartis  Confidential  Page 40  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
The IRT system will search (after the PASI response status has been updated by in vestigator or 
designee in IRT) the databases of core studies at Week 52 to identify whether or not the subject 
has been on secukinumab (s.c. 150 mg or 300 mg) at the time of completion of Week 52 visit in the core study. 
For the subjects classified as PASI  75 responders at Week 52  
Once investigator or designee has entered Week 52 PASI response status in the IRT and also 
registered with IRT the completion of Week 52 visit of the core studies on secukinumab treatment, a subject will be eligible for randomization in the extension study. 
The Week 52 visit in the core study is the randomization visit for CAIN457A2302E1 (extension 
study).  
Based on the fulfillment of inclusion/exclusion criteria by the subject and IRT notification from the database of core studies at Week 52 (explained above), the investigator (or designee) will call the IRT set up of extension study (CAIN457A2302E1).The IRT can be contacted via the Interactive Voice Response System (IVRS) or Interactive Web Response System (IWRS). The IRT will assi gn a randomization number to the subject, which will be used to link the subject 
to a treatment groups (secukinumab 150 mg or placebo secukinumab 150 mg or secukinumab 300 mg or placebo secukinumab 300 mg) and will specify a unique medication number for th e 
first package of investigational treatment to be dispensed to the subject. The randomization number will not be communicated to the caller or any of the site staff members.  
The randomization numbers at Week 52 will be generated using the following procedure to ensure that treatment assignment is unbiased and concealed from subjects and investigator staff. A subject randomization list will be produced by the IRT provider using a validated system that automates the random assignment of subject numbers to randomization numbers. These randomization numbers are linked to the different treatment groups, which in turn are linked to medication numbers. A separate medication list will be produced by or under the responsibility of Novartis Drug Supply Management usi ng a validated system that automates the random 
assignment of medication numbers to packs containing the investigational drug(s).  
Randomization will be stratified by geographical region and by body weight (< 90 kg or ≥90 
kg) collected at Week 52.  
The rand omization scheme for subjects will be reviewed and approved by a member of the 
Audit Readiness, Validation & Randomization Group within IIS IA&R (Integrated Information Science Integrated Analytics and Reporting). 
For the subjects classified as partial responders at Week 52  
The same randomization process used for PASI 75 responders at Week 52 will be followed for 
partial responders at Week 52. 
A randomization numbers will be assigned to partial responders. These randomization numbers 
will be linked to the two different treatment groups (secukinumab 150 mg, secukinumab 300 
mg) which correspond to the treatment received in the core studies. Partial responders at Week 52 will then continue to receive the treatment they were assigned in the core studies.  
Novartis  Confidential  Page 41  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
5.4 Treatment blinding  
Subjects, investigator staff, persons performing the assessments, and data analysts will remain 
blind to the identity of the study treatment from the time of randomization until final database lock, using the following methods: 
1. Randomization data are kept strictly confidential until the time of unblinding, and will not 
be accessible by anyone else involved in the study.  
2. The identity of the treatments will be concealed by the use of investigational treatment that are all identical in packaging,  schedule of administration and appearance.  
In order to maintain blind in this study, placebo is used.  
During the double blinded period of the study,  unblinding will only occur in the case of subject 
emergencies ( see Section 5.5.10), at the time of the primary endpoint at Week 68, and when the 
patients enter the open label part of the study at Week 156After all subjects complete Week 68, designated sponsor team members will be unblinded, whereas the subjects, investigator staff, and persons performing the assessments will remain blinded until Week 156  to ensure reliable efficacy and safety measures. At Week 156 all subjects will enter the open label period and subjects, investigator staff, and persons  performing the visit assessments will become 
unblinded.  
In case the results of the core study are published while the extension study is ongoing, the data 
will be published in groups only, with limited ability to unblind individual subjects (The exceptio n to this might be rare safety events that, if occurring in only one treatment group, 
would allow unblinding of the affected subjects). However, since this would be relevant to only a very small group of subjects, if any, no impact on the overall validity of the extension study is expected. Nevertheless, the integrity of the primary endpoint is not affected since no unblinding with respect to placebo in the randomized withdrawal is performed. 
5.5 Treating the subject 
5.5.1  Subject numbering 
Subjects in the extension study CAIN457A2302E1 will be assigned a uniquely identified subject number for the extension study. The uniquely identified subject number is composed by the study identifier (CAIN457A2302E1), 4- digit study site identifier assigned by Novartis for 
the site  in the core study and a 3- digit sequential number assigned by the investigator in the core 
study (e.g.,CAIN457A2302E1_1234001). The last 7 digits of the unique subject identifier will remain the same for the subject in the core study and the extension study.  
Subjects will be given the ICF during one of the scheduled visits of the core study (e.g., Week 48 [Visit 20] or at earlier visit in study CAIN457A2302 or CAIN457A2303) to read and 
understand for their participation in this extension study. Subjects will NOT  be signing the 
ICF before  completing the assessments on Week 52 visit of the core study (e.g., Visit 21 of the 
study CAIN457A2302 or CAIN457A2303) and unless the investigator has entered t he Week 
52 PASI response in the IRT, and registered the completion of the core study Week 52 visit in the IRT, and the IRT confirms that the subject was on secukinumab in the core study. 
Novartis  Confidential  Page 42  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
Subjects who are eligible (as decided by the investigator or designee) based on the 
inclusion/exclusion criteria and IRT notification (see Section 5.3)  will be asked to sign the ICF. 
In order to enter data for extension study CAIN457A2302E1, the site is to select a CRF book, add the subject’s number from the core study (e.g., CAIN457A2302 or CAIN457A2303) and update the electronic data capturing (EDC) system with this number. 
If the subject fails to be treated for any reason, the IRT must be notified immediately and the 
reason for not being treated will be entered on the Screening Epoch Disposition electronic Case 
Repot Form (eCRF). The data or information regarding demography for the subjects not randomized will be available as a listing from the core study databases. The Inclusion/Exclusion eCRF for the extension study CAIN457A2302E1 is to be completed for the subjects not randomized (after signing the ICF), along with Adverse Events eCRF (for study CAIN457A2302E1) for any SAE that occurred after signing the ICF. If a subject fails to be treated in the extension study, the subject completes the follow -up visits in the respective core 
study.  
5.5.2   Dispensing the investigational treatment  
Each study site will be supplied by Novartis with study treatment in packaging of identical appearance.  
The boxes containing single prefilled syringes with study treatment solution (secukinumab or placebo secukinumab) has a 2- part label. A unique medication number is printed on each part 
of this label. The blinded qualified study site staff personal will identify the study treatment box to dispense to the subject by contacting the IRT and obtaining the medication number(s). Immediately before dispensing the box containing PFS with study treatment, blinded qualified study site staff personal will d etach the outer part of the label from the boxes and affix it to the 
source document (Drug Label Form) for that subject’s unique subject number.  
At Week 160, and once the home administration is operationally set up, subjects will be 
expected to perform ho me administrations at the protocol specified time points. For these cases 
the investigator will dispense, via IRT, an appropriate number of investigational treatment packages for home administrations and detach outer part of the label from the packaging. T he 
subjects will record the date(s) of administration at home and will return the used medication and packaging at their next visit to the site. Subjects will be asked to return all unused medication and packaging the latest at the completion of the study or at the time of discontinuation of the investigational treatment. Site staff will record in the appropriate documents the dates of the administration.  Detailed instructions will be provided separately. 
5.5.3  Storage of investigational treatment  
Single PFS wi th study treatment solution (secukinumab or placebo) will be packed in individual 
boxes. The boxes must be received by a designated person at the study site, handled and stored 
safely and properly, and kept in a secured location to which only the investigator and designees have access. Upon receipt, PFS should be stored according to the instructions specified on the treatment labels. PFS and/or clinical supplies are to be dispensed and administered only in accordance with the protocol. 
Novartis  Confidential  Page 43  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
The boxes containing the PFS with study treatment solution should be kept at 2 to 8°C (36°F 
and 46°F). PFS should be protected from direct exposure to light. Therefore the PFS must be stored protected from light. 
The medication label will be in the local language and will comply with the legal requirements 
of each country. The label will include storage conditions for the investigational treatment but no information about the subject except for the medication number.  
The investigator (or designee) must maintain an accurate reco rd of the shipment and dispensing 
of study treatment in a drug accountability log. Monitoring of drug accountability will be performed by the field monitor during site visits and at the completion of the trial.  
At the conclusion of the study, and as appropriate during the course of the study, the investigator (or designee) will return all used and unused study treatment, packaging, drug labels, and a copy of the completed drug accountability log to the Novartis monitor or to the Novartis address provided i n the investigator folder at each site.  
5.5.4  Instructions for prescribing and taking study treatment  
Each subject will require two boxes of syringe set (PFS) per dose throughout the study. 
• One secukinumab 150 mg PFS and one placebo secukinumab PFS (150 mg group) OR  
• Two secukinumab 150 mg PFS (300 mg group) OR   
• Two placebo secukinumab 150 mg PFS (Placebo group)  
All study treatment kits assigned to the subject during the study will be record ed/databased in 
the IRT.  
The syringes with the ready -to-use study treatment solution (PFS) will be provided by the site 
staff during the study visit.  
All doses of study treatment (secukinumab and/or placebo secukinumab) will be injected at the study site a fter Week 52 assessments for study CAIN457A2302 or CAIN457A2303 have been 
completed. It is preferred that subject should self-inject, however, if a subject is not able or not willing to self -administer, administration will be performed by study site staff.  
The first study treatment administration (self or by study site staff) will occur at randomization visit (Week 52) after inclusion/exclusion criteria have been confirmed, the core study scheduled assessments at Week 52 have been performed, and the schedul ed blood samples have been 
drawn, and only after the investigator has registered the completion of the core study with IRT.  
For subjects willing to self -inject, the first use at randomization visit (Week 52) will take place 
under guidance and the supervision of one site staff member. At the randomization visit (Week 52) the subjects will be instructed through the site staff by walking them through the “Instructions For Use” on how to self -inject via PFS. At the following visits, subjects will 
receive the PF S at the study site.  
NOTE: The needle cover of the syringe contains dry rubber (latex), which should not be handled by persons sensitive to this substance. 
Novartis  Confidential  Page 44  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
At study visits when pre -dose blood samples have to be drawn ( Table 6 -1), the study treatment 
will be injected only after the blood samples have been taken. 
At each visit, all study assessments, including the completion of health -related quality of life 
(HRQoL) tools (as reported by subjects), should be completed prior to the injection of study 
treatment.  
After Week 256, no further study treatment will be administered. In addition, no study treatment is administered during the follow -up period and follow-up 2 period. 
All dates, times of injections, mode of injection (self or by study site staff) during the study must be recorded on the Dosage Administration Record eCRF. Immediately before dispensing the package for injection, investigator staff will detach the outer part of the label from the packaging  and affix it to the source document (Drug Label Form) for that subject’s unique 
subject number.  
Administration  
Secukinumab solution for s.c. injection or placebo secukinumab solution (active or placebo, 
respectively) will be provided in PFS. 
The study treatment solution must be injected in non- affected areas of the skin. If possible, 
throughout the trial administer the study treatment to one of the following body regions, 
changing the injection site from visit to visit: right thigh, left thigh, right stomach, left stomach, upper outer arm (when assisted by attendant).  
Prior to administration the boxes containing the PFS with study treatment solution should be allowed to come to room temperature unopened for about 20 minutes before administration. Used PF S should be disposed immediately after use in a sharps container OR according to the 
regulatory needs of the respective countries. 
Home administration 
During the open label period, after approximately two years of study of self -administered 
treatment under  the supervision of site staff during the double blinded period, subjects will be 
expected to self -administer the PFS at home when they are not visiting the site for any other 
trial related procedures.  
The subjects will be allowed to self -administer treatment at home (starting Week 160) only if 
they have exhibited correct use for self -administering the PFS at the site.  
It is important that during the self -administration period at home, subjects contact the 
investigator / site staff in case they are experiencing any AE/SAEs or have any concerns.  
If the subject is not able / not confident to self -administer the PFS, he/she should visit the site 
every 4 weeks during the open label treatment period, according to the visit schedule, and either 
the staff or the s ubject will administer the study drug. However, during those visits no other 
assessments will be performed.  
5.5.5  Permitted dose adjustments and interruptions of study treatment   
No dose adjustments or interruptions are permitted. 
Novartis  Confidential  Page 45  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
5.5.6  Rescue medication  
Rescue medi cation is not permitted in this study.  
5.5.7  Concomitant treatment  
The investigator must consider the baseline and ongoing concomitant treatment in core study 
(e.g., CAIN457A2302 or CAIN457A2303) Concomitant medications eCRF, Surgeries and Medical Procedures eCRF, and Prior Psoriasis Therapy eCRF page at Week 52 randomization visit before a subject enters the extension study (CAIN457A2302E1). The Week 52 concomitant medication data for the extension study will be the same as the baseline concomitant medication  data of the core study for all three eCRFs. All concomitant medications 
that were ongoing from the core study at the Week 52 randomization visit will be followed in the extension on the applicable Concomitant medications eCRF or Surgeries and Medical Procedures eCRF.  
The investigator should instruct the subject to notify the study site about any new treatments he/she takes after the start of the extension study treatment. All medications and significant non -
drug therapies (including physical therapy and blood transfusions) administered after the subject starts study treatment must be listed on the Concomitant medications eCRF or the Surgeries and Medical Procedures eCRF. Start date, end date, dose, unit, frequency, route and reason for administration or cha nge are to be recorded.  
5.5.8  Prohibited Treatment  
 Use of any treatments displayed in Table 5 -1 that could confound the efficacy is NOT  allowed 
for any indication during the study excluding the treatment -free follow -up 2 period. 
The investigator should instruct the subject to notify the study site about any new treatments 
he/she takes after the start of the study treatment. All prohibited medications and significant non-drug therapies administered after the subject starts treatment with study treatment must be 
listed on the Concomitant medications eCRF or the Surgeries and Medical Procedures eCRF.  
Table 5-1 Prohibited treatment  
Prohibited treatments†,‡  Time period before randomization visit at 
Week 52  
Alefacept, briakinumab, efalizumab, ustekinumab  6 months  
Biological immunomodulating agents other than 
above (e.g., adalimumab, etanercept, infliximab)  12 weeks  
Other systemic immunomodulating treatments§ (e.g., 
MTX, cyclosporine A, corticosteroids§, 
cyclophosphamide)  4 weeks  
Other systemic psoriasis treatments* (e.g., retinoids, 
fumarates)  4 weeks  
Photochemotherapy (e.g., PUVA)  4 weeks  
Phototherapy (e.g., UVA, UVB)  2 weeks  
Novartis  Confidential  Page 46  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
Prohibited treatments†,‡  Time period before randomization visit at 
Week 52  
Use of opical treatment ** that is likely to impact signs 
and symptoms of  psoriasis for >14 days* (e.g., corticosteroids [CS], vitamin D analogues,  pimecrolimus, retinoids, salicylvaseline, salicylic acid, lactic acid,  tacrolimus, tar, urea, α -hydroxy or fruit 
acids)  2 weeks  
Live virus vaccinations during extension study  6 weeks  
Any investigational treatment or participation in any 
interventional clinical trial during extension trial  4 weeks or 5 half -lives (whichever Is longer)  
†If a subject inadvertently used the prohibited treatment in core study (e.g., CAIN457A2302 or CAIN457A2303) without undue 
safety risk till completion of Week 52, he/she must have completed the time period as defined in the table above. Subjects who 
have not completed an adequate time period (table above) will not be eligible for the current extension study.  
‡In case of undue safety risk for the subject, the subject should discontinue study treatment at the discretion of the investi gator. If 
the subject received a live virus vaccination during the study, the subject must discontinue study treatment. 
§Inhalative CS with only a topical effect (e.g., to treat asthma) are not considered “ systemic immunomodulating treatments” and 
are therefore acceptable as co- treatment.  
*There is no restriction on the use of anti -histamines or the use of corticosteroids in the eye or ear 
** Topical corticosteroid (CS) treatment, or use of other topical treatment that is likely to impact signs and symptoms of psori asis, 
is not allowed for treatment of psoriasis, except when applied to the face, scalp, and/or genitoanal area for ≤14 consecutive days. 
Topical corticosteroid use for indications other than psoriasis not on an area affected with psoriasis is allowed for ≤14 consecuti ve 
days.  
5.5.9  Discontinuation of study treatment and premature subject withdrawal  
Subjects may voluntarily withdraw from the study for any reason at any time. They may be 
considered withdrawn if they state an intention to withdraw, fail to return for visits, or become lost to follow -up for any other reason. 
Discontinuation from a treatment period  
If premature withdrawal occurs for any reason, the investigator must make every effort to determine the primary reason for a subject’s premature withdrawal from the study and record this information on the end of randomized withdrawal /treatment  EoT eCRF (Week 156) or if the subject is discontinued during the open label period on the OL-EoT eCRF (Week 260). 
Study treatment must be discontinued under the following circumstances:  
• Withdrawal of informed consent 
• Emergence of the following AEs: the AEs that in the judgment of the investigator, taking 
into account the subject’s overall status, prevent the subject from continuing participation in the study (for example, sepsis or serious infection).
  
• Any laboratory abnormalities that in the judgment of the investigator, taking into  consideration the subject’s overall status, prevents the subject from continuing participation in the study.  
• Pregnancy (see sections 6.5.6 and 7.3) 
• Use of prohibited treatment as per recommendations in Table 5 -1. 
• Any other
 protocol deviation that results in a significant risk to the subject’s safety  
Novartis  Confidential  Page 47  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
In addition to the requirements mentioned above for study treatment discontinuation, the 
investigator should discontinue study treatment for a given subject if, on balance, he/ she 
believes that continuation would be detrimental to the subject’s well- being.  
Subjects discontinued from study treatment should NOT  be considered withdrawn from the 
study. If the subject discontinues treatment during the randomized withdrawal/double bli nded 
treatment or open label period then  the site staff must record the date and primary reason for stopping study treatment on the appropriate EoT eCRF  
When subject discontinues the study treatment, then assessments described at Week 260 should 
be perfo rmed approximately four weeks after their last dose of secukinumab and the subject 
should then return per appropriate schedule for assessments described at Week 264 and Week 268 (follow-up period). Subsequently, these subjects should enter the follow-up 2 period.  
The investigator must contact the IRT when the subject completes the assessments on Week 
156 and/or Week 260 due to study treatment discontinuation. 
Study treatment must  be discontinued after emergency unblinding. 
The appropriate personnel from the study site and Novartis will assess whether study treatment 
should be discontinued for any subject whose treatment code has been broken inadvertently for any reason.  
See Section 6  for the required ass essments of these subjects after study treatment 
discontinuation. 
Withdrawal from a treatment- free period  
If premature withdrawal occurs for any reason in the treatment -free follow -up period, or follow -
up 2 period, the investigator must make every effort t o determine the primary reason for a 
subject’s premature withdrawal from the study and record this information on the applicable 
end of study period eCRF (follow -up period completion eCRF [Week 268]) or Follow -up 2 
period completion eCRF, respectively).  
Subjects who withdraw from follow -up 2 period should perform the Week 268 assessments (see 
Table 6 -1). 
Premature subject withdrawal  
Subjects who state an intention to withdraw prematurely from the study will be asked to return 
for follow -up visits to assess safety after cessation of therapy and, if willing, to assess duration 
of effect (e.g., rebound assessments). If the subject returns to the study site to have his/her follow- up visits (Week 264 and Week 268), the investigator will follow the study treatment 
discontinuation procedures. 
The investigator must contact the IRT when the subject completes the assessments of  the EoT/ 
OL-EoT visit to register the subject’s early completion of the study due to subject withdrawal.  
Novartis  Confidential  Page 48  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
Lost to follow -up 
For subjects who are lost to follow -up (i.e. those subjects whose status is unclear because they 
fail to appear for study visits without stating an intention to withdraw), the investigator should 
show “due diligence” by documenting in the source documents steps taken to contact the subject, e.g., dates of telephone calls, registered letters, etc.  
5.5.10  Emergency unblinding of treatment assignment  
Emergency breaking of the assigned treatment code should only be undertaken when it is 
essential to treat the subject safely and efficaciously. Most often, study treatment discontinuation and knowledge of the possible treatment assignments are sufficient to treat a study subject who presents with an emergency condition. Emergency code breaks are performed 
using the IRT. When the investigator or his/her blinded designee contacts the system to unblind a subject, he/she must provide the requested subject identifying information and the date, time, and reason for unblinding. The investigator will then receive details of the treatment for the specified subject and a fax confirming this information. The system will automatically inform the Novartis monitor for the study site and the Clinical Trial Head that the code has been broken.  
It is the  investigator’s responsibility to ensure that there is a procedure in place to allow access 
to the IRT access codes in case of emergency. The investigator (or designee) will inform the subject how to contact his/her backup in cases of emergency when he/she  is unavailable. The 
protocol number, study treatment name if available, subject number, and instructions for contacting the local Novartis CPO (or any entity to which it has delegated responsibility for emergency code breaks) to the subject in case an emergency treatment code break is required at a time when the investigator and backup are unavailable.  
Study treatment for the study subject must be discontinued after emergency unblinding. 
Subjects who are prematurely unblinded will be discontinued from the study treatment and 
requested to return for the applicable end of period visit (end of randomized withdrawal period visit or the end of the treatment period visit [Week 260], two follow-up visits at Week 264 and Week 268 and follow-up 2 period. 
5.5.11  Study completion and post -study treatment  
A subject entering into the extension study CAIN457A2302E1 will be said to have completed 
the extension study after he/she has completed all visits and assessments as defined in Table 6 -
1 and received all doses of the study treatment in accordance with the protocol. 
The extension study as a whole will be considered complete when eligible subjects rolled over 
from the core study (e.g., CAIN457A2302 or CAIN457A2303)  have com pleted as per protocol 
the visits and assessments defined in Table 6 -1 for the extension study CAIN457A2302E1. 
The investigator also must provide follow -up medical care for all subjects who are prematur ely 
withdrawn from the study, or must refer them for appropriate ongoing care. 
Subjects who complete the extension study CAIN457A2302E1 may be eligible to enter another 
planned extension trial. 
Novartis  Confidential  Page 49  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
5.5.12  Early study termination  
The study can be terminated at any time for any reason by Novartis . Should this be necessary, 
the subject should be seen as soon as possible and properly managed as described in Section 6  
for a prematurely withdrawn subject. The investigator may be informed of additional 
procedures to be followed in order to ensure that adequate consideration is given to the protection of the subject’s interests. The investigator will be responsible for informing Institutional Review Boards (IRBs) and/or Independent Ethics Committees (IECs) of the early termination of the trial.  
6 Visit schedule and assessments  
Table 6 -1 lists all of the assessments and indicates with an “x” when the visits are performed . 
Subjects should be seen for all visits on the designated day within the allowed “visit window” specified below or as close to it as possible.  
During the treatment periods, subjects may be seen at an unscheduled visit, e.g., if they experience deteriorati on of psoriasis, or AEs that in the opinion of the investigator need 
intervention or repeated laboratory testing. During these unscheduled visits, study treatment will NOT be administered.  
A visit window of “±5” will be allowed for Week 52 to Week 256 during randomized withdrawal and/or treatment period, the open label period or the follow -up period. Patients are 
expected to adhere as close as possible to the visit schedule.  
Relapse visits (R1, R2, and R3) will have visit window of “±2” days. Time schedule of relapse visits cannot be anticipated and will be different for each subject experiencing first full relapse (a loss of >50% of the maximum PASI gain compared to baseline of the core study). 
Subjects who discontinue study treatment will continue to be followed for safety assessments. 
They are not considered withdrawn from the study. 
Subjects who discontinue study treatment before completing the study, and those who 
prematurely withdraw from the study for any reason should be scheduled for a study visi t 4 
weeks after their last study treatment administration, at which time all the assessments listed for EoT (Week 260) will  be performed (see Section 5.5.10). Subjects will return to the study 
site for further assessments as indicated under the follow-up visits (Week 264 and 268). 
Only subjects who prematurely discontinued study treatment should enter follow -up 2 period 
after completion of follow -up visits (Weeks 264 and 268). Follow -up 2 period includes  
telephone calls every 3 months until 4 years from the time subjects have been enrolled into CAIN457A2302E1 as well as potential unplanned assessments e.g physical examinations, vital signs and laboratory assessments during this time.   
If they refuse to return for the needed assessments in the follow -up period or are unable to do 
so, every effort should be made to contact them or a knowledgeable informant by telephone or by sending appropriate correspondence (i.e. certified letter) immediately. At this cont act, the 
safety (e.g., potential occurrence of AE or SAE) and the primary reason for a subject’s premature withdrawal should be determined. 
Novartis  Confidential  Page 50  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
At a minimum, subjects will be contacted for safety evaluations during the 12 weeks following 
the last dose of study  treatment, including final contact at the 12 week point. Documentation of 
attempts to contact the subject should be recorded in the subject record. 
Order of assessments:  
• Subject to complete HRQoL tools prior to any investigator assessments. Order of HRQoL  
tools is: DLQI©, EQ-5D©, HAQ©-DI (subjects with history of PsA at baseline of core 
study). Note: EQ-5D© will not be performed during the open label period. 
• Investigator to complete investigator assessments. Order is:  
1. IGA 
2. PASI  
• All remaining study visit pr ocedures (e.g., laboratory sample collection, vital signs 
measurements) must be completed prior to study treatment dosing.  
• Enter PASI and IGA assessments into eCRFs BEFORE contacting IRT at any scheduled 
visit during the double blind period 
• Contact IRT to register the subject visit.  
• Syringe set boxes of study treatment (secukinumab or placebo secukinumab) are made available to the subjects for self -injection or administration by study site staff  
Novartis  Confidential  Page 51  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
Table 6-1 Assessment schedule  
 *Randomized withdrawal and/or treatment period  (Year 1 and 2)  
Unscheduled  
visit 
Relapse 1 (R1)b 
Relapse 2 (R2) b 
Relapse 3 (R3) b 
Week (Relative to Baseline 
of core studies)  52a 56 60 64 68 72 76 80 84 88 92 96 100 104 108 112 116 120 124 128 132 136 140 144 148 152 156 
Visit window (in days)  ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 
Day 365 393 421 449 477 505 533 561 589 617 645 673 701 729 757 785 813 841 869 897 925 953 981 1009  1037  1065  1093  
Visit at the site  x x x x x x x x x x x x x x x x x x x x x x x x x x x     
Obtain informed consent x                          x18     
Inclusion/exclusion criteria1 x                          x     
Demography and other 
characteristics2 x                               
Physical examination x3 x x x x x x x x x x x x x x x x x x x x x x x x x x     
Height4 x                               
Weight  x3 x      x      x   x   x       x     
Vital signs  x3 x x x x x x x x x x x x x x x x x x x x x x x x x x x    
Urinalysis (local)  x3   x   x   x    x   x   x   x    x     
Lab analysis:  
chemistry and 
hematology5 x3 x x x x x x x x x x x x x x x x x x x x x x x x x x x    
Fasting Labs:  
lipid panel5 x3   x   x   x    x   x   x   x    x     
Fasting Labs:  
plasma glucose4,5 x3   x   x   x    x   x   x   x    x     
Serum pregnancy test5  x6             x             x x7    
Urine pregnancy test 
(local)6 x3   x   x   x    x   x   x   x    x     
ECG (standard 12 lead)  x3   x   x   x    x   x   x   x    x     
Blood sample for IG8 x3      x       x      x   x    x x9    

Novartis  Confidential  Page 52  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
 *Randomized withdrawal and/or treatment period  (Year 1 and 2)  
Unscheduled  
visit 
Relapse 1 (R1)b 
Relapse 2 (R2) b 
Relapse 3 (R3) b 
Week (Relative to Baseline 
of core studies)  52a 56 60 64 68 72 76 80 84 88 92 96 100 104 108 112 116 120 124 128 132 136 140 144 148 152 156 
Visit window (in days)  ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 
Day 365 393 421 449 477 505 533 561 589 617 645 673 701 729 757 785 813 841 869 897 925 953 981 1009  1037  1065  1093  
Blood sample for PK8 x3,10 x x x10 x x x10 x x x10 x x x x10 x x x10 x x x10 x x x10 x x x x10 x9    
PASI  x3 x x x x x x x x x x x x x x x x x x x x x x x x x x x x11 x11 x11 
Assessment of rebound 
symptoms12 x3 x x x x x x x x x x x x x x x x x x x x x x x x x x x    
IGA mod  2011  x3 x x x x x x x x x x x x x x x x x x x x x x x x x x x x11 x11 x11 
EQ-5D© x3   x   x   x    x   x   x   x    x     
DLQI© x3   x   x   x    x   x   x   x    x     
HAQ -DI©14 x3   x   x   x    x   x   x   x    x     
Adverse event (AE) assessment  x3 x x x x x x x x x x x x x x x x x x x x x x x x x x x x11 x11 x11 
Serious AE assessment  x3 x x x x x x x x x x x x x x x x x x x x x x x x x x x x11 x11 x11 
Concomitant medications  x3 x x x x x x x x x x x x x x x x x x x x x x x x x x x x11 x11 x11 
Randomization via IRT15 x                               
Administration of  study 
treatment  x x x x x x x x x x x x x x x x x x x x x x x x x x x 20  x x x 
Complete PASI and IGA eCRF 
and call IRT  x x x x x x x x x x x x x x x x x x x x x x x x x x x  x x x 
End of screening phase 
completion eCRF  x                               
End of blinded randomized 
withdrawal/ treatment period 
(EoT): submit  EoT period 
completion  eCRF and call IRT                            
x     
End of follow -up period: submit 
follow -up period completion  
eCRF                             
    
Call to subjects from study -
coordinator reminding the visit  x x x x x x x x x x x x x x x x x x x x x x x x x x x  x x x 
 
 
 
Novartis  Confidential  Page 53  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
 Open Label  treatment period (Year 3 and 4)  
Unscheduled  visits 21 Follow -up 
period  Follow -
up 2 
period  
Week (Relative to 
Baseline of core 
studies)  160 164 168 172 176 180 184 188 192 196 200 204 208 212 216 220 224 228 232 236 240 244 248 252 256 260 264 
/F4 268  /F8 Phone 
call every three 
months  
Visit window (in days)  ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5  
Day 1121  1149  1177  1205  1233  1261  1289  1317  1345  1373  1401  1429  1457  1485  1513  1541  1569  1597  1625  1653  1681  1709  1737  1765  1793  1821  1849  1877   
Visit at the sites19   x   x   x    x   x   x   x    x  x x  
Home administration17 x x  x x  x x  x x x  x x  x x  x x  x x x      
Physical examination    x   x   x    x   x   x   x    x  x x  
Height4                               
Weight                           x   x  
Vital signs    x   x   x    x   x   x   x    x x x x  
Urinalysis (local)                           x   x  
Lab analysis:  
chemistry including 
amylase and lipase 
and hematology5      x       x      x       x x x x  
Fasting Labs:  
lipid panel5                          x   x  
Fasting Labs:  
plasma glucose 4,5      x       x      x       x   x  
Serum pregnancy test5                           x x7    
Urine pregnancy test 
(local)6      x       x      x       x   x  

Novartis  Confidential  Page 54  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
 Open Label  treatment period (Year 3 and 4)  
Unscheduled  visits 21 Follow -up 
period  Follow -
up 2 
period  
Week (Relative to 
Baseline of core 
studies)  160 164 168 172 176 180 184 188 192 196 200 204 208 212 216 220 224 228 232 236 240 244 248 252 256 260 264 
/F4 268  /F8 Phone 
call every three 
months  
Visit window (in days)  ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5  
Day 1121  1149  1177  1205  1233  1261  1289  1317  1345  1373  1401  1429  1457  1485  1513  1541  1569  1597  1625  1653  1681  1709  1737  1765  1793  1821  1849  1877   
ECG (standard 12 
lead)       x       x      x       x   x  
Blood sample for IG8                          x x9  x  
Blood sample for PK8                          x10 x9  x10  
PASI    x   x   x    x   x   x   x    x x x x  
Assessment of 
rebound symptoms12                          x  x13 x  
IGA mod  2011    x   x   x    x   x   x   x    x x x x  
DLQI©       x       x      x       x     
HAQ -DI©14      x       x      x   x    x     
Adverse event (AE) 
assessment    x   x   x    x   x   x   x    x x x x x 
Serious AE 
assessment    x   x   x    x   x   x   x    x x x x x 
Concomitant 
medications    x   x   x    x   x   x   x    x x x x x 
Complete PASI and 
IGA eCRF and call IRT    x   x   x    x   x   x   x    x     
Administration of study 
treatment  x x x x x x x x x x x x x x x x x x x x x x x x x      
Novartis  Confidential  Page 55  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
 Open Label  treatment period (Year 3 and 4)  
Unscheduled  visits 21 Follow -up 
period  Follow -
up 2 
period  
Week (Relative to 
Baseline of core 
studies)  160 164 168 172 176 180 184 188 192 196 200 204 208 212 216 220 224 228 232 236 240 244 248 252 256 260 264 
/F4 268  /F8 Phone 
call every three 
months  
Visit window (in days)  ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5  
Day 1121  1149  1177  1205  1233  1261  1289  1317  1345  1373  1401  1429  1457  1485  1513  1541  1569  1597  1625  1653  1681  1709  1737  1765  1793  1821  1849  1877   
End of open label 
treatment period (OL-
EoT): submit  EoT 
period completion  
eCRF and call IRT                           x     
End of follow -up 
period: submit follow -
up period completion  
eCRF                              x  
End of follow -up 2 
period: submit follow -
up 2 period completion  
eCRF                               x 
Call to subjects from 
study -coordinator 
reminding about the 
visit   x   x   x    x   x   x   x    x  x x  
 
eCRF:electronic case report form; PK:pharmacokinetics; IG:immunogenicity  
*For subjects classified as PASI 75 responders at Week 52 of the core study (e.g., CAIN457A2302 or CAIN457A2303), the study consists of 5 or 6  
periods – screening period, randomized withdrawal period, treatment period, open label period (OL) ,follow -up period and follow -up 2 period; For 
subjects classified as partial responders at Week 52 of the core study (e.g., CAIN457A2302 or CAIN457A2303), the study consists of 4 or 5 periods – 
screening period, treatment period, open label period ,follow -up period and follow -up 2 period; The screening period will be the duration between signing 
the informed consent form and randomization registered with Interactive Response Technology (IRT). 
Novartis  Confidential  Page 56  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
aSubjects would be randomized on the same day (Week 52) which is end of maintenance period of the core study (e.g.,CAIN457A2302 or 
CAIN457A2303).  
bRelapse visits  (R1, R2 and R3) will have visit window of ±2 days.  
1These assessments are supported by and are stored with the source documentation. However, data regarding to which inclusion/exclusion criteria are 
not met are captured on the Inclusion/Exclusion Screen eCRF.  
2 Investigator must consider the baseline data of core study (e.g., CAIN457A2302 or CAIN457A2303) Demography eCRF, Smoking History eCRF, 
Cardiovascular History eCRF, Medical History eCRF, Psoriasis History eCRF, Psoriatic Arthritis History eCRF, and Prior Psoriasis Therapy eCRF at 
Week 52 before a subject enters the extension study. The data for these assessments at Week 52 visit for extension study will  be same as the baseline 
data of the core study. 
3 Data for these assessments already have been collected at end of maintenance visit (Week 52) of the core study (e.g. CAIN457A2302 or 
CAIN457A2303). The data on the eCRFs for these assessments in extension study at Week 52 will be same as end of maintenance visit (Week 52) of the core study. AE and SAE data will be again collected after completion of core study Week 52 visit assessments. PASI response status from Week 52 records of the core study to be entered in the IRT by the unblinded site personal from core study for randomization in the extension study.  
4 The data for this assessment to be collected freshly at Week 52 (randomization).  
5 Samples will be shipped to and analyzed by the central laboratory.  
6To be done for female subjects for whom local urine pregnancy test at end of maintenance period (Week 52) of core study is positive. The study drug 
treatment should not be given until the results confirm that subject is not pregnant.  
7If there is a positive urine pregnancy test, study treatment must be withheld and a serum pregnancy test must be done at the same visit.  
8Samples will be shipped by the sites and stored by the central laboratory. Samples will be shipped to reference laboratories for analysis. Each PK and 
IG sample is to be collected pre- dose.  
9An unscheduled IG and or PK sample is collec ted only to replace an IG or PK sample not taken at a regular scheduled visit.  
10 The PK blood sampling at these scheduled visits must be collected for all subjects. PK blood collections at other time points  are “event driven” i.e., PK 
blood samples will only be collected in case of relapse.    
11Relapse visits (R1 to R3) are the visits in the treatment period. The time schedule for these 3 relapse visits will be different for each subject. A subject 
will make these relapse visits after a full relapse (a loss of >50% of the maximum PASI gain compared to baseline of the core study) occurred on the 
previous scheduled visit.  PASI and IGA mod 2011 assessments, and data on AEs, SAEs and concomitant medications will be collected during these 3 
relapse visits. 12Rebound assessments to be done during the randomized withdrawal period as well as during the treatment period.  Note, the duration of 
randomized withdrawal period until the subject experiences the relapse is different for each subject and does not have definite end.  
13Unscheduled rebound assessment only to be done for an unscheduled visit that occurs during the follow- up period.  
14 Only for subjects with psoriatic arthritis (PsA) recorded on the Psoriatic Arthritis History eCRF during screening in core st udy.  
Novartis  Confidential  Page 57  
Amendment Protocol v03 Clean   Protocol No. CAIN457A2302E1  
 
15 The investigator must complete the core study Week 52 assessments, enter the PASI response on the eCRF and register the completion of Week 52 
visit in the IRT system of core study. Based on the fulfillment of inclusion/exclusion criteria by the subject and IRT notification from the database of core 
studies at Week 52, the investigator must call the IRT set up of extension study (CAIN457A2302E1).  
16 PASI and other assessments must be completed, entered into the eCRFs before calling the IRT at each site visit from Week 56 to Week 256. For 
Week 52 refer to footnote 14.  
17Patients who cannot self -administer medication at home may come to the site for administration of the medication.  
18 Informed consent for the extension amendment may  be obtained any time prior to the first open label study exposure.  
19 The visits at the sites are scheduled every 12 weeks, except for the visits between Week 192 - Week 208 and between Week 244 – Week 260, which 
are scheduled every 16 weeks.  
20  Dosing only to be performed if the subject  enters the open label treatment period. First treatment of the open label period will be administered at 
Week 156 once all assessments of Visit Week156 are performed, the call to IRT is done and the subject  has signed the revised informed consent for amendment 1. Placebo subjects who enter the open label period will be given once weekly s.c. injections of secukinumab for 4 consecutive weeks and 
then s.c. injections every 4 weeks. Any subject starting on secukinumab 150 mg may continue on 150 mg every 4 weeks or switch to 300 mg at Week 
156 or any other regular site visit if the investigator decides the subject would benefit from the higher dose.21 During follow -up 2 period unscheduled 
visits may include unplanned assessments like physical examinations, vital signs and laboratory assessments if investigator considers this necessary.
Novartis  Confidential  Page 58  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
6.1 Information to be collected on screening failures  
All subjects who have signed an informed consent but who cannot or chose not to enter the 
randomized withdrawal or treatment period will be considered screen failures. The IRT must be called within 2 days and the reason for not being randomized will be entered on the Screening Phase Disposition electronic Case Report Form (eCRF). The Screening visit date, the 
Demography eCRF, Informed Consent eCRF, Inclusion/Exclusion Criteria eCRF must be 
completed. If the subject has any SAE in the screening peri od (between signing the ICF and 
being randomized), the Adverse Event eCRF and a paper SAE form must be completed.  
If a subject fails to be treated in the extension study, the subject completes the follow -up visits 
in the respective core study.  
The Withdrawal of Consent eCRF should be completed if consent was withdrawn during the 
screening period before the subject was randomized. The Death eCRF should be completed in the case of a death.  
6.2 Subject demographics/other baseline characteristics  
6.2.1  Subject demographics  
The investigator must consider the baseline data of the core study (e.g., CAIN457A2302 or CAIN457A2303) Demography eCRF at Week 52 randomization visit before a subject enters the extension study.  
Subject demographic and baseline characteristics data t o be collected on all subjects include: 
date of birth, age, sex, race, ethnicity, source of subject referral, prior and concomitant 
medications (relative to core studies), and relevant medical history/current medical condition present before signing informed consent. The demographic data of the extension study will be the same as the demographic data of the core study.  
6.2.2  Other baseline characteristics  
The investigator must consider the baseline data of the core study (e.g., CAIN457A2302 or CAIN457A2303) Smoking History eCRF, Cardiovascular History eCRF, Medical History 
eCRF, Psoriasis History eCRF, Psoriatic Arthritis History eCRF, and Prior Psoriasis Therapy eCRF at Week 52 randomization visit before a subject enters the extension study. The data on these eCRFs in the extension study will be same as the data entered for these eCRFs in the core 
study.  
6.3 Treatment exposure and compliance 
All doses of study treatment administration will be recorded on the appropriate Dosage Administration Record eCRF page. 
Com pliance will be assessed by Novartis study personnel at each visit using box counts and 
information provided by the investigator and/or site staff. 
Novartis  Confidential  Page 59  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
6.4 Efficacy 
All efficacy assessments should be performed prior to administration of study treatment.  
It is important to perform the IGA before the PASI,  as the knowledge of PASI scoring can 
potentially influence how the evaluator scores the IGA. Therefore, the following order should 
be applied when performing the efficacy assessments during study visits: 
• Investigator’s Global Assessment (IGA mod 2011; scale from 0 – 4)  
• Psoriasis Area and Severity Index (PASI; score from 0 – 72) 
• Rebound assessment 
6.4.1  Investigator’s global assessment (IGA mod 2011)  
IGA mod 2011 will be conducted for overall psoriatic disease as  indicated in Table 6 -1. It is 
recommended that the same evaluator conducts the assessment throughout the study whenever 
possible. 
The IGA mod 2011 rating scale for overall psoriatic disease is shown in Table 6 -2. 
The IGA mod 2011 scale has been used in the core studies (e.g., CAIN457A2302 and 
CAIN457A2303), and in secukinumab phase II studies in collaboration with Health Authorities, in particular th e FDA.  
The IGA mod 2011 used in this study is static, i.e., it refers exclusively to the subject’s disease state at the time of the assessments, and does not attempt a comparison with any of the subject’s previous disease states, whether at baseline of cor e study or at a previous visit.  
The IGA mod 2011 score will be recorded in the eCRF. 
Table 6-2 The IGA mod 2011 rating scale  
Score  Short 
description Detailed description  
0 Clear  No signs of psoriasis. Post -inflammatory hyperpigmentation may be 
present.  
1 Almost clear  Normal to pink coloration of lesions; no thickening; no to minimal  
focal scaling  
2 Mild Pink to light red coloration; just detectable to mild thickening;  
predominantly fine scaling  
3 Moderate  Dull bright red, clearly distinguishable erythema; clearly 
distinguishable to moderate thickening; moderate scaling  
4 Severe  Bright to deep dark red coloration; severe thickening with hard edges; 
severe / coarse scal ing covering almost all or all lesions  
Note: Involvement of nails is not part of the assessment.  
Based on this scale, a subject will be considered as IGA 0 or 1 responder if the subject achieves 
a score of 0 or 1 and improved by at least 2 points on the IGA scale compared to baseline.  
6.4.2  Assessment of psoriasis area and severity index (PASI)  
The investigator or qualified designee will complete the PASI assessment as indicated in Table 
6-1. Whenever possible, the same evaluator should perform this assessment at all visits.  
Novartis  Confidential  Page 60  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
A PASI score ( Fredriksson and Pettersson 1978, Weisman et al 2003 , Gottlieb et al 2005 ) will 
be derived as indicated in Table 6 -3. The head, trunk, upper limbs and lower limbs are assessed 
separately for erythema, thickening (plaque elevation, induration), and scaling (desquamation). 
The average degree of severity of each sign in each of the four body regions is assigned a score of 0-4. The area covered by lesions on each body region is estimated as a percentage of the total 
area of that particular body region. Furth er practical details help the assessment:  
1. The neck is assessed as part of the head.  
2. The axillae and groin are assessed as part of the trunk.  
3. The buttocks are assessed as part of the lower limbs. 
4. When scoring the severity of erythema, scales should not be removed. 
Table 6-3 The PASI scoring system  
Body region  Erythema  (E)  Thickening (plaque 
elevation, induration, I)  Scaling(desquamation) 
(D) Area score  
(based on 
true 
area %, A)* 
Head (H) †  0=none  
1=slight  
2=moderate  
3=severe  
4=very severe  0=none  
1=slight  
2=moderate  
3=severe  
4=very severe  0=none  
1=slight  
2=moderate  
3=severe  
4=very severe  0 = 0%  
1 = 1 -9% 
2 = 10- 29% 
3 = 30- 49% 
4 = 50- 69% 
5 = 70- 89% 
6 = 90 -100%  
Trunk (T) ‡ 0=none  
1=slight  
2=moderate  
3=severe  
4=very severe  0=none  
1=slight  
2=moderate  
3=severe  
4=very severe  0=none  
1=slight  
2=moderate  
3=severe  
4=very severe  0 = 0%  
1 = 1 -9% 
2 = 10- 29% 
3 = 30- 49% 
4 = 50- 69% 
5 = 70- 89% 
6 = 90 -100%  
Upper limbs 
(U) 0=none  
1=slight  
2=moderate  
3=severe  
4=very severe  0=none  
1=slight  
2=moderate  
3=severe  
4=very severe  0=none  
1=slight  
2=moderate  
3=severe  
4=very severe  0 = 0%  
1 = 1 -9% 
2 = 10- 29% 
3 = 30- 49% 
4 = 50- 69% 
5 = 70- 89% 
6 = 90 -100%  
Lower limbs 
(L) § 
 0=none  
1=slight  
2=moderate  
3=severe  
4=very severe  0=none  
1=slight  
2=moderate  
3=severe  
4=very severe  0=none  
1=slight  
2=moderate  
3=severe  
4=very severe  0 = 0%  
1 = 1 -9% 
2 = 10- 29% 
3 = 30- 49% 
4 = 50- 69% 
5 = 70- 89% 
6 = 90 -100%  
*Percentage (not score) of body region (not whole body) affected will be entered in the eCRF  
†Neck is assessed as part of the Head (H) body region.  
‡Axillae and groin are assessed as part of the Trunk (T) body region.  
§Buttocks are assessed as part of the Lower limbs (L) body region.  
Because the head and neck, upper limbs, trunk and lower limbs correspond to approximately 
10%, 20%, 30% and 40% of the body surface area, respectively, the PASI score is calculated 
using the formula: 
Novartis  Confidential  Page 61  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
PASI = 0.1(E H+IH+D H)AH + 0.2(E U+IU+D U)AU + 0.3(E T+IT+D T)AT + 0.4(E L+IL+D L)AL 
The keys for the letters are provided in Table 6 -3. 
PASI scores can range from a lower value of 0, corresponding to no signs of psoriasis, up to a 
theoretic maximum of 72.0. 
The investigator is only responsible for collecting the components or scoring signs and total 
regional area. PASI calculations, including changes over time will be done by Novartis via the 
PASI Score eCRF. At Week 52, the investigator or qualified designee should ensure that all the information required for the PASI calculation was entered into the PASI Score eCRF at Week 52 and that a PASI score is available prior to contacting IRT. The Investigator or qualified designee will enter the Week 52 PASI score into the IRT system at Week 52 before subject receives the study treatment.  
Based on PASI at Week 52, a subject to be eligible must be either a PASI 75 responder or partial responder according to the definitions stated below:  
• PASI 75 responders: subjects with PASI 75 response (subjects achieving ≥ 75% 
improvement [reduction] in PASI score compared to baseline of the core study) at Week 52  
• Partial responders: subjects with PASI 50 response (subjects achieving ≥ 50% improvement [reduction] in PASI score compared to baseline of the core study, but not achieving a PASI 75 response) at Week 52  
During the study, at each visit, the PASI score will be calculated and response will be classified according to the definitions from CHMP guidelines for psoriasis CHMP/EWP/2454/ 02 2004  
• PASI 75 response:  subjects achieving ≥ 75% improvement (reduction) in PASI score 
compared to baseline of the core study are defined as PASI 75 responders 
• PASI 50 response:  subjects achieving ≥ 50% improvement (reduction) in PASI score 
compared to baseline of the core study are defined as PASI 50 responders 
• PASI 90 response:  subjects achieving ≥ 90% improvement (reduction) in PASI score 
compared to baseline of the core study are defined as PASI 90 responders  
• PASI 100 response/remission:  complete clearing of psoriasis (PASI=0)  
• Relapse:  when the achieved maximal PASI improvement from baseline of core study is 
reduced by >50% 
For subjects in PASI 75 responder group and entering the randomized withdrawal period, PASI 
response status at each visit (after Week 52 visit) will be calculated to determine if subject will enter the treatment period. PASI at the visit will be compared to the PASI baseline of the core study to assess if su bject meets criteria for " first full relapse " (loss of >50% of maximum PASI 
gain compared to PASI baseline of the core study). Sites will have to enter relapse assessment into eCRFs and update the IRT at each visit in randomized withdrawal period. Subjects  with 
first full relapse then stop randomized withdrawal period and enter treatment period.  
6.4.3  Assessment of rebound  
Rebound of disease will be assessed as indicated in Table 6 -1.  
Novartis  Confidential  Page 62  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
In addition to the asse ssment of PASI, the investigator will assess whether new pustular 
psoriasis, or new erythrodermic psoriasis, or more inflammatory psoriasis occurred (yes/no). 
Definitions related to rebound 
• Rebound: A Subject experiences a rebound, if PASI increases to > 1 25% of baseline 
(where baseline is the PASI at the randomization of the core study) PASI, or if new 
pustular psoriasis, or new erythrodermic psoriasis, or more inflammatory psoriasis occurs within 8 weeks after the last dose of study treatment has been adm inistered.  
6.4.4  Appropriateness of efficacy assessments  
The PASI score, the assessment of the severity of the psoriasis symptoms and the extent to which the subject’s body area is affected by the disease, is considered acceptable by Health Authorities ( CHMP/EWP/2454/02 2004) to assess efficacy in conjunction with IGA mod 2011. 
6.5 Safety  
All blood draws and safety assessments should be done prior to study treatment administration. Appropriate safety assessments (e.g., evaluation of AEs and SAEs including injection site 
reactions) should be repeated after the dose is administered. 
• Evaluation of all AEs and SAEs including injection site reactions  
• Physical examination  
• Vital signs  
• Laboratory assessments  
• Hematology  
• Clinical chemistry  
• Urinalysis  
• Immunogenicity (IG; assessment of anti-secukinumab antibody development) 
• ECG  
• Pregnancy and assessments of fertility  
See Table 6 -1  
6.5.1  Physical examination  
A physical examina tion, including general appearance, skin, neck, eyes, ears, nose, throat, 
lungs, heart, abdomen, back, lymph nodes, extremities, vascular and neurological systems will 
be performed as indicated in Table 6-1. 
 If possible, assessments for an individual subject should be performed by the same member of 
the study site staff throughout the study. Information for all physical examinations must be included in the source documentation at the 
study site. Significant findings that are present prior to the signing of the informed consent form will have been already entered during core study in the Medical History screen on the subject’s 
eCRF. Significant findings made after signing informed consent which meet the definition of 
an AE must be recorded on the Adverse Event screen of the subject’s eCRF (see Section 7 ). 
Novartis  Confidential  Page 63  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
6.5.2  Vital signs  
Vital signs (including blood pressure and pulse measurements) will be assessed at every 
scheduled visit as indicated in Table 6 -1.  
After the subject has been sitting for five minutes, with back supported and both feet placed on the floor, systolic and diastolic blood pressure will be measured twice (measurements separated 
by 1 to 2 minutes) using a validated device, with an appropriately sized cuff. In case the cuff sizes available are not large enough for the subject's arm circumference, a sphygmomanometer with an appropriately sized cuff may  be used ( Mancia et al 2007 ). On the Vital Signs eCRF, the 
average of the two measurements will be entered. If possible, assessments should be performed by the same study site staff member throughout th e study.  
Normal blood pressure will be defined as a systolic pressure of 90 to <120 mmHg, and a diastolic blood pressure of 60 to <80 mmHg under the measurement conditions outlined above. Notable blood pressure will be hypertension (systolic ≥140 mmHg and/ or diastolic ≥ 90 mmHg) 
or hypotension (systolic <90 mmHg and/or diastolic <60 mmHg). A blood pressure indicative of prehypertension (systolic 120 to < 140 mmHg and/or diastolic 80 to < 90 mmHg) will not be regarded as notable ( Chobanian et al 2003). A normal pulse rate will be defined as a rate of 60 
to 100 beats per minute under the measurement conditions outlined above. Notable pulse rates are a rate below 60 bpm (bradycardia) or above 100 bpm (tachyc ardia).  
Whether action needs to be taken to address notable vital signs will be decided by the investigator, taking into account the overall status of the subject. No specific action is foreseen as part of the study protocol. 
6.5.3  Height and weight  
Height and body weight will be measured as listed in Table 6 -1. Height and body weight will 
be measured in indoor clothing, but without shoes. If possible, body weight assessments should 
be performed by the same s tudy site staff member and using the same scale throughout the 
study. The body weight recorded at Week 52 will be used to stratify the subject population for randomization at Week 52. 
6.5.4  Laboratory evaluations  
Subjects should avoid smoking within the hour preceding the blood draws. A central laboratory 
will be used for analysis of all specimens listed below, unless noted otherwise. Details on the collections, shipment of samples and reporting of results by the central laboratory are provided to investigators in the laboratory manual. Refer the Laboratory Manual for identification of 
laboratory reference range values and the schema for notification of site staff and Novartis for out of range values.  
Appendix 1 shows the extended laboratory ranges that are considered clinically notable.  
Whether action needs to be taken to address notable laboratory values will be decided by the investigator, taking into account the overall status of the subject. No specific action is foreseen as part of the study protocol. 
Novartis  Confidential  Page 64  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
Hematology  
Hemoglobin, hematocrit, red blood cell count, white blood cell count with differential 
(neutrophils including bands, lymphocytes, monocytes, eosinophils, basophils) and platelet count will be measured at all scheduled study visits, within the visit window specified in Table 
6-1. 
Clinical chemistry  
Serum chemistries will include urea, creatinine, total bilirubin, AST (SGOT), ALT (SGPT), 
GGT, alkaline phosphatase, sodium, potassium, bicarbonate, calcium, phosphorous, total protein, albumin, uric acid, amylase and lipase.  Serum chemistries will be mea sured at all 
scheduled study visits within the visit window specified in Table 6 -1.
 
Local urinalysis 
Dipsticks will be provided by the central laboratory to the study sites for local urinalysis 
assessme nts. The sites will record the results in the appropriate eCRF page for each subject. 
Standard dipstick measurements for specific gravity, protein, glucose, pH, blood, urine blood dipstick (non- hemolyzed), urine blood dipstick (hemolyzed), bilirubin, ketones and WBC will 
be done at scheduled visits as indicated in Table 6 -1. 
Immunogenecity (IG)  
Blood samples for IG (anti -secukinumab antibodies) will be taken pre -dose at the scheduled 
timepoints as indica ted in Table 6 -1 and Appendix 2, Table 13 -2. Blood samples (approximately 
2 mL) will be collec ted into serum separator tubes (SST). The blood sample will be allowed to 
clot over a minimum of 30 minutes at room temperature prior to harvesting of the serum. The serum will be obtained by centrifugation at approximately 2500 revolutions per minute (rpm ) 
for 10 minutes. 
Serum samples will be placed on ice, split into 2 aliquots (labeled plain barrier polypropylene 
tubes) and then stored (within 30 minutes of collection) at approximately -70°C to -20°C prior 
to shipment on dry ice to the central laborator y. Shipment of stored aliquots from the site to the 
central lab should be on a monthly basis. To the extent possible, the site should send each aliquot to the central laboratory separately. If a study site does not have the facility to store aliquots at the conditions specified, then they will maintain the sample on dry ice at the site and ship on 
dry ice on the day of collection. The central lab will ship one aliquot of the samples on dry ice to the analytical laboratory. The remaining aliquots must be kept at the central lab as a backup sample. Remaining samples will only be disposed of after approval by the Clinical Trial Head (typically 6 to 12 months after the clinical study report [CSR] is published). 
All blood samples will be taken by direct venipuncture. The actual sample collection date and 
exact time of collection will be entered on the Blood collection for IG eCRF or the Unscheduled blood collection for IG eCRF, as appropriate. Sampling problems will be noted in the ‘Reason sample not taken’ sectio n of the eCRF. 
A laboratory manual will be provided by the central laboratory with detailed information on sample collection, sample handling and shipment. 
Novartis  Confidential  Page 65  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
Tubes and labels will be provided by the central laboratory with study/sample type and sample 
number preprinted on the label. 
Further details on labeling of the IG samples can be found in Appendix 3, Section 13.3.2. 
6.5.5  Electrocardiogram (ECG)  
A standard 12- lead ECG will be performed as indicated in Table 6 -1. At each visit when an 
ECG is done, the investigator must review and initial the tracing. The tracing must then be 
stored with the subj ect's source documents.  
All ECGs must be performed on the ECG machines provided to the study site. All ECGs will be independently reviewed by a central reader. Instructions for the collection and transmission of the ECGs to the independent reviewer will be provided in the ECG investigator manual. 
Even though there is no exclusion criterion specifically based on the ECG, clinically significant 
findings from the ECG assessment made at Week 52 of the core study must be discussed with the Novartis Medical Monitor prior to enrolling the subject in the extension study. 
If the ECG findings are clinically relevant and would prevent the subject from participating in 
the study (taking into account the subject's overall status as well as the medication profile), the subject should not receive study treatment.  
6.5.6  Pregnancy and assessments of fertility  
Before entering the extension study, the investigator must consider the results of serum β- hCG 
test already performed on all women of child -bearing potential at the time of e ntering the core 
studies (e.g., CAIN457A2302 and CAIN457A2303). 
All women of child -bearing potential who are eligible to participate in this extension study will 
have a local urine pregnancy test as indicated in Table 6 -1. If positive, they will undergo a 
serum pregnancy evaluation conducted at the central laboratory Any woman whose resulting pregnancy test is positive (based on serum β- hCG as defined by 
the central laboratory) at the randomization visit Week 52 will have to discontinue from this 
extension study and return to the follow-up assessments in the core study. A positive urine pregnancy test during the treatment periods of the study requires immediate 
interruption of study treatment until serum β-hCG is performed and found to be negative. If the 
serum β -hCG test is positive, the subject must be discontinued from the trial (see Section 5.5.10) 
6.5.7  Appropriateness of safety measurements  
The safety measures used in this study are reliable and relevant standard measures for a biologic immunomodulating agent in psoriasis.  
6.6 Other assessments  
These includes (as indicated in Table 6 -1) 
• Waist circumference and hip circumference  
• Fasting laboratory evaluations,  
• HRQoL assessments such as 
Novartis  Confidential  Page 66  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
1. DLQI© 
2. EQ-5D© 
3. HAQ©-DI (subjects with PsA at baseline of the core study)  
• PK assessments will be done as indicated in Table 6 -1.  
  
Note: EQ -5D assessments will not be performed during the open label period. 
6.6.1  Waist circumference and hip circumference 
Waist and hip circumference (cm o r inches) will be measured twice and recorded in the source 
documentation by the investigator (or designee) at scheduled visits as indicated in Table 6 -1. 
The average of the two measurements will be recorded in the eCRF. Waist/hip circumference 
ratio will be calculated from the waist and hip circumference measurements. Waist and hip circumference will be measured as follows ( WHO Document, 1988, Lohman TG, 1988).  
The subject should stand with weight evenly balanced on both feet 25- 30 cm apart. Mark the 
level of the lowest rib margin with a marker pen, palpate the iliac crest in the mid -axillary line 
and mark this level on the skin as well. Apply an elastic tape (e.g., a narrow string of silk covered elastic rubber band) horizontally midway between the lowest rib margin and the iliac crest (this is to assist in defining the levels of the waist circumference). The tape should  be tied firmly 
enough to stay in position around the abdomen about the level of the umbilicus. 
The subject should be asked to breathe normally and at the time of making the measurements, 
the subject should be asked to breathe out gently to prevent from contracting their muscles or holding their breath. Measure the circumference of the tape using a plastic tape measure (not elastic or metal).  
Repeat the above with the elastic tape around the point yielding the maximum circumference over the buttocks. 
It is recommended that the observer sits in front of the subject and that the same study site staff 
member carries out the assessment throughout the study wherever possible Note: waist and hip  circumference will not be performed during the open label period. 
6.6.2  Fasting laboratory evaluations  
Fasting (8 hour duration with water ad libitum ) laboratory tests will be assessed as indicated in 
Table 6 -1. 
Subjects should avoid smoking within the hour preceding the blood draws. 
A central laboratory will be used for analysis of all fasting laboratory specimens. Details of the 
collections, shipment of samples and reporting of results by the central laboratory are provided to the investigators in the Laboratory Manual. 
6.6.2.1  Plasma glucose  
Fasting plasma glucose will be taken as a fasting blood sample at scheduled visits as indicated 
in Table 6 -1. 

Novartis  Confidential  Page 67  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
6.6.2.2  Lipid panel  
A lipid profile including High Density Lipoprotein (HDL), Low Density  Lipoprotein (LDL), 
cholesterol, triglycerides, lipoprotein (a), apolipoprotein B, apolipoprotein A -1, and adiponectin 
will be measured from a fasting blood sample at scheduled visits as indicated in Ta ble 6 -1. 
6.6.3  Resource utilization  
Not applicable.  
6.6.4  Health -related Quality of Life (HRQoL)  
The impact of psoriasis on various aspects of subject’s HRQoL will be assessed by the 
following validated instruments: 
• Dermatology Life Quality Index© (DLQI©) 
• EuroQOL 5- Dimension© Health Status Questionnaire (EQ -5D©) 
• Health Assessment Questionnaire©- Disability Index (HAQ©-DI) (subjects with PsA at 
baseline of core study)  
At the appropriate scheduled visits (see Table 6 -1), questionnaires are to be completed by each 
subject in the language with which she/he is most facile, and before she/he sees the investigator 
for clinical assessments. Responses will be collected using digitized paper with a digital pen. 
The dig itized paper will serve as source documentation; the pen will be transferred to its 
docking station for transmittal of the subject’s responses to the vendor’s database. Subjects are to initial and date the white box (and not the shaded area of the form) at  the bottom left hand 
portion of the last page of the questionnaire. In those countries not permitting subjects to initial documents, the date and 3- letter initials of the country in which the subject participates is to be 
used. By ensuring that the initials are placed in the white box, the subject’s initials will not be copied when the digital pen activates its camera to record a digitized copy of the completed questionnaires. The digitized pen writes in green ink. Only this pen may be used for making corrections and only the subject may make corrections. Corrections must be “single -lined” 
through, and should be dated and where permitted, initialed by the subject. 
The subject is to be given sufficient space and time to complete the questionnaires. The study  
coordinator is to check the questionnaires for completeness and encourage the subject to 
complete any missing responses. The original questionnaires will be kept with the subject’s file as source documentation.  
Completed questionnaires will be reviewed a nd examined by a blinded staff member at the site 
(not the investigator or evaluator of the subject for the physician assessments), before the 
clinical examination, for responses that may indicate potential AEs or SAEs. The investigator is to review not only the responses to the questions in the questionnaires but also to look for unsolicited comments written by the subject. If AEs or SAEs are confirmed by the investigator, then she/he must record the events as per instructions given in Section 7  of the protocol. 
Investigators and study coordinators are not to encourage subjects to change the responses reported in the completed questionnaires. Study coordinators are to complete the header information at the top  of the questionnaire prior to distributing it to the subjects. 
Novartis  Confidential  Page 68  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
6.6.4.1  Dermatology Life Quality Index© (DLQI©) 
The DLQI© is a 10 -item general dermatology disability index designed to assess HRQoL in 
adult subjects with skin diseases such as eczema, psoriasis, acn e, and viral warts ( Finlay and 
Khan, 1994). The measure is self -administered and includes domains of daily activities, leisure, 
personal relationships, symptoms and feelings, treatment, and work/school. The measure  is 
widely used: it has been tested across 32 different skin conditions and is available in 55 
languages. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories, ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI
© total score is a sum of the 
10 questions. Scores range from 0 to 30, and higher scores indicate greater HRQoL impairment. Additionally, each subscale of the DLQI
© may be analyzed separately.  
The DLQI© questionnaire (date of publication 1994) will be completed by the subject as 
indicated in Table 6 -1. 
6.6.4.2  EuroQOL 5 -Dimension© (EQ-5D©) Health Status Questionna ire 
The EQ -5D© is a generic instrument to assess each subject’s health status. It provides a simple 
descriptive profile and a single index value for health status. The instrument essentially consists of 2 pages – the EQ -5D
© descriptive system and the EQ vi sual analog scale (VAS). The EQ -
5D© descriptive system comprises the following 5 dimensions: mobility, self -care, usual 
activities, pain/discomfort and anxiety/depression. 
Each dimension has 3 response levels: no problems, some problems, severe problems. T he 
subject is asked to indicate her/his health state by ticking (or placing a cross) in the box against 
the most appropriate statement in each of the 5 dimensions. 
The VAS records the respondent’s self -rated health on a vertical scale where the endpoints are 
labeled ‘Best imaginable health state’ and ‘Worst imaginable health state’. This information 
can be used as a quantitative measure of health outcome as judged by the individual respondents. 
The EQ -5D
© questionnaire (date of publication 1990) is to be completed by the subject at the 
visits indicated in Table 6 -1. 
6.6.4.3  Health Assessment Questionnaire©- Disability Index (HAQ©-DI) 
(subjects with PsA only)  
The HAQ© was developed by Stanford University and is one of the most widely used measures 
to assess the long -term influence of chronic disease on a subject's level of functional ability and 
activity restriction. Although originally developed for use in subje cts with rheumatic disease, 
the HAQ© has been employed across a large variety of disease areas. The disability assessment 
component of the HAQ©-DI, assesses a subject's level of functional ability and includes 
questions of fine movements of the upper extre mity, locomotor activities of the lower extremity, 
and activities that involve both upper and lower extremities. There are 20 items in eight 
categories of functioning including dressing & grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. The stem of each item asks over the past week "Are you able 
to …" perform a particular task. Each item is scored on a 4 -point scale from 0 to 3, representing 
normal (without any difficulty [0]), with some difficulty (1), with much difficulty (2), and 
Novartis  Confidential  Page 69  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
unable to do (3). The HAQ©-DI also includes questions about the use of ‘aids or devices’ and 
aid from other people to supplement the answers given to the 20 items.  
The purpose of the HAQ©-DI in this study is to assess the functional ability of subj ects with 
PsA at baseline of the core study.  
The HAQ©-DI questionnaire will be completed by the subject as indicated in Table 6 -1 by all 
subjects with a medical history of PsA recorded on the Psoriatic Arthritis History eCRF during 
the screening period of the core study. 
6.6.5  Pharmacokinetics  
At all study sites, blood samples will be collected for PK at the scheduled visits as indicated in 
Table 6 -1. 
For a detailed description of the blood sampling schema, including time points, refer to the 
Blood Log in Appendix 2, Table 13 -1.  
All blood samples will be taken by direct venipuncture. Blood samples (approximately 2 mL, not less than 1.5 mL) will be collected into SST. The blood sample will be allowed to clot over a minimum of 30 minutes at room temperature prior to harvesting of the serum. The serum wi ll 
be obtained by centrifugation at approximately 2,500 rpm for 10 minutes. 
Serum samples will be placed on ice, split into 2 aliquots (polypropylene tubes) and then stored 
(within 30 minutes of collection) at -70°C to -20°C (approximately) prior to shipme nt to the 
central laboratory. Shipment of stored aliquots from the site to the central lab should be on a monthly basis. To the extent possible, the site should send each aliquot to the central laboratory separately. If a study site does not have the facil ity to store aliquots at the conditions specified, 
then samples must be stored on dry ice at the site and shipped on dry ice on the day of collection. The central lab will ship one aliquot of the samples on dry ice to the analytical laboratory. The remaini ng aliquots must be kept at the central lab as a backup sample. Remaining samples will 
only be disposed of after approval by the Clinical Trial Head (typically 6 to 12 months after the Clinical study report (CSR) is published). 
The actual sample collection  date and exact time of collection will be entered on the Blood 
collection for PK eCRF or the Unscheduled blood collection for PK eCRF, as appropriate. 
Sampling problems will be noted in the ‘Reason sample not taken’ section of the eCRF. 
PK sample handling, labeling and shipment instructions  
A laboratory manual will be provided by the central laboratory with detailed information on 
sample collection, sample handling and shipment. Tubes and labels will be provided by the central laboratory with study/sample type and sample number preprinted on the label. 
Further details on labeling of the PK samples can be found in Appendix 3, Section 13.3.1. 
PK sample stability  
Secukinumab is stable in serum samples for at least 20 months at -20°C or at -80°C.   
Novartis  Confidential  Page 70  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
PK analytical methods 
An Enzyme -Linked Immunosorbent Assay (ELISA) method will be used for bioanalytical 
analysis of secukinumab in serum, with an anticipated lower limit of quantification (LLOQ) of 
80 ng/mL. The detailed method description to assess secukinumab concentration will be described in the bioanalytical raw data of the study and in the respective BDR.  
6.6.7  Other biomarkers  
Not applicable.  
6.6.8  Prospective suicidality assessment  
Not applicable.  
7 Safety monitoring  
7.1 Adverse events 
An AE is any untoward medical occurrence (i.e., any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a subject or clinical 
investigation  subject after providing written informed consent  for participation in the study. 
Therefore, an AE may or may not be temporally or causally associated with the use of a study 
treatment. Medical conditions/diseases present before starting study treatment ar e only 
considered AEs if they worsen after starting study treatment. Abnormal laboratory values or test results constitute AEs only if they induce clinical signs or symptoms, are considered clinically significant, or require therapy.  
The occurrence of AEs should be sought by non -directive questioning of the subject at each 
visit or each telephone call during the study. AEs also may be detected when they are volunteered by the subject during or between visits or through physical examination, laboratory test, or other assessments.  
Abnormal laboratory values or test results constitute AEs only if they fulfill at least one of the following criteria:  
• they induce clinical signs or symptoms,  
• they are considered clinically significant,  

Novartis  Confidential  Page 71  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
• they require therapy.  
Clinically significant abnormal laboratory values or test results should be identified through a 
review of values outside of normal ranges/clinically notable ranges, significant changes from baseline or the previous visit, or values which are considered to be non- typical in subject with 
underlying disease.  
The investigator must consider the AEs still ongoing at Week 52 of the core study (e.g., 
CAIN457A2302 or CAIN457A2303) at the time a subject enters the extension study. The ongoing AEs from the core study will be followed to final outcome in the extension study clinical trial database. New AEs with onset while subject is in the extension study will be entered in the Adverse Event eCRF of the extension study. 
Investigators have the responsibility for managing the safety of individual subject and 
identifying adverse events. Alert ranges for labs and other test abnormalities are included in Appendix 1. 
AEs sho uld be recorded in the Adverse Events eCRF under the signs, symptoms or diagnosis 
associated with them accompanied by the following information. 
• The severity grade  
• mild: usually transient in nature and generally not interfering with normal activities  
• mode rate: sufficiently discomforting to interfere with normal activities  
• severe: prevents normal activities  
• its relationship to the  study treatment (suspected: Yes or No) 
• its duration (start and end dates) or if continuing at final examination)  
• whether it con stitutes a SAE  
• action taken with study treatment  
• concomitant medications taken  
• outcome and  
• whether the AE led to study discontinuation 
An SAE is any AE (appearance of [or worsening of any pre -existing] undesirable sign[s], 
symptom[s] or medical conditions[s]) which meets any one of the following criteria  
• is fatal or life -threatening  
• results in persistent or significant disability/incapacity  
• constitutes a congenital anomaly/birth defect  
• requires inpatient hospitalization or prolongation of existing hospitalization, unless 
hospitalization is for : 
• routine treatment or monitoring of the studied indication, not associated with any 
deterioration in condition 
• elective or pre- planned treatment for a pre -existing condition that is unrelated to the 
indication  under study and has not worsened since signing the informed consent  
Novartis  Confidential  Page 72  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
• treatment on an emergency outpatient basis for an event not fulfilling any of the 
definitions of a SAE given above and not resulting in hospital admission  
• social reasons and respite care in the absence of any deterioration in the subject’s general condition  
• is medically significant, i.e., defined as an event that jeopardizes the subject or may require medical or surgical intervention to prevent one of the outcomes listed above. 
Unlike  routine safety assessments, SAEs are monitored continuously and have special 
reporting requirements; see Section 7.2. 
All AEs should be treated appropriately. The action taken to treat the AE should be  recorded 
on the Adverse Event eCRF.  
AEs that occur after informed consent has been obtained must be captured on the Adverse event 
eCRF. Once an AE is detected, it should be followed until its resolution or until it is judged to be permanent, and assessment should be made at each visit (or more frequently, if necessary) of any changes in severity, the suspected relationship to the study treatment the interventions required to treat it, and the outcome. 
Information about common side effects already known about the investigational drug can be 
found in the IB or will be communicated between IB updates in the form of Investigator Notifications (IN). This information will be included in the informed consent given to the subject and should be discussed with the s ubject during the study as needed.  
The investigator should also instruct each subject to report any new AE (beyond the protocol observation period) that the subject, or the subject’s personal physician, believes might reasonably be related to study treatment. This information should be recorded in the investigator’s source documents; however, if the AE meets the criteria of an SAE, it must be reported to Novartis. 
7.2 Serious adverse events 
To ensure patient safety, every SAE, regardless of causality, occurring  during  following time 
periods must be reported to Novartis within 24 hour s of learning of its occurrence:   
• after the subject has provided informed consent and until 12 weeks after the last administration of study treatment or 30 days after the subject has stopped the study participation (defined as last visit of the study at Week 268)  for subjects who don’t enter follow-up 2 period  
• after the subject has provided informed consent and until the last telephone contact for patients who enter follow-up 2 period  
Any SAEs experienced after these periods should only be reported to Novartis if the investigator suspects a causal relationship to study treatment.  
Recurrent episodes, complications, or progression of the initial SAE must be reported as follow -
up to the original episode, regardless of when the event occurs. This report must be submitted within 24 hours of the investigator receiving the follow -up information. An SAE that is 
considered completely unrelated to a previously reported one should be reported separately as 
a new event.  
Novartis  Confidential  Page 73  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
Information about all SAEs (either initial or follow -up information) is collected and recorded 
on the paper Serious Adverse Event Report Form (SAE report form) or where available the 
Serious Adverse Event Form within the remote data capturing (RDC) system. The investigator must assess the relationship to each specific study treatment and complete the paper or 
electronic SAE report form in its entirety in English.   
When SAEs are recorded on the paper SAE form, these should be faxed within 24 hours of 
awareness of the SAE to the local Novartis Drug Safety and Epidemiology (DS&E) 
Department. The telephone and fax number of the contact persons in the local department of DS&E, specific to the site, are listed in the investigator folder provided to each site. The original 
copy of the SAE Report Form and the fax confirmation sheet must be kept with the case report form documentation at the study site.  
When SAEs are recorded electronically in the Oracle Clinical/ Remote Data Capture (OC/RDC) system, these should be entered, saved and e -signed within 24 hours of awareness of the SAE . 
These data will automatically be submitted to Novartis DS&E immediately after investigator signature or 24 hours after entry, whichever occurs first. 
The Investigator must assess the relationship to the study treatment.  
Note that any follow -up information provided should describe whether the event has resolved 
or continues, if and how it was treated, whether the blind was broken or not and whether the 
subject continued or withdrew from study participation. Each re -occurrence, complication, or 
progression of the original event should be reported as a follow -up to that event regardless of 
when it occurs. 
If the SAE is not previously documented in the IB or Package Insert (new occurrence) and is 
thought to be related to the study treatment, a DS&E Department associate may urgently require further information from the investigator for Health Authority reporting. Novartis may need to issue an Investigator Notification (IN) to inform all investigators involved in any study with the same investigational treatment that this SAE has been reported.
 Suspected Unexpected Serious 
Adverse Reactions (SUSARs) will be collected and reported to the competent authorities and relevant ethics committees in accordance with Directive 2001/20/EC or as per national regulatory requirements in participating countries. 
7.3 Pregnancy reporting  
To ensure subject  safety, each pregnancy occurring while the subject is on study treatment must 
be reported to Novartis within 24 hours of learning of its occurrence. The pregnancy should be followed up to determine outcome, including spontaneous or voluntary termination, details of 
the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal and/or newborn complications. 
Pregnancy should be recorded on a Clinical Trial Pregnancy Form and reported by the 
investigator to the local Novart is DS&E Department. Pregnancy follow -up should be recorded 
on the same form and should include an assessment of the possible relationship to the study treatment  
Any SAE experienced during pregnancy must be reported on the SAE Report Form. 
Novartis  Confidential  Page 74  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
7.4 Data Monitoring Committee 
A data monitoring committee (DMC) will review the safety data of this trial at selected time 
intervals at least until the Week 68 PEA. Details regarding the DMC process will be available in relevant secukinumab DMC charter. 
8 Data review and database management  
8.1 Site monitoring 
Before study initiation, at a site initiation visit or at an investigator’s meeting, a Novartis representative will review the protocol and eCRFs with the investigators and their staff. During the study, the field monit or will visit the site regularly to check the completeness of subject 
records, the accuracy of entries on the eCRFs, the adherence to the protocol and to Good Clinical Practice, the progress of enrollment, and to ensure that study treatment is being stored , 
dispensed, and accounted for according to specifications. Key study personnel must be available to assist the field monitor during these visits.  
The investigator must maintain source documents for each subject in the study, consisting of case and visit n otes (hospital or clinic medical records) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or assessments. All information on eCRFs must be traceable to these source documents in the 
subject’s file. The investigator must also keep the original ICF signed by the subject and a 
signed copy is given to the subject. 
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency with the eCRF entrie s. Novartis monitoring standards require full verification for 
the presence of informed consent, adherence to the inclusion/exclusion criteria, documentation of SAEs, and of data that will be used for all primary and safety variables. Additional checks of the consistency of the source data with the eCRFs are performed according to the study -
specific monitoring plan. No information in source documents about the identity of the subjects will be disclosed.  
8.2 Data collection 
Designated investigator staff will enter the data required by the protocol into the OC/RDC system. Designated investigator site staff will not be given access to the system until they have been trained.  
Automatic validation procedures within the system check for data discrepancies during and 
after data entry and, by generating appropriate error messages, allow the data to be confirmed or corrected online by the designated investigator site staff. The investigator must certify that the data entered into the eCRFs are complete and accurate. After database lock, the investigator will receive copies of the subject data for archiving at the investigational site.  
8.3 Database management and quality control 
Novartis staff [or CRO working on behalf of Novartis] review the data entered into the eCRFs by in vestigational staff for completeness and accuracy and instruct the site personnel to make 
Novartis  Confidential  Page 75  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
any required corrections or additions. Novartis personal will not make any corrections or 
additions to the data. Queries are sent to the investigational site using an  electronic data query. 
Designated investigator site staff is required to respond to the query and confirm or correct the data. If the electronic query system is not used, a paper Data Query Form will be faxed to the site. Site personnel will complete and sign the faxed copy and fax it back to Novartis staff that 
will make the correction to the database. The signed copy of the Data Query Form is kept at the investigator site.  
Concomitant medications entered into the database will be coded using the World He alth 
organization (WHO) Drug Reference List, which employs the Anatomical Therapeutic Chemical classification system. Concomitant procedures, non- drug therapies and AEs will be 
coded using the Medical dictionary for regulatory activities (MedDRA) terminolo gy. 
Laboratory samples will be processed centrally and the results will be sent electronically to Novartis (or a designated CRO).  
ECG readings will be processed centrally and the results will be sent electronically to Novartis (or a designated CRO).  
Subjec ts will use electronic pens to enter data on HRQoL tools. This data will be processed 
centrally and the results will be sent electronically to Novartis (or a designated CRO).  
Randomization codes and data about all study treatment dispensed to the subject a nd all IVR 
recorded dosage changes will be tracked using an IRT. The system will be supplied by a vendor, who will also manage the database. The database will be sent electronically to Novartis (or a designated CRO).  
Each occurrence of a code break via IRT  will be reported to the clinical team and monitor.  The 
code break functionality will remain available until study shut down or upon request of Novartis. 
9 Data analysis  
Treatment groups for analysis will include: 
• Subjects who were PASI 75 responders at Wee k 52 
• Secukinumab 150 mg 
• Secukinumab 300 mg 
• Placebo (secukinumab 150 mg in core studies) 
• Placebo (secukinumab 300 mg in core studies) 
• Subjects who were re-treated after relapse with secukinumab 150 mg or 300 mg • Secukinumab 150 mg 
• Secukinumab 300 mg 
Novartis  Confidential  Page 76  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
• Subjects  who were partial responders at Week 52  
• Secukinumab 150 mg 
• Secukinumab 300 mg 
For open- label period analyses subjects being switched from 150 mg to 300 mg will be 
summarized as well.  
NOTE: Week 52 assessments refer to Baseline extension assessments  
9.1 Analysi s sets  
The following analysis sets will be used in this trial: 
Randomized set : The randomized set will be defined as all subjects who were randomized. 
Unless otherwise specified, mis -randomized subjects (mis -randomized in IRT) will be excluded 
from the ra ndomized set. Mis -randomized subjects will be defined as those subjects where IRT 
contact is made by the site either prematurely or inappropriately prior to confirmation of the 
subject’s final randomization eligibility and double -blind study treatment was not administered 
to the subject. 
Full analysis set (FAS) : The FAS will be comprised of all subjects from the randomized set to 
whom study treatment has been assigned. Following the intent -to-treat principle, subjects will 
be analyzed according to the treat ment assigned to at randomization, but actual stratum, if 
stratified randomization is used.  
Safety set : The safety set includes all subjects who took at least one dose of study treatment 
during the treatment period. Subjects will be analyzed according to t reatment received.  
9.2 Subject demographics and other baseline characteristics  
Demographics and baseline characteristics 
Summary statistics will be presented for continuous demographic and baseline characteristic 
variables for each treatment group and for all  subjects in the randomized set. The number and 
percentage of subjects in each category will be presented for categorical variables for each treatment group and all subjects. 
Medical history  
Any significant prior or active medical condition at the time of signing informed consent will 
be coded using the MedDRA dictionary. These medical conditions will be summarized by 
primary system organ class and preferred term.  
To establish a baseline level of cardiovascular risk, the number and percentage of subjects wi th 
pre-solicited cardiovascular risk factors will be summarized by treatment group. The number 
of cardiovascular risk factors that each subject has will also be summarized by treatment group. If it is unknown whether or not a subject currently or previousl y experienced a specific 
cardiovascular risk factor, it will be assumed that cardiovascular risk factor did not occur for that subject.  
Novartis  Confidential  Page 77  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
Psoriasis specific medical history will be summarized by treatment group. Previous treatments 
for psoriasis and whether or not response was achieved will be summarized by treatment group.  
All the medical history information will be retrieved from the core studies.  
9.3 Treatments 
Study treatment 
The analysis of study treatment data will be based on the safety set.  
The duration of exposure to study treatment will also be summarized by treatment group. In 
addition, the number and percentage of subjects with cumulative exposure levels (e.g., any exposure, ≥ 1 week, ≥ 2 weeks, ≥ 3 weeks, ≥ 4 weeks, ≥ 8 weeks, etc.) will be presented. 
Prior and concomitant medication  
Prior and concomitant medications will be summarized in separate tables by treatment group.  
Prior medications are defined as treatments taken and stopped prior to first dose of study 
treatment. Any medication given at lea st once between the day of first dose of randomized study 
treatment and the date of the last study visit will be a concomitant medication, including those which were started pre -baseline and continued into the period where study treatment is 
administered.  
Medications will be presented in alphabetical order, by Anatomical Therapeutic Classification (ATC) codes and grouped by anatomical main group. Tables will show the overall number and percentage of subjects receiving at least one treatment of a particular ATC code and at least one treatment in a particular anatomical main group.  
Significant prior and concomitant non- drug therapies and procedures will be summarized by 
primary system organ class and MedDRA preferred term.  
The number and percentage of subjects  receiving different classes of prior psoriasis therapy 
(biologic systemic therapy, non -biologic systemic therapy, topical, phototherapy, 
photochemotherapy) will be presented by treatment group as well as the reasons for stopping their previous prior psori asis therapies (primary lack of efficacy, secondary lack of efficacy, 
lack of tolerability, other) and the total duration of exposure to psoriasis therapies previously. 
Prior concomitant medications will be retrieved from the core studies.  
9.4 Analysis of the primary variable  
9.4.1  Variable  
The primary variable is the cumulative rate of subjects who lost PASI 75 response up to Week 
68 (time=0 being defined as Week 52).  
Novartis  Confidential  Page 78  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
9.4.2  Statistical model, hypothesis, and method of analysis 
The statistical hypotheses are that the cumulative rate for subjects who lost PASI 75 response 
up to Week 68 are not different between secukinumab 150 mg and corresponding placebo as 
well as between secukinumab 300 mg and corresponding placebo. 
Let p j(t) denote the proportion of PASI 75 responde rs at time t for treatment group j, and let 
p0,j(t) denote the proportion of PASI 75 responders at time t  for placebo group j , j=1, 2, where  
• 0,j corresponds to placebo (secukinumab 150 mg in core studies) for j=1 and to placebo 
(secukinumab 300 mg in core studies) for j=2, 
• 1 corresponds to secukinumab 150 mg, 
• 2 corresponds to secukinumab 300 mg. 
The following hypotheses will be tested for 52 weeks≤ t ≤68 weeks 
• H1: p1(t) – p0,1(t) = 0 versus H A1: p1(t)– p 0,1(t) ≥ 0, 
• H2: p2(t) – p0,2(t) = 0 versus H A2: p2(t) – p 0,2(t) ≥ 0, 
In other words • H
1: Secukinumab 150 mg is not different from placebo with respect to the cumulative rate 
for subjects who lost PASI 75 response up to Week 68 
• H2: Secukinumab 300 mg is not different from placebo with respect to the cumulative rate 
for subjects who lost PASI 75 response up to Week 68 
Number and percentage of subjects with loss of PASI 75 response based on the number of 
subjects in the full analysis set at risk as denominator will be provided by treatment group.  
For loss of PASI 75 response, between- treatment differences will be evaluated using a log -rank 
test, stratified by geographical region and body weight stratum, to compare the survival 
functions between secukinumab treatment groups versus placebo. The hazard ratios for  these 
comparisons for loss of PASI 75 response and their corresponding 95% confidence intervals will be computed using a stratified Cox proportional hazards regression model with treatment group, core study and baseline PASI of core study and baseline PASI of extension study as explanatory variable and stratified by geographical region and body weight stratum. The primary analysis will be the log -rank test. Subjects who have not lost PASI 75 response up to 
Week 68 will be considered as censored observations.  
The Kaplan -Meier estimates of the (1 minus cumulative rate loss of PASI 75 response) for each 
treatment will be plotted. The plot will include the number of subjects at risk for each treatment group at pre- specified time points (e.g., visits).  
The number of subjects with loss of PASI 75 response, number of subjects in the analysis set, estimate of cumulative rate up to Week 68, median event time, and its estimated standard error, as estimable will be provided for each treatment group. In addition, for pr e-specified time 
intervals (e.g., 4-week intervals) the following will be presented: 
• for each treatment group and time interval: subjects at risk, subjects with loss of PASI 75 
response, subjects with loss of PASI 75 response divided by subjects at risk, cumulative subjects with event and cumulative event probability including 95% confidence interval. 
Novartis  Confidential  Page 79  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
• for treatment comparisons the hazard ratio derived via Cox regression as well as log -rank 
test and Wilcoxon test.  
Separate analyses will be performed for com parison of 150 mg secukinumab with placebo and 
300 mg secukinumab with placebo. The two placebo groups will not be pooled for this analysis.  
Testing strategy  
The familywise error will be set to α=2.5% (one -sided). The two hypotheses H 1 (referring to 
150 mg) and H 2 (referring to 300 mg) will be tested at α/2=1.25% one -sided. In case, a null 
hypothesis has been rejected for one dose, but not for the other dose, the alpha can be shifted to 
the other dose and the null hypotheses can be retested at level α=2.5% (one- sided). The 
graphical approach of [Bretz et al (2009)] for sequentially rejective testing procedures is used to illustrate the testing strategy (Figure 9 -1): 
Figure 9-1 Testing strategy  
 
Other secondary endpoints will not be included in the testing strategy. 
9.4.3  Handling of missing values/censoring/discontinuations  
For the primary analysis subjects who did not lose PASI 75 response before Week 68 but with 
missing values at Week 68 will be considered as censored. Other time -to-event analyses will be 
handled analogously. 
For other analyses (not time to event) missing values with respect to response variables based 
on PASI score and IGA mod 2011 score will be imputed with non-r esponse regardless of the 
reason for missing data (e.g., premature study discontinuation, missed visit, administrative issues).  
Following the intent -to-treat principle for subjects who prematurely discontinue treatment, but 
who are observed in the follow -up period, efficacy data collected in follow -up periods will be 
linked to planned but missed study visits as well, following imputation schemes described in the analysis plan (e.g., if a subject discontinues treatment at Week 56, but has follow -up visit 
F4, the PASI score observed at Visit F4 might be used for Week 60 assessments). 
The last observation carried forward method will be applied to PASI score and IGA mod 2011 score. Note, that responses based on PASI score or IGA mode will be imputed differently  as 
described above.  
If all post Randomization Visit efficacy values are missing for one efficacy parameter then these missing values will not be imputed and this subject will be removed from the analysis of the corresponding variable, i.e., it might be th at the number of subjects providing data to an analysis 

Novartis  Confidential  Page 80  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
is smaller than the number of subjects in the FAS. In addition, missing baseline values will not 
be imputed. 
9.4.4  Supportive analyses  
Sensitivity analyses will be performed as follows: 
• Subjects fulfilling at least one of the following criteria will be classified as non -responders 
with respect to PASI  75 and IGA 0 or 1 response at Week 68 and the Cox proportional 
hazards regression analysis of the primary analysis will be repeated:  
• subjects with missing inje ction (s) up to Week 68,  
• dropouts due to AEs, unsatisfactory therapeutic effect up to Week 68, and 
• subjects with missing data at Week 68.  
• PASI 75 will be evaluated using Cox proportional hazards regression as described above 
with multiple imputations instead of non-responder imputation for missing values. Within 
this analysis the PASI score will be imputed and response variables will be derived based on the imputed scores. For each treatment group values will be imputed separately. Further details will be given in the analysis plan. 
In addition, the secukinumab treatment groups will also be compared, i.e. a Cox proportional hazards regression will be fitted as described above including all four treatment groups. Placebo (secukinumab 150 mg in core studies) and Placebo (secukinumab 300 mg in core studies) will be compared as well as secukinumab 150 mg and secukinumab 300 mg. 
9.5 Analysis of secondary variables  
9.5.1  Efficacy variables  
Subjects who were PASI 75 responders at Week 52  
PASI  50, PASI  75, PASI  90, PASI  100 and IGA 0 or 1 response over time  
Summary statistics for PASI  50, PASI  75, PASI  90, PASI  100 and IGA 0 or 1 response by visit 
will be presented in contingency tables and will include absolute and relative frequencies. Confidence intervals for response r ates will be derived as well based on the score method 
including continuity correction ( Newcombe, 1998 ). 
For PASI  50, PASI  75, PASI  90, PASI  100 and IGA 0 or 1 response at each visit, each 
secukinumab dose regimen will be compared to placebo (up to last visit with more than 5% of subjects in placebo group) by means of the stratified Cochran- Mantel -Haenszel -test as well as 
by means of a logistic regression model with treatment group, geographical region, body weight 
stratum, and baseline PASI as effects.  
For PASI  50, PASI  75, PASI  90 and IGA 0 or 1 response the placebo- adjusted response rates 
including 95% confidence interval (based on normal approximation) will be derived by visit. Figures will be provided as well displaying estimates for responder rates by treatment including confidence intervals. 
Novartis  Confidential  Page 81  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
Subjects that were re- randomized at Week 52, hence who PASI 75 responder will be split into 
two subgroups based on the IGA 0 or 1 response at Week 52. For each of these subgroups 
summary statistics for PASI  50, PASI  75, PASI  90, PASI  100 and IGA 0 or 1 response by visit 
will be presented in contingency tables and will include absolute and relative frequencies.  
Loss of PASI 75 response over time 
The loss of PASI 75 response will be repeated, but not truncated at Week 68 and subjects who 
did not lose PASI 75 response up to Week 68 will not be considered as censored. In a ddition, 
the secukinumab treatment groups will also be compared, i.e. a Cox proportional hazards regression will be fitted as described above including all four treatment groups. Placebo (secukinumab 150 mg in core studies) and Placebo (secukinumab 300 mg in core studies) will 
be compared as well as secukinumab 150 mg and secukinumab 300 mg. 
Loss of IGA 0 or 1 response over time  
Loss of IGA 0 or 1 response over time will be analyzed analogously to the loss of PASI 75 
response, but it will be restricted to the subset of subjects who have been IGA 0 or 1 responder at Week 52.  
PASI score over time 
Summary statistics will be provided for absolute PASI scores as well as for percent change from 
baseline by visit and treatment group. Figures will also be provided. 
IGA mod 2011 score over time 
Summary statistics for the IGA mod 2011 score over time will be presented by visit and 
treatment group in contingency tables.  
Relapse  
Relapse will be analyzed analogously to loss of PASI 75 response. Additional analyses will be performed for relapses observed in the follow- up period. 
Rebound 
Rebound is defined as a worsening of PASI of > 125% of the value at baseline (core study), or 
new pustular, erythrodermic or more inflammatory psoriasis occurring within 8 weeks of stopping therapy (i.e., if this definition is fulfilled at more than 8 weeks after last study treatment 
administration, this is not defined as rebound). The number and percentage of subjects experiencing rebound will be presented by visit and treatment group. 
Novartis  Confidential  Page 82  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
Subje cts who were re -treated after relapse with secukinumab 150 mg or 300 mg  
Time to PASI 75 response  
Kaplan -Meier estimates including 95% confidence intervals for cumulative rate of subjects 
gaining PASI  75 response after relapse will be calculated (time point  of re -initiation of 
secukinumab therapy will be defined as time zero).  
Time to IGA 0 or 1 response  
Time to IGA 0 or 1 response will be analyzed analogously to time to PASI 75 response but 
limited to the subset of subjects who were not IGA 0 or 1 responde r at time of relapse.  
PASI  50, PASI  75, PASI  90, PASI  100 and IGA 0 or 1 response over time  
Summary statistics for PASI  50, PASI  75, PASI  90, PASI  100 and IGA 0 or 1 response by visit 
after relapse will be presented in contingency tables and will include absolute and relative 
frequencies. Confidence intervals for response rates will be derived as well based on the score method including continuity correction ( Newcombe, 1998).  
PASI score over time 
Summary statistics will be provided for absolute PASI scores as well as for percent change from 
baseline by visit and treatment group. Figures will also be provided. 
IGA mod 2011 score over time 
Summary statistics for the IGA mod 2011 score over time will be presented by vis it and 
treatment group in contingency tables.  
Relapse  
This analysis will be the same as for “subjects who were PASI 75 responders at Week 52”  
Rebound This analysis will be the same as for the “subjects who were PASI 75 responders at Week 52”  
Subjects who were partial responders at Week 52  
PASI  50, PASI  75, PASI  90, PASI  100 and IGA 0 or 1 response over time  
Summary statistics for PASI  50, PASI  75, PASI  90, PASI  100 and IGA 0 or 1 response by visit 
will be presented in contingency tables and will include a bsolute and relative frequencies. 
Confidence intervals for response rates will be derived as well based on the score method 
including continuity correction ( Newcombe, 1998 ). 
Novartis  Confidential  Page 83  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
PASI score over time 
Summary statistics w ill be provided for absolute PASI scores as well as for percent change from 
baseline by visit and treatment group. Figures will also be provided. 
IGA mod 2011 score over time 
Summary statistics for the IGA mod 2011 score over time will be presented by visi t and 
treatment group in contingency tables.  
Relapse  
This analysis will be the same as for the “subjects who were PASI 75 responders at Week 52”  
Rebound This analysis will be the same as for the “subjects who were PASI 75 responders at Week 52”  
9.5.2  Safety  variables 
All safety evaluations will be performed on the Safety set. For adverse events an analysis based 
on pooled treatment groups “any secukinumab 150 mg” and “any secukinumab 300 mg” will also be done. In the analysis of the subjects who were re -treated after relapse with secukinumab 
150 mg or 300 mg only safety data after re -treatment after relapse will be reported. With the 
exception of adverse events that qualify as "treatment emergent" (see definition below), data collected from telephone visits a nd unscheduled visits in follow -up period 2 will only be 
included in individual patient listings, but not in summary tables.  
Adverse events 
Treatment emergent adverse events are defined as any events started after the first dose of  
 study treatment and within 84 days after the last study treatment, or events present prior to the 
first dose of study treatment, but increased in severity based on preferred term within 84 days after the last study treatment.  
AEs will be summarized by presenting, for each treat ment group, the number and percentage 
of subjects having any AE, having an AE in each primary system organ class and having each individual AE (preferred term). Summaries will also be presented for AEs by severity and for study treatment related AEs. If a subject reported more than one adverse events with the same 
preferred term, the adverse event with the greatest severity will be presented. If a subject reported more than one adverse events within the same primary system organ class, the subject will be c ounted only once with the greatest severity at the system organ class level, where 
applicable.  
Confidence intervals for relative frequencies will be derived as well according to the score method including continuity correction by Newcombe, 1998. 
Separate summaries will be provided for death, serious adverse event, other significant adverse 
events leading to discontinuation and adverse events leading to dose adjustment (including study treatment discontinuation).  
Novartis  Confidential  Page 84  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
A graphical display of relative frequencies within system organ classes and relative risks, if 
appropriate, will be presented. 
For infections, time -to-event analysis will be done. Results will be tabulated and the Kaplan-
Meier estimates for the cumulative rate will be plotted.  
Additional analyses will be provided for adjudicated adverse events. In supplementary analyses, exposure  (or observation) -time adjusted analyses in terms of 
incidence rate and event rate will be provided.  
Laboratory data  
The summary of laboratory evaluations will be presented for three groups of laboratory tests 
(hematology, serum chemistry and urinalysis). Descriptive summary statistics for the change from baseline to each study visit will be presented. These descriptive summaries will be presented by test group, laboratory test and treatment group. Change from baseline will only be summarized for subjects with both baseline and post baseline. 
For each parameter, the maximum change from baseline within each study period will be 
analyzed analogously.  
In addition, shift tables will be provided for all parameters to compare a subject’s baseline laboratory evaluation relative to the visit’s observed value. For the shift tables, the normal laboratory ranges will be used to evaluate whether a particular laboratory test value was normal, low, or high for each visit value relative to whether or not the baseline value was normal, low, or high. These summaries will be presented by laboratory test and treatment group. Shifts will be presented  for most extreme values post- baseline.  
Immunogenicity  
Summary statistics for baseline, each post- baseline visit and change from ba seline to each visit 
will be provided. Summary statistics will be provided for the percent of subjects with immunogenicity. If appropriate, shift tables will also be presented. 
Vital signs  
Analysis of the vital sign measurements using summary statistics fo r the change from baseline 
for each post -baseline visit will be performed. These descriptive summaries will be presented 
by vital sign and treatment group. Change from baseline will only be summarized for subjects 
with both baseline and post- baseline values.  
ECG  
Summary statistics will be presented for ECG variables by visit and treatment group.  
Novartis  Confidential  Page 85  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
9.5.3  Health -related Quality of Life (HRQoL)  
EQ-5D© 
The EQ -5D© is a questionnaire with 5 questions (regarding mobility, self -care, usual activities, 
pain/discomfort, and anxiety/depression) each with three categories (no problem, moderate 
problem, severe problems) and a health state assessment from 0 (worst possible health state) to 
100 (best possible health state). The number and percentage of subjects in each of the thr ee 
categories for each question will be presented by visit and treatment group. Summary statistics will be shown for the health state assessment by visit and treatment group. 
DLQI
©  
The DLQI© measures functional disability of subjects with dermatological d isorders that are 
greater than 18 years of age and had been utilized as a relevant clinical measure in atopic 
dermatitis, as well as other dermatitis clinical trials. The DLQI© is a simple, validated, self -
administered 10- item questionnaire.  The instrument contains six functional scales (i.e., 
symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). For the DLQI
©, each question will be answered with the following response: “not 
at all,” “a little,” “a lot,” or “very much”. Seven scores will be derived from the DLQI©: the 
total score of each of the six dimensions as well as the total score over all items. The higher the score, the more quality of life is impaired.  
For each of the seven scores the percentage chan ge from baseline will be derived. Summary 
statistics will be provided for absolute values as well as for the percentage change by visit and treatment group.  
For the “subjects who were PASI 75 responders at Week 52” the following analysis will be performed as well:  
The absolute value and the percentage change from baseline of DLQI
© total score will be 
analyzed with the Van -Elteren test using type -II weights, for all pairwise comparisons between 
secukinumab treatment groups versus placebo. The Van- Elteren tes t will be performed at each 
visit. Language of the questionnaire and body weight stratum will be the strata adjusted for in the Van -Elteren test. In addition, stratified Hodges -Lehmann estimates for the median as well 
as confidence intervals will be derived for the absolute values and percentage change to baseline for each treatment group as well as for all pairwise comparisons between secukinumab treatment groups versus placebo. 
It is understood that conclusions obtained from the confidence intervals of these estimates 
(mean or Hodges -Lehmann estimates for the median) will not be completely consistent with the 
testing results (Van -Elteren test) which constitute the key analysis for drawing conclusions. 
Novartis  Confidential  Page 86  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
In addition, summary statistics will be provided for number of subjects achieving DLQI 0 or 
1. For the “subjects who were PASI 75 responders at Week 52” the secukinumab treatment 
groups will be compared to placebo by means of Fisher’s exact test . 
HAQ©-DI (for subjects with PSA at baseline of the core study)  
Summary statistics will be derived for HAQ©-DI score over time for all subjects with psoriatic 
arthritis recorded on the Psoriatic Arthritis History eCRF at screening visit of the core study.  
Absolute and relative frequencies for HAQ©-DI response will also be presented. HAQ©-DI 
response is defined by an improvement of 0.3 score points compared to baseline. 
9.5.4  Pharmacokinetics  
All completed subjects with quantifiable PK measurements of secukinumab will be included in 
the PK data analysis. Serum concentrations will be expressed in mass per volume units. All concentrations below the limit of quantification or missing data will be labeled as such in the concentration data listings. PK concentrations will be summarized by visit and treatment group. In addition to mean, standard deviation, coefficient of variation, median and quartiles, the geometric mean and geometric coefficient of variation and n(log) will be presented.  
9.5.6  B
iomarkers  
Not applicable.  
  
 
   
9.6 Interim analyses  
One interim analysis is planned for this study. At time of marketing authorization submission of the AIN457A project blinded safety data of this study will be reported. 
A PEA is p lanned to be performed when all subjects have completed the visit at which the 
primary endpoint is assessed (Week 68). At this time point, the Sponsor will be unblinded, 
whereas investigators and study participants will remain blinded.  

Novartis  Confidential  Page 87  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
All data collected u p to Week 68 will be analyzed. 
Additional interim analyses may be conducted at various time points for publications or health 
authority requests. The study procedures will not be modified as a result of these interim analyses  
9.7 Sample size calculation  
Assump tions for the number of subjects eligible for randomized withdrawal (i.e for the 
analysis of primary endpoint): 
• Drop -out rate on secukinumab at Week 12 in core studies: 5% (estimate from 
CAIN457A2211) 
• Drop -out rate on placebo at Week 12 in core studies: 15% (from CAIN457A2211) 
• Placebo PASI 75 response rate at Week 12: 5% (conservative assumption) 
• Drop -out rate on secukinumab up to Week 52 in core studies: 15% (common for 
secukinumab induction and placebo induction regimens, as in Leonardi et al, 2008) 
• PASI 75 response rate at Week 52 on secukinumab 150 mg in core studies: 65% (from 
dosing rationale in protocols of core studies) (power would be larger for 300 mg if we would assume similar loss of PASI75 rates)  
• Type -I-error rate is defined to one-sided 2.5%  
With these assumptions it is estimated to have 414 subjects eligible per dose  to enter the 
randomized withdrawal, with a randomization ratio of 2:1 this would be 276 subjects on 150 
mg and 138 subjects on placebo. With about 400 subjects the study would have more than 90% power to detect differences in the cumulative rates if 10% of subjects on secukinumab lost PASI 75 response versus 23% on placebo, PASS 2008 software (Log Rank Survival Power Analysis - Simple ).  
 
10 Ethical considerations  
10.1 Regulatory and ethical compliance  
This clinical study was designed and shall be implemented and reported in accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local regulations (including European Directive 2001/20/EC, US Code of Federal Regulations Title 21, and Japanese Ministry of Health, Labor, and Welfare), and with the ethical principles laid down in the Declaration of Helsinki. 
10.2 Informed consent procedures 
Eligible subjects may only be included in the study after providing written (witnessed, where required by law or regulation), IRB/IEC -approved informed consent, or, if incapable of doing 
so, after such consent has been provided by a legally acceptable representative of the subject. In cases where the subject’s representati ve gives consent, the subject should be informed about 
the study to the extent possible given his/her understanding. If the subject is capable of doing so, he/she should indicate assent by personally signing and dating the written informed consent 

Novartis  Confidential  Page 88  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
document or a separate assent form. Informed consent must be obtained before conducting any 
study- specific procedures (i.e. all of the procedures described in the protocol). The process of 
obtaining informed consent should be documented in the subject source docum ents. 
Novartis will provide to investigators in a separate document a proposed informed consent form 
that complies with the ICH GCP guideline and regulatory requirements and is considered appropriate for this study. Any changes to the proposed consent form  suggested by the 
investigator must be agreed to by Novartis before submission to the IRB/IEC, and a copy of the approved version must be provided to the Novartis monitor after IRB/IEC approval. 
Women of child bearing potential should be informed that taki ng the study treatment may 
involve unknown risks to the fetus if pregnancy were to occur during the study and agree that 
in order to participate in the study they must adhere to the contraception requirement for the duration of the study. If there is any question that the subject will not reliably comply, they should not be entered in the study. 
10.3 Responsibilities of the investigator and IRB/IEC  
The protocol and the proposed informed consent form must be reviewed and approved by a properly constituted IRB/IEC before study start. A signed and dated statement that the protocol and informed consent have been approved by the IRB/IEC must be given to Novartis before study initiation. Prior to study start, the investigator is required to sign a protocol signature p age 
confirming his/her agreement to conduct the study in accordance with these documents and all of the instructions and procedures found in this protocol and to give access to all relevant data and records to Novartis monitors, auditors, Novartis Clinical  Quality Assurance representatives, 
designated agents of Novartis, IRBs/IECs/REBs, and regulatory authorities as required. If an inspection of the clinical site is requested by a regulatory authority, the investigator must inform Novartis immediately that this request has been made.  
10.4 Publication of study protocol and results  
Novartis assures that the key design elements of this protocol will be posted in a publicly accessible database such as clinicaltrials.gov. In addition, upon study completion and finalization of the study report the results of this trial will be either submitted for publication and/or posted in a publicly accessible database of clinical trial results.  
11 Protocol adherence  
Investigators ascertain they will apply due diligence to avoid protocol deviations. Under no circumstances should the investigator contact Novartis or its agents, if any, monitoring the trial to request approval of a protocol deviation, as requests to approve deviations will not be granted. 
This protocol defines the study objectives, the study procedures and the data to be collected on 
study participants.   Under no circumstances should an investigator collect additional data or 
conduct any additional procedures for any research related purpose involving any investigational drugs.  
If the investigator feels a protocol deviation would improve the conduct of the study this must 
be considered a protocol amendment, and unless such an amendment is agreed upon by Novartis 
Novartis  Confidential  Page 89  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
and approved by the IRB/IEC it cannot be implemented. All s ignificant protocol deviations will 
be recorded and reported in the CSR. 
11.1 Protocol Amendments  
Any change or addition to the protocol can only be made in a written protocol amendment that 
must be approved by Novartis, Health Authorities where required, and the IRB/IEC. Only 
amendments that are required for subject safety may be implemented prior to IRB/IEC approval. 
Notwithstanding the need for approval of formal protocol amendments, the investigator is expected to take any immediate action required for the safety of any subject included in this study, even if this action represents a deviation from the protocol. In such cases, Novartis should be notified of this action and the IRB/IEC at the study site should be informed within 10 working days. 
12 References  
References are available upon request  
Bretz F, Maurer W, Brannath W, Posch M (2009) A graphical approach to sequentially rejective multiple test procedures. Statistics in Medicine; 28: 586 -604. 
Chobanian AV, Bakris GL, Black HR (2003) Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension; 42:1206–1252. 
Committee for medicinal products for human use (CHMP), European Medicines Agency for 
the Evaluation of Medicines for Human Use (2001) Guideline for choice of control group in clinical Trials. CPMP/ICH/364/96 corr document. London, UK. 
Committee for medicinal products for human use (CHMP), European Medicines Agency for 
the Evaluation of Medicines for Human Use (2004) Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis. CHMP/EWP/2454/02 corr document. London, UK.  
Finlay AY, Khan GK (1994) Dermatology Life Quality Index (DLQI): A simple practical measure for routine clinical use. Clin Exp Dermatol; 19:210–216. 
Lohman TG, Roche AF (1988) Anthropometric standardization reference manual. Martoral 
R(eds) Champaign, IL: Human Kinetics. 
Leonardi CL, Kimball AB, Papp KA, et al (2008) Efficacy and safety of ustekinumab, a 
human interleukin- 12/23 monoclonal antibody, in patients with psoriasis: 76- week results 
from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 371:1665–
1674.  
Mancia G, De Backer G, Dominiczak A, et al. (2007) Guidelines for the Management of 
Arterial Hyper tension: The Task Force for the Management of Arterial Hypertension of the 
European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J 
Hypertens; 25:1105–1187. 
Novartis  Confidential  Page 90  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
Newcombe RG (1998) Two-sided confidence intervals for the single proportion: comparison 
of seven methods. Statistics in Medicine; 17: 857-872. 
Novartis  Confidential  Page 91  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
13  Appendices  
13.1 Appendix 1: Clinically notable laboratory values and vital signs 
The following criteria will be used to define expanded limits and notable abnormalities of 
keylaboratory tests. Notable values for blood pressure and pulse are presented in Section 6.5.2 
Whether action needs to be taken to address notable laboratory or vital signs values will be 
decided by the investigator, taking into account the overall status of the subject. No specific action is foreseen as part of the study protocol. 
Liver Function and Related Variables  
Alanine transaminase (ALT) (SGPT):  > 3 x Upper Limit of Normal (ULN)  
Aspartate transaminase (AST) (SGOT):  > 3 x ULN  
Total bilirubin:     > 2 x ULN  
Alkaline phosphatase:    > 2.5 x ULN Renal Function and Electrolyte Variables  
Creatinine (serum):     > 1.5 x ULN  
Potassium:      > 6 mmol/L or < 3 mmol/L 
Sodium:      > 160 mmol/L or < 115 mmol/L Hematology Variables 
Hemoglobin:      ≥ 20 g/dL decrease from baseline 
Platelet count:     < Lower Limit of Normal (LLN)  
White blood cell count:    < 0.8 x LLN Neutr ophils      < 0.9 x LLN 
Eosinophils      > 1.1 x ULN 
Lymphocytes      > 1.1 x ULN 
Urinalysis Variable  
Protein urine dipstick:    ++* 
 
* ++ is ≥ 100 mg/dL 
Novartis  Confidential  Page 92  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
13.2 Appendix 2: Blood collection log for pharmacokinetics (PK) and 
immunogenicity (IG) 
Table 13-1 Blood collection log for PK  
Visit Name  Time point  Volume  
(approx.)  Analyte  Sample number  PK collection number**  
Week 521 Pre-dose  (2 mL)  AIN457 for PK  (5) (5) 
Week 56  Pre-dose  2 mL AIN457 for PK  6 5 
Week 60  Pre-dose  2 mL  AIN457 for PK  7 5 
Week 642 Pre-dose  2 mL  AIN457 for PK  8 5 
Week 68  Pre-dose  2 mL  AIN457 for PK  9 5 
Week 72  Pre-dose  2 mL  AIN457 for PK  10 5 
Week 762 Pre-dose  2 mL  AIN457 for PK  11 5 
Week 80  Pre-dose  2 mL  AIN457 for PK  12 5 
Week 84  Pre-dose  2 mL  AIN457 for PK  13 5  
Week 882 Pre-dose  2 mL  AIN457 for PK  14 5 
Week 92  Pre-dose  2 mL  AIN457 for PK  15 5 
Week 96  Pre-dose  2 mL  AIN457 for PK  16 5 
Week 100  Pre-dose  2 mL  AIN457 for PK  17 5 
Week 1042 Pre-dose  2 mL  AIN457 for PK  18 5 
Week 108  Pre-dose  2 mL  AIN457 for PK  19 5 
Week112  Pre-dose  2 mL  AIN457 for PK  20 5 
Week 1162 Pre-dose  2 mL  AIN457 for PK  21 5 
Week 120  Pre-dose  2 mL  AIN457 for PK  22 5 
Week 124  Pre-dose  2 mL  AIN457 for PK  23 5 
Week 1282 Pre-dose  2 mL  AIN457 for PK  24 5 
Week 132  Pre-dose  2 mL  AIN457 for PK  25 5 
Week 136  Pre-dose  2 mL  AIN457 for PK  26 5 
Week 1402 Pre-dose  2 mL  AIN457 for PK  27 5 
Week 144  Pre-dose  2 mL  AIN457 for PK  28 5 
Week 148  Pre-dose  2 mL  AIN457 for PK  29 5 
Week 152  Pre-dose  2 mL  AIN457 for PK  30 5 
Week 1562  Pre-dose  2 mL  AIN457 for PK  31 5 
Week  2602 672 hours*  2 mL  AIN457 for PK  32 5 
Week 2682(F8) 2016 hours*  2 mL  AIN457 for PK  33 5 
1The data and sample numbering for Week 52 visit (randomization) will have been collected as part of 
the end of maintenance visit (Week 52) from core study (e.g., CAIN457A2302 or CAIN457A2303)  
2The PK blood sampling at these time point must be collected for all subjects. PK blood collections at 
the other time points are “event driven” i.e., PK blood samples will only be collected in case of relapse.  
*Scheduled post -dose time points for sample numbers 32 and 33 (672 hours and 2016 hours post -
dose, respectively) refer to the last dose given at Week 256 as time 0.  
**If a PK sample is collected at an unscheduled visit, the sample numbers will follow the pattern 1001, 
1002 etc.  
Novartis  Confidential  Page 93  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
Table 13-2 Blood collection log for IG  
Visit Name  Time point  Volume  
(approx.)  Analy te IG collection 
number**  
Week 521 Pre-dose  (2 mL)  anti-AIN457 for IG  (503a)  
Week 76  Pre-dose  2 mL  anti-AIN457 for IG  504 
Week 104  Pre-dose  2 mL  anti-AIN457 for IG  505 
Week 128  Pre-dose  2 mL  anti-AIN457 for IG  506 
Week 140  Pre-dose  2 mL  anti-AIN457 for IG  507 
Week 156  Pre-dose  2 mL  anti-AIN457 for IG  508 
Week 260  672 hours*  2 mL  anti-AIN457 for IG  509 
Week 268 (F8)  2016 hours*  2 mL  anti-AIN457 for IG  510 
1The data and sample numbering for Week 52 visit (randomization) will have been collected as part of 
the end of maintenance visit (Week 52) from core study (e.g., CAIN457A2302 or CAIN457A2303)  
* Scheduled post -dose time points for sample numbers 509 and 510 (672 hours and 2016 hours post -
dose, respectively) refer to the last dose given at Week 256 as time 0.  
** If a IG sample is collected at an unscheduled visit, the sample numbers will follow the pattern, 3001, 
3002, etc.  
 
Novartis  Confidential  Page 94  
Amendment Protocol  v03 Clean   Protocol No. CAIN457A2302E1  
 
13.3 Appendix 3: Pharmacokinetics (PK) and immunogenicity (IG) 
sample labeling information 
13.3.1  PK sample handling  
The samples must be labeled as in the following example and as provided by the central 
laboratory  
Study code:   CAIN457A2302E1  
Site:  cccc (4 digits for the current site number)  
Subject:  Ccccrrr (4 digits for the site number where the subject was randomiz ed 
concatenated with 3 digits for the assigned subject number. Add ‘0’ ahead of the numbers if 
needed to obtain the correct number of total digits) 
Sample number: As indicated in Table 13 -1 
Analyte:   AIN457 for PK 
Labels will be provided by the central laboratory with all information preprinted.  
As PK samples are managed by a central laboratory, no added label should cover the original 
label.  
 
13.3.2  IG sample handling  
The samples must be labeled as in the following example and as provided by the central 
laboratory  
Study code:   CAIN457A2302E1  
Site:   cccc (4 digits for the current site number)  
Subject:   Ccccrrr  
(4 digits for the site number where the subject was randomi zed 
concatenated with 3 digits for the assigned subject number. Add ‘0’ 
ahead of the numbers if needed to obtain the correct number of total digits)  
Sample number: As indicated in Table 13 -2 
Analyte:   anti-AIN457 for IG 
Labels will be provided by the central laboratory with all information preprinted.  
As IG samples are managed by a central laboratory, no added label should cover the original label.  